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Simon, bedankt om mij af en toe op mijn werkpunten te wijzen en om mij het volle 
vertrouwen te schenken in mijn functie als assistent. Jouw professionele aanpak in 
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rond trombose en hemostase aan de Kulak op te starten? Al was je niet rechtstreeks betrokken 
bij mijn onderzoek, ik heb op heel wat vlakken veel van jou geleerd. Je bent niet alleen een 
uitstekend onderzoeker, maar ook een fantastisch persoon. Mocht er op het Kulak-kerstbal 
een lifetime achievement award in de categorie ‘Leukste Prof’ uitgereikt worden, dan stemde 
ik voor jou! 
 
 Ik wil graag de leden van de examencommissie bedanken voor het kritisch nalezen van mijn 
thesis. Jullie suggesties betekenden een wetenschappelijke meerwaarde voor deze scriptie. 
 
In het kader van mijn assistentschap richt ik graag een woord van dank aan Jan Beirlant en 
Hans Pottel. Een assistent van de faculteit Geneeskunde die doctoreert aan de faculteit 
Wetenschappen… Geen evidentie, maar jullie inspanningen hebben ertoe bijgedragen dat ik 
deze functie kon opnemen. Eenmaal aangesteld, kwam ik onder de vleugels van Prof. M. De 
Cuyper. Marcel, jij leerde me de kneepjes van het assistentschap en deed me dankzij jouw 
enthousiasme en kennis inzien dat organische chemie best wel cool in elkaar zit. Een ideaal 
uitgangspunt om tijdens de werkzittingen en practica het enthousiasme van de studenten aan 
te wakkeren! Ook al geniet je ondertussen van je welverdiende emeritaat, ik denk nog vaak 
terug aan onze goede samenwerking. Ook een welgemeende dankjewel aan Prof. W. 
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Frederik, het spreekt voor zich dat ik jou als eerste vermeld. Op de werkvloer een fantastische 
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  I 
SUMMARY 
 
Von Willebrand factor (VWF) is a multimeric plasma glycoprotein that plays a dual role in 
hemostasis: (I) VWF promotes the adhesion of platelets to exposed subendothelium at sites of 
vascular injury, and (II) acts as a carrier molecule for clotting factor VIII, thereby protecting 
it from premature clearance. Upon endothelial injury, VWF binds to collagen and adopts a 
conformation that allows binding of glycoprotein (GP) Ib on platelets. The VWF-GPIb 
interaction slows down platelets and enables them to roll over the surface and to engage other 
platelet receptors. In turn, rolling platelets become activated, firmly attach, and aggregate in 
order to seal off the injured vessel wall. The platelet-tethering capacity of VWF mainly 
depends on its multimeric size, with ultra-large (UL-) VWF multimers being hyperreactive. 
In circulation, VWF multimer size, and hence its thrombogenic potential, is regulated by the 
proteolytic enzyme ADAMTS13 (a disintegrin and metalloprotease with thrombospondin-1 
motifs, member 13). Under normal conditions, ADAMTS13 cleaves large, highly reactive 
VWF multimers anchored to endothelial membrane or in circulation specifically into smaller, 
less reactive VWF multimers. 
 
Biosynthesis of VWF is restricted to endothelial cells and megakaryocytes, the precursor 
cells of platelets. Endothelial cell-derived VWF is either constitutively secreted into plasma 
and subendothelium, or stored in Weibel-Palade bodies. VWF that is produced in 
megakaryocytes ends up in α-granules of platelets. VWF present in storage granules is 
enriched in UL-VWF multimers that are secreted in a regulated process in response to a range 
of stimuli. Although endothelial cell- and platelet-derived VWF are products from the same 
gene, various biochemical differences between both VWF sources have been described. 
Whereas it is generally believed that endothelial cell-derived VWF, and in particular plasma 
VWF, is the major contributor in hemostasis and thrombosis, little is known on the 
contribution of platelet-derived VWF in these processes.  
To gain more insight into the in vivo biological activity of platelet-derived VWF, we 
performed crossed bone marrow transplantations between wild-type C57BL/6J and VWF 
knock-out (Vwf-/-) mice to generate chimeric mice with VWF only in platelets (VWF PLT 
chimeric mice) and chimeric mice specifically lacking platelet VWF (VWF EC chimeric 
mice). Tail clip bleeding times and arterial occlusion times following FeCl3-induced arterial 
thrombosis in VWF EC chimeric mice were normal compared to wild-type mice, whereas 
bleeding times were prolonged and no occlusive thrombi were formed in VWF PLT chimeric 
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mice. These data indicate that platelet-derived VWF alone is not able to support normal 
hemostasis and arterial thrombus formation and that platelet-derived VWF is not essential in 
these processes. However, using a mouse model of ischemic stroke, we have demonstrated 
that the local release of platelet-derived VWF alone can promote intracerebral thrombosis 
following ischemic brain injury. Indeed, transient occlusion of the middle cerebral artery of 
VWF PLT chimeric mice resulted in stroke lesions and intracerebral deposition of 
fibrin(ogen) that were similar to those observed in both wild-type mice and VWF EC 
chimeric mice. In addition, we found that platelet-derived VWF fosters ischemic stroke 
injury via GPIb-dependent mechanism. This study sheds an unexpected new light on the 
biological activity of platelet-derived VWF and further supports the idea that blocking the 
VWF-GPIb axis would be an interesting novel treatment strategy in ischemic stroke.  
 
Cleavage of VWF by ADAMTS13 is crucial to maintain normal hemostasis. Severe 
ADAMTS13 deficiency (<5-10% of normal activity) caused by mutations in the ADAMTS13 
gene can result in congenital thrombotic thrombocytopenic purpura (TTP). TTP is a rare 
thrombotic disorder that is characterized by the accumulation of UL-VWF multimers and 
spontaneous deposition of VWF- and platelet-rich thrombi in the microcirculation. Patients 
suffering from acute TTP episodes most often present with thrombocytopenia, hemolytic 
anemia, and organ damage, ultimately leading to death if left untreated. Treatment of 
congenital TTP is infusion of fresh frozen plasma in order to increase plasma ADAMTS13 
activity levels (>5-10% of normal values). Patients at high risk for disease recurrence often 
receive prophylactic plasma infusions of which the number depends on the patient’s 
phenotype. However, plasma infusion can result in complications and carries the risk for 
viral/prion transmission. Moreover, lifelong plasma therapy is stressful and has a negative 
impact on the patient’s quality of life. Given the severity of the disease and the limitations of 
plasma prophylaxis, gene therapy for congenital TTP would offer an interesting alternative, 
as correction of the underlying defect would result in lifelong expression of ADAMTS13 
avoiding the need for plasma infusion.  
In this study, we used the non-viral Sleeping Beauty (SB100X) transposon system to deliver 
a functional copy of the Adamts13 gene to ADAMTS13 knock-out (Adamts13-/-) mice. Liver-
directed hydrodynamic co-delivery of a transposon plasmid encoding ADAMTS13, along 
with a hyperactive transposase source resulted in expression of high levels of transgene 
ADAMTS13 up to 25 weeks after delivery. Evaluation of the VWF multimer distribution 
revealed a decrease in the relative amount of high molecular weight VWF multimers in 
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Adamts13-/- mice expressing high levels of transgene ADAMTS13 compared to non-treated 
Adamts13-/- mice, indicating that the therapeutic gene was biologically active in vivo. 
Moreover, using a mouse model of TTP, we demonstrated that Adamts13-/- mice that received 
therapeutic gene transfer were protected against TTP after challenge with recombinant VWF. 
Up to 20 weeks after gene transfer, no profound thrombocytopenia, hemolytic anemia, and 
organ damage were observed when mice expressing high levels of transgene ADAMTS13 
were challenged. In conclusion, these data demonstrate that SB transposon-mediated gene 
therapy is a potent strategy to prevent acute TTP episodes in mice. Therefore, we believe that 
the present study may pave the way to a SB transposon-mediated gene therapy that will cure 
congenital TTP in humans. 
 
An increasing body of evidence has suggested that a dysregulated balance between VWF and 
ADAMTS13, i.e. high VWF and/or low ADAMTS13 activity levels, may play a causal role 
in a variety of diseases. During the last decade, clinical studies have demonstrated that human 
malaria is associated with endothelial cell activation, the accumulation of UL-VWF 
multimers, and a reduction in ADAMTS13 activity. Whether these alterations constitute 
epiphenomena or play an active role in malaria-associated acute respiratory distress 
syndrome (MA-ARDS), a common complication of malaria with a high mortality rate, is 
currently unknown.  
To address this issue, we used an established murine model of MA-ARDS, in which wild-
type C57BL/6J mice were infected with Plasmodium (P.) berghei NK65 parasites. During the 
course of infection, VWF antigen levels were increased whereas VWF multimer distribution 
and ADAMTS13 activity levels were normal. At end-stage disease, however, a marked 
decrease in high molecular weight VWF multimers and a significant reduction in 
ADAMTS13 activity were observed. This was accompanied by a profound 
thrombocytopenia. Lack of VWF did not prevent thrombocytopenia from occurring, 
indicating that VWF does not contribute to malaria-related thrombocytopenia. Absence of 
VWF slightly but significantly altered disease course as evidenced by shortened survival 
times in Vwf-/- mice. Interestingly, we observed elevated peripheral blood parasitemia levels 
but reduced pulmonary pathology in Vwf-/- mice compared to wild-type mice. The biological 
mechanism by which VWF might influence peripheral blood parasitemia levels and 
pulmonary pathology in MA-ARDS is still unclear. Further studies will be of great 
importance to clarify the mechanisms that link VWF/ADAMTS13 alterations and malaria 
disease progression, and to explore new therapeutic avenues.  
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SAMENVATTING 
 
Von Willebrand factor (VWF) is een geglycosyleerd multimeer eiwit dat een dubbele rol in 
de hemostase vervult: (I) VWF bevordert de adhesie van bloedplaatjes aan blootgesteld 
subendotheliaal weefsel ter hoogte van de beschadigde bloedvatwand, en (II) bindt en 
beschermt stollingsfactor VIII tegen vroegtijdige proteolyse in de circulatie. Bij beschadiging 
van het endotheel bindt VWF aan collageen en ondergaat het een conformatieverandering die 
een interactie met glycoproteïne (GP) Ib op bloedplaatjes toelaat. De interactie tussen VWF 
en GPIb remt de bloedplaatjes af en stelt hen in staat om over het endotheel te rollen en 
andere bloedplaatjesreceptoren aan te wenden. Rollende bloedplaatjes worden op hun beurt 
geactiveerd, hechten zich vervolgens stevig vast, en vormen finaal een aggregaat zodat de 
beschadigde bloedvatwand gedicht wordt. De capaciteit van VWF om bloedplaatjes te binden 
hangt van de multimeergrootte af, waarbij de ‘ultralange’ (UL-) VWF multimeren 
hyperreactief zijn. In de circulatie wordt de grootte van de VWF multimeren, en bijgevolg de 
trombogene activiteit van VWF, gereguleerd door het enzym ADAMTS13 (‘A Disintegrin 
and Metalloprotease with ThromboSpondin-1 motifs, member 13’). Onder normale 
omstandigheden knipt ADAMTS13 de grote, meest reactieve VWF multimeren, die aan het 
endotheel verankerd zijn of vrij in circulatie voorkomen, in kleinere, minder reactieve 
multimeren. 
 
De synthese van VWF is beperkt tot endotheelcellen en megakaryocyten, de voorlopercellen 
van bloedplaatjes. VWF van endotheliale oorsprong (VWF EC) wordt ofwel consitutief in het 
plasma en de subendotheliale ruimte gesecreteerd, ofwel als UL-VWF multimeren 
opgeslagen in Weibel-Palade lichaampjes. VWF dat in megakaryocyten aangemaakt wordt, 
komt in de granules van bloedplaatjes terecht (VWF PLT). Het opgeslagen VWF is rijk aan 
UL-VWF multimeren die op een gereguleerde manier worden vrijgezet na stimulatie van het 
endotheel of bloedplaatjes. Hoewel VWF EC en VWF PLT door hetzelfde gen gecodeerd 
worden, werden reeds verscheidene biochemische verschillen tussen beide beschreven. 
Hoewel er in het algemeen van uitgegaan wordt dat VWF EC, en in het bijzonder plasma 
VWF, de belangrijkste bijdrage in het proces van hemostase en trombose levert, is er weinig 
gekend over de rol van VWF PLT in deze processen. 
Om meer inzicht te verwerven in de in vivo biologische activiteit van VWF PLT werden 
beenmergtransplantaties tussen wild type C57BL/6J muizen en VWF-deficiënte muizen (Vwf-
/-) uitgevoerd. Op deze manier werden enerzijds chimere muizen met enkel VWF in 
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bloedplaatjes (VWF PLT chimere muizen) en anderzijds chimere muizen met enkel VWF in 
endotheelcellen (VWF EC chimere muizen) ontwikkeld. In vergelijking met wild type 
muizen was de bloedingstijd en arteriële trombusvorming in VWF EC chimere muizen 
normaal, terwijl in VWF PLT chimere muizen de bloedingstijd verlengd was, alsook geen 
occlusieve trombus gevormd werd, Deze data tonen aan dat VWF PLT niet essentieel is in 
het proces van hemostase en arteriële trombusvorming, en dat VWF PLT alleen niet in staat 
is om deze processen te ondersteunen. In een muismodel voor ischemische beroerte werd 
echter aangetoond dat de lokale vrijzetting van VWF PLT kan bijdragen tot intracerebrale 
trombose na het optreden van ischemische hersenschade. Tijdelijke occlusie van de middelste 
cerebrale arterie resulteerde immers in een herseninfarct en een intracerebrale afzetting van 
fibrine/fibrinogeen in VWF PLT chimere muizen, waarvan de omvang vergelijkbaar was met 
deze in wild type muizen en VWF EC chimere muizen. De bijdrage van VWF PLT in de 
ontwikkeling van het infarct verliep bovendien via een GPIb-afhankelijk mechanisme.  
Deze studie werpt een nieuw licht op de biologische activiteit van VWF PLT en steunt het 
idee dat het blokkeren van de VWF-GPIb as een interessante nieuwe strategie is voor de 
behandeling van ischemische beroerte. 
 
Het knippen van VWF door ADAMTS13 is van cruciaal belang voor het behoud van de 
hemostase. Een ernstig tekort van ADAMTS13 (<5-10% van de normale activiteit) als gevolg 
van mutaties in het ADAMTS13 gen kan aanleiding geven tot congenitale trombotische 
trombocytopenische purpura (TTP). TTP is een zeldzame trombotische aandoening die 
gekenmerkt wordt door een opstapeling van UL-VWF multimeren in plasma en de afzetting 
van VWF- en bloedplaatjes-rijke klonters ter hoogte van de microcirculatie. Tijdens een acute 
fase presenteren patiënten zich met trombocytopenie, hemolytische anemie, en orgaanschade, 
hetgeen tot de dood kan leiden indien geen adequate behandeling voorhanden is. De 
standaardbehandeling voor congenitale TTP is de infusie van vers ingevroren plasma, 
teneinde de ADAMTS13 activiteit in plasma te verhogen (>5-10% van de normale waarde). 
Patiënten met een hoog risico op herval komen in aanmerking voor een profylactische 
behandeling, waarbij het aantal infusies afhankelijk is van het fenotype van de patiënt. De 
infusie van plasma kan echter leiden tot complicaties en de overdracht van 
ziekteverwekkende virussen en prionen. Bovendien gaat een levenslange plasmatherapie 
gepaard met stress en heeft het een negatieve impact op de levenskwaliteit van de patiënt. 
Gezien de ernst van de aandoening en de beperkingen van de huidige behandeling zou 
gentherapie als een belangrijke alternatieve behandelingsoptie beschouwd kunnen worden. 
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Herstel van het onderliggend genetisch defect zou immers resulteren in een levenslange 
expressie van ADAMTS13 waardoor infusie van plasma niet langer noodzakelijk is. 
In deze studie maakten we gebruik van het niet-viraal Sleeping Beauty (SB) transposon 
systeem om een functioneel kopij van het ADAMTS13 gen in ADAMTS13-deficiënte 
(Adamts13-/-) muizen te introduceren. Hydrodynamische injectie van transposon DNA, dat 
codeert voor ADAMTS13, in combinatie met plasmide DNA dat codeert voor hyperactief 
transposase resulteerde in de lever-gemedieerde expressie van hoge hoeveelheden transgeen 
plasma ADAMTS13, en dit tot 25 weken na toediening. Analyse van het multimeerpatroon 
toonde aan dat de relatieve hoeveelheid hoog moleculair gewicht multimeren in deze muizen 
verlaagd was ten opzichte van niet-behandelde Adamts13-/- muizen, wat aangeeft dat het 
transgeen ADAMTS13 biologisch actief was. Sterker nog, gentherapeutisch-behandelde 
Adamts13-/- muizen waren beschermd tegen TTP. In Adamts13-/- muizen die hoge 
hoeveelheden transgeen ADAMTS13 tot expressie brengen werd immers geen uitgesproken 
trombocytopenie, hemolytische anemie, en orgaanschade waargenomen na het toedienen van 
een hoge dosis exogeen recombinant VWF, en dit tot en met 20 weken na gentransfer. Alles 
samen tonen deze data aan dat deze niet-virale gentransferstrategie een veelbelovende 
therapie is om acute TTP in muizen te voorkomen. We zijn er dan ook van overtuigd dat de 
huidige onderzoeksresultaten zullen bijdragen tot de ontwikkeling van een klinisch relevante 
SB transposon-gemedieerde strategie voor de behandeling van congenitale TTP.  
 
Een toenemend aantal publicaties doet vermoeden dat er mogelijk een oorzakelijk verband 
bestaat tussen tal van aandoeningen en een verstoord evenwicht tussen VWF en 
ADAMTS13, d.i. een verhoogde VWF en/of een verlaagde ADAMTS13 activiteit. 
Gedurende de afgelopen 10 jaren hebben klinische studies aangetoond dat de humane malaria 
vorm gepaard gaat met de activatie van endotheelcellen, een opstapeling van UL-VWF 
multimeren in plasma, en een afname van de activiteit van ADAMTS13. Of deze 
veranderingen al dan niet een oorzakelijke rol spelen in malaria-geassocieerde ‘acute 
respiratory distress syndrome’ (MA-ARDS), een frequent voorkomende, vaak lethale 
complicatie van malaria, is tot op heden niet gekend. 
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Om dit te onderzoeken maakten we gebruik van een muismodel voor MA-ARDS, waarbij 
wild type C57BL/6J muizen met Plasmodium (P.) berghei NK65 parasieten geïnfecteerd 
werden. Tijdens het verloop van de infectie was de hoeveelheid VWF in plasma verhoogd, 
terwijl zowel het multimeerpatroon van VWF als de activiteit van ADAMTS13 normaal was. 
In het eindstadium van de ziekte werd echter een opmerkelijke daling in hoog moleculair 
gewicht multimeren en ADAMTS13 activiteit waargenomen. Dit ging eveneens gepaard met 
een uitgesproken trombocytopenie. Afwezigheid van VWF kon dit laatste niet voorkomen, 
wat erop wijst dat VWF niet in het proces van malaria-geassocieerde trombocytopenie 
betrokken is. Na infectie overleefden VWF-deficiënte muizen significant minder lang dan 
wild type muizen, al was het verschil beperkt. Opmerkelijk was dat de parasitemiewaarden in 
perifeer bloed en de longpathologie in geïnfecteerde VWF-deficiënte muizen respectievelijk 
verhoogd en verlaagd waren ten opzichte van geïnfecteerde wild type muizen. Het 
mechanisme waarmee VWF de parasitemie en longpathologie in MA-ARDS mogelijks 
beïnvloedt, blijft momenteel onduidelijk. Verdere studies zijn dan ook noodzakelijk om de 
link tussen de progressie van MA-ARDS en de veranderingen in VWF en ADAMTS13 
verder uit te klaren, en om nieuwe behandelingsopties te verkennen. 
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AA amino acid 
AAV adeno-associated virus 
ADAMTS13 a disintegrin and metalloprotease with thrombospondin-1 
motifs, member 13 
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BAL broncho-alveolar lavage 
BMT bone marrow transplantation 
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CRISPR-associated  
C-terminal carboxyl-terminal 
CUB complement component C1r/C1s, urinary epidermal growth 
factor and bone morphogenetic protein-1 
DAB 3,3’-diaminobenzidine 
DTCS non-catalytic ADAMTS13 domains including disintegrin 
domain (D), thrombospondin-1 motif (T), cysteine domain (C), 
and spacer domain (S) 
DDAVP 1-desamino-8-D-arginine vasopressin 
DNA deoxyribonucleic acid 
EC endothelial cell 
ECM extracellular matrix 
ELISA enzyme-linked immunosorbent assay 
F clotting factor 
FRETS-VWF73 fluorescent resonance energy transfer using a short fluorogenic 
73 amino acid VWF peptide 
FVIII:C clotting factor VIII activity 
GP glycoprotein 
HMW high molecular weight 
HRP horseradish peroxidase 
HT hepes tyrode 
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KO knockout 
LDH lactate dehydrogenase 
LMW low molecular weight 
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M metalloprotease domain 
MA-ARDS malaria-associated acute respiratory distress syndrome 
MCA middle cerebral artery 
MDTCS ADAMTS13 truncated after spacer domain 
MMW medium molecular weight 
MNC mononuclear cell 
NAC N-acetylcysteine 
N-terminal amino-terminal 
P Plasmodium 
PBS phosphate buffered saline 
pDNA plasmid DNA 
PEI polyethylenimine 
PEX plasma exchange 
PPP platelet-poor plasma 
PRP platelet-rich plasma 
rADAMTS13 recombinant ADAMTS13 
RBC red blood cell 
RT room temperature 
rVWF recombinant von Willebrand factor 
SB Sleeping Beauty 
SDS sodium dodecyl sulphate 
T thrombospondin motif 
TBS tris buffered saline 
TBST tris buffered saline containing 0.05% Tween20 
TF tissue factor 
TIR terminal inverted repeat 
TMA thrombotic microangiopathy 
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tMCAO transient middle cerebral artery occlusion 
t-PA tissue-plasminogen activator 
TTC 2,3,5-triphenyltetrazolium chloride 
TTP thrombotic thrombocytopenic purpura 
UL ultra large 
u-PA urokinase-plasminogen activator 
VWD von Willebrand disease 
VWF von Willebrand factor 
VWF EC chimeric mice expressing VWF only in endothelial cells 
VWF PLT chimeric mice expressing VWF only in platelets 
VWFpp VWF propeptide 
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WT wild-type 
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1.1. HEMOSTASIS 
Blood is a liquid tissue that plays a crucial role in the human body: it provides organs with 
necessary nutrients and removes metabolites. To accomplish this task, blood relies on 
different cell types that are suspended in a protein-rich aqueous solution (plasma). Blood 
cells are derived from immature progenitor cells, called hematopoietic stem cells, residing in 
the bone marrow (Figure 1). In the presence of specific growth factors progenitor cells 
mature, differentiate, and finally give rise to 3 types of blood cells that are released into the 
blood stream. Erythrocytes (or red blood cells, RBCs) are the most abundant cells (4-6 
million cells per µl), accounting for 40-45% of the total blood volume. These anucleated, 
biconcave cells contain hemoglobin enabling them to transport oxygen and carbon dioxide. 
Thrombocytes (or platelets), like erythrocytes, lack a nucleus as these small discoid-shaped 
cells are derived from the cytoplasm of megakaryocytes. Platelets constitute the second 
largest number of blood cells in circulation (200-500 thousand cells per µl) and primarily 
maintain the integrity of the blood vessel wall through their ability to promote repair of 
injured blood vessels and stop bleeding. Leukocytes (or white blood cells) are less numerous 
(4-11 thousand cells per µl) and account for only 1% of the total blood volume. Depending 
on their structural and functional characteristics, these nucleated cells contribute to the innate 
or adaptive immune response thereby protecting the human body against foreign 
microorganisms such as viruses and bacteria. 
 
 
Figure 1: Blood cell components. Circulating blood cells are derived from immature progenitor cells 
(hematopoietic stem cells) residing in the bone marrow. During maturation and differentiation, 
progenitor cells give rise to different blood cell lineages (red blood cells, white blood cells, and 
platelets) that are released into the blood stream. Figure adapted from lyceum.algonquincollege.com 
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Erythrocytes represent the largest cell mass, occupying the greatest part of the lumen and 
pushing the leukocytes and platelets to the vessel wall in flowing blood. Whereas the velocity 
of blood flow is relatively low near the vessel wall, it progressively increases near the center 
of the vessel. The sliding motion of adjacent layers of fluid moving at different velocities 
creates a ‘shearing’ effect, an effect that is associated with the application of tangential forces 
in the direction of flow. The tangential force of the flowing blood exerted on the endothelial 
surface of the blood vessel is called shear stress. This hemodynamic mechanical force is 
directly proportional to the shear rate, which is characterised as the difference in flow 
velocity as a function of the distance to the vessel wall (expressed in cm/s per cm, or inverse 
seconds s-1). In turn, the shear rate is directly proportional to the blood flow and viscosity, 
and indirectly proportional to the vessel diameter. Consequently, cells within blood vessels 
with a small diameter and high flow (such as arterioles and capillaries) experience high shear 
stress, whereas cells circulating in vessels with a large diameter and low flow (such as veins 
and large arteries) experience low shear stress. 
Preservation of a normal blood flow is the result of a dynamic physiological process called 
hemostasis that is crucial to supply organs with essential nutrients. Hemostasis enables an 
organism to seal off an injured vessel wall, to keep blood in its fluid state, and to remove a 
blood clot after restoration of the vessel wall. Historically, the hemostatic process was 
divided into primary hemostasis, where platelet-vessel wall interactions lead to the formation 
of an initial platelet plug, and secondary hemostasis or coagulation, where clotting factors 
interact to generate insoluble fibrin that strengthens and stabilizes the initial platelet 
thrombus. However, current insights indicate that both processes happen simultaneously and 
are mechanistically intertwined (Figure 2).1 Finally, fibrinolysis also plays an important role 
in hemostasis. The fibrinolytic pathway ensures blood flow by limiting thrombus growth and 
removing the clot after tissue repair. 
 
1.1.1. Primary hemostasis 
Under normal conditions platelets flow over the intact endothelial surface with no adhesion 
or aggregation. Upon vessel injury, however, blood is exposed to the procoagulant 
subendothelial extracellular matrix (ECM) and platelet adhesion, activation, and aggregation 
occurs. These platelet-vessel wall interactions depend on local rheological conditions, i.e. the 
hemodynamic mechanical forces that differ throughout the circulation.2 At low shear rates 
(<800 s-1, such as veins and large arteries) platelets interact directly with ECM proteins such 
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as collagen, fibronectin, and laminin, whereas at high shear rates (>800 s-1, such as small 
arteries and capillaries) platelets bind via intermediary proteins (e.g. von Willebrand factor, 
VWF) to the ECM. Multiple platelet receptors are involved in this process and cooperate to 
form a stable adhesive platelet plug.3 The platelet glycoprotein (GP) Ib-IX-V receptor 
complex is crucial for the initial recruitment of platelets, in particular at sites of high shear 
rates.4,5 GPIb-IX-V interacts with VWF, a multimeric plasma glycoprotein that is bound to 
collagen present in the ECM and acts as an adhesive surface for circulating platelets. Through 
fast association-dissociation kinetics, the VWF-GPIb-IX-V interaction decelerates platelets 
enabling them to roll over the surface and allowing them to engage other platelet receptors 
like GPVI and integrin α2β1.6 Direct binding of GPVI and α2β1 to collagen allows the rolling 
platelets to firmly attach to collagen.4,7 
 
 
Figure 2: Schematic representation of the hemostasis process. Discoid, non-activated rolling 
platelets interact with subendothelial collagen and von Willebrand factor (VWF) at sites of vascular 
injury. Initial reversible adhesion activates rolling platelets, a process that is associated with an 
increased intracellular Ca2+ concentration, as depicted by the heat map (green: low Ca2+ signal; red: 
high Ca2+signal). Activated platelets spread, secrete agonists from storage granules, and bind VWF 
and fibrinogen through integrin activation resulting in irreversible adhesion and aggregation. In 
concert with these events, thrombin is generated which in turn has multiple effects including platelet 
activation and amplification of the coagulation cascade via active coagulation factors bound to the 
phosphatidylserine (PS)-rich platelet surface. Increased amounts of thrombin propagate clot formation 
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and ultimately convert soluble fibrinogen into insoluble fibrin strands that stabilize the initial platelet 
thrombus. Adapted from Versteeg et al.1  
VWF/GPIb-IX-V and GPVI/collagen binding induce cell-signalling pathways that are 
associated with an intracellular increase in Ca2+ concentration and subsequent platelet 
activation (Figure 2).8,9 Morphological alterations (from discoid to irregular shape), secretion 
of agonists from storage granules (such as platelet-activating molecules ADP and 
thromboxane) or cross-linking agents (VWF and fibrinogen)), and conformational transitions 
of integrins (αIIbβ3 or GPIIb/IIIa) from a low-affinity to a high-affinity state, are the main 
processes that characterize platelet activation. Following irreversible platelet adhesion, 
binding of the activated integrin receptor GPIIb/IIIa to both VWF and fibrinogen results in 
cross-linking of platelets and the formation of a platelet aggregate.5,10 Local feedback 
activation, by means of agonist secretion from storage granules, is crucial for further 
aggregation and subsequent growth of the primary platelet plug. 
 
1.1.2. Secondary hemostasis 
Following endothelial injury, coagulation factors respond through a complex cascade of 
reactions, called the coagulation cascade (Figure 3). Herein, each clotting factor exists as an 
inactive serine protease that is converted by an upstream activated enzyme. Tissue factor 
(TF), a membrane protein that is abundantly expressed on the surface of subendothelial cells, 
is considered the key initiator of coagulation.11 Following vascular damage, TF acts as an 
enzyme cofactor and forms a complex with circulating activated clotting factor VII (FVIIa). 
The TF:FVIIa complex leads to subsequent activation of clotting factor X and prothrombin 
after which small amounts of thrombin are produced. Thrombin in turn plays a central role in 
coagulation as it exerts multiple effects.12 Thrombin activates platelets and additional 
circulating coagulation factors that are involved in the amplification of the coagulation 
process. These additional clotting factors (FV, FVIII, FIX, and FX) are bound to the 
phosphatidylserine-rich surface membrane of a.o. activated platelets and contribute to a 
positive feedback loop that enhances thrombin generation (Figure 3). In addition to its crucial 
role in clot propagation, thrombin also cleaves fibrinogen to generate insoluble fibrin strands 
that upon cross-linking by FXIII form a solid fibrin meshwork that stabilizes the primary 
hemostatic plug. 
Natural inactivation of the coagulation system via inhibitory pathways is essential to prevent 
uncontrolled, widespread clot formation. Coagulation is predominantly downregulated by the 
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protease inhibitors tissue-factor pathway inhibitor and antithrombin, and by the enzyme-
based protein C/protein S pathway (Figure 3). Both protease inhibitors eliminate coagulation 
factors by targeting the active sites: tissue-factor pathway inhibitor directly binds and inhibits 
FXa or the TF:FVIIa complex, whereas antithrombin, one of the most important inhibitors, 
displays high affinity for thrombin, as well as FIXa and FXa. In contrast, protein C in 
complex with protein S does not attack the active site but proteolytically inactivates FVIIIa 
and FVa.  
 
 
Figure 3: Schematic overview of the secondary hemostasis. The coagulation cascade is mainly 
initiated by the interaction between exposed tissue factor (TF) and circulating activated clotting factor 
VII (FVIIa) (extrinsic pathway). The TF:FVIIa complex activates FX (FXa) which results in the 
formation of the prothrombinase complex and the subsequent generation of small amounts of 
thrombin. In turn, thrombin performs multiple reactions including the conversion of fibrinogen into 
fibrin and the activation of the transglutaminase FXIII (FXIIIa) generating cross-linked fibrin strands 
(XL-fibrin). Thrombin generation is propagated by means of positive feedback loops and another 
pathway in which negatively charged surfaces from activated platelets and additional coagulation 
factors (FXII, FXI, FIX, and FVIII) are involved (intrinsic pathway). Endogenous thrombolytic 
agents, such as tissue-type and urokinase-type plasminogen activators (tPA and uPA, respectively), 
drive plasmin-mediated fibrinolysis which results in the degradation of cross-linked fibrin and the 
prevention of excessive thrombus formation. Both coagulation and fibrinolysis are under control of 
several inhibitory pathways. For example, the protease-inhibitor tissue-factor pathway inhibitor 
(TFPI) reduces coagulation by targeting the active site of FXa whereas activated thrombin-activatable 
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fibrinolysis inhibitor (TAFIa) tempers fibrinolysis by diminishing the efficiency of plasminogen 
activation by tPA. Figure adapted from Mutch.13  
 
1.1.3. Fibrinolysis 
After the damage in the vessel wall is repaired, another cascade of proteases, called the 
fibrinolytic system, dissolves the clot and counteracts pathological thrombus formation 
(Figure 3).14,15 Plasmin is the primary ‘fibrinolysin’ and is activated from plasminogen by 
either urokinase-type plasminogen activator (u-PA) or tissue-type plasminogen activator (t-
PA). Plasmin degrades the thrombus by cleaving the fibrin polymers that stabilize the 
thrombus. Like the coagulation process, the fibrinolytic system is highly regulated to assure 
balanced hemostasis.16 The most potent regulator, α2-antiplasmin, directly inhibits plasmin 
activity. Other important antifibrinolytic proteins attenuate fibrinolysis by limiting de novo 
plasmin generation either through inhibition of plasminogen activation  (e.g. plasminogen-
activator inhibitor (PAI)-1 and PAI-2) or through modification of the fibrin surface (e.g. 
thrombin-activatable fibrinolysis inhibitor) (Figure 3).  
 
The balance between procoagulant and anticoagulant mechanisms ensure proper hemostasis. 
Genetic or acquired defects in one of the abovementioned phases may result in either 
excessive hemorrhage or pathological thrombus formation (thrombosis). In this introduction 
we will focus on VWF and its regulating enzyme, the VWF-cleaving protease ADAMTS13. 
We will discuss how genetic or acquired defects may affect their activity and contribute to 
bleeding- and thrombosis-related events.  
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1.2. VON WILLEBRAND FACTOR 
VWF is a multimeric plasma glycoprotein that fulfils a dual role in hemostasis. On the one 
hand, VWF acts as a molecular bridge between platelets and the subendothelial ECM at sites 
of vascular injury under high shear conditions (Figure 2). On the other hand, VWF acts a 
carrier for FVIII in circulation, thereby protecting FVIII against premature proteolytic 
degradation. Reduced levels or malfunctioning of VWF may result in bleeding episodes, 
whereas elevated levels or hyperreactivity is associated with thrombotic events.17,18 This 
demonstrates that both levels and activity of circulating VWF need to be tightly regulated.  
 
1.2.1. Biosynthesis and secretion of VWF 
The VWF gene is located on the short arm of chromosome 12 and contains 52 exons that span 
approximately 180 kilobase (kb). VWF is made exclusively in endothelial cells (ECs) and 
megakaryocytes as a 9 kb pre-pro-VWF monomer transcript that consists of a signal peptide 
(22 amino acids (AAs)), a propeptide (741 AAs), and a mature VWF subunit (2050 AAs). 
This VWF precursor protein is subjected to a series of intracellular processes including 
removal of the signal peptide and propeptide, glycosylation, and multimerization (Figure 4).19  
After translocation to the endoplasmatic reticulum, the signal peptide is removed to give a 
precursor, pro-VWF. Following glycosylation, pro-VWF dimers are formed by interprotein 
disulfide bridge formation through cysteine residues located in the carboxyl (C)-termini of 
pro-VWF subunits (‘tail-to-tail’ dimerization). In turn, these pro-VWF dimers are transported 
to the Golgi apparatus where they are further glycosylated and aligned in a side-by-side 
manner. Subsequently, amino (N)-terminal domains of pro-VWF subunits are covalently 
linked via interchain disulfide bridge formation. In this way, a pool of multimers with 
variable size, ranging from 2 to >60 subunits, is generated (‘head-to-head’ multimerization). 
In addition, the VWF propeptide (VWFpp) is cleaved but remains non-covalently associated 
with the mature VWF subunit. 
Following synthesis, the differentially sized multimers are packaged into secretory granules. 
In ECs, VWF multimers are stored in specific, rod-shaped secretory organelles called 
Weibel-Palade bodies (WPBs; Figure 5A-B).20,21 Newly formed immature WPBs are 
trafficked to the cell periphery where they will either undergo exocytosis basally or become 
anchored to F-actin allowing maturation of the WBPs for regulated release.19,22 During 
maturation, multimerization is continued within the organelle and VWF multimers are 
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assembled into helicoidal structures or tubules (Figure 5C).23,24 Whereas random fusion of 
immature WPBs with the plasma membrane accounts for basal VWF release, helical 
assembly of VWF in mature WPBs enables rapid, orderly secretion of massive amounts of 
large VWF multimers upon agonist-induced stimulation of the endothelium. 
 
 
Figure 4: Intracellular processing of VWF. The VWF gene is transcribed as pre-pro-VWF mRNA 
and directed to the endoplasmatic reticulum (ER). After removal of the signal peptide, pro-VWF 
monomers are glycosylated and covalently linked via their carboxyl (C)-termini to form pro-VWF 
dimers. In the Golgi, glycosylation continues, multimers are formed via amino (N)-terminal linkage of 
pro-VWF dimers, and the VWF propeptide is cleaved from the mature VWF subunit. Following 
synthesis, VWF multimers are transported and packaged into secretory organelles. Whereas VWF in 
α-granules and WBPs is secreted via regulatory pathways, VWF from endothelial cells is also 
released in a constitutive manner. Figure adapted from Haberichter.25  
In megakaryocytes and platelets, the VWF multimers are stored within the α-granules and 
also organized in tubular structures.26 In contrast with ECs, platelets only release their VWF 
cargo upon agonist stimulation.  
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Figure 5: Morphology of Weibel-Palade bodies (WPBs) in endothelial cells. (A) 
Immunofluorescent image showing numerous WPBs after staining with an antibody against VWF. 
(B-C) Electron microscopic images demonstrating the rod-shaped size of WPBs (B, arrows) and the 
tubular structure of VWF within these secretory granules (C). Figures adapted from (A,B) Valentijn et 
al.27 and (C) Metcalf et al.23 
 
The newly synthesized VWF multimers exists in various sizes, and are referred to as low (L), 
medium (M), high (H), and ultra-large (UL) molecular weight (MW) VWF multimers. Under 
normal conditions, the LMW, MMW, and HMW VWF multimers circulate in the blood (i.e. 
plasma VWF), whereas the UL-VWF multimers remain in their storage organelles awaiting 
agonist-induced release.  
 
1.2.2. Structure-function relationship 
As mentioned above, VWF is best known for its contribution to the hemostatic process: it 
mediates the attachment of platelets at sites of vascular injury and act as a carrier for FVIII. 
The biological activity of circulating VWF depends on the ability to interact with its 
physiological ligands. Each VWF monomer is composed of homologous domains arranged in 
the following order: D1-D2-D’-D3-A1-A2-A3-D4-C1-C2-C3-C4-C5-C6-CK in which D1-
D2 represents VWFpp and D’-D3-A1-A2-A3-D4-C1-C2-C3-C4-C5-C6-CK the mature VWF 
subunit.28 Whereas VWFpp plays an important role in the de novo multimerization process 
and packaging of VWF25,29,30, the mature VWF subunit contributes to platelet adhesion and 
aggregation. Indeed, many of the domains within the mature VWF subunit contain functional 
binding or cleavage sites that contribute to specific procoagulant functions (Figure 6). The 
D’/D3 domains interact with FVIII. The A1 domain is important for binding with GPIbα on 
platelets. The A1 domain is also involved in collagen binding, although the major collagen-
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binding site is located within the A3 domain. The A2 domain contains the cleavage site for 
the VWF-cleaving protease, A Disintegrin And Metalloprotease with ThromboSpondin-1 
motifs, member 13 (ADAMTS13). The C4 domain interacts with the platelet receptor 
GPIIb/IIIa.  
 
 
Figure 6: Domain structure of VWF. VWF is synthesized as pre-pro-VWF monomer subunit 
consisting of a signal peptide, a propeptide, and a mature VWF subunit. Pro-VWF monomers, 
consisting of the VWF propeptide and the mature VWF subunit, undergo ‘tail-to-tail’ dimerization 
and ‘head-to-head’ multimerization through the formation of disulfide bonds between the cysteine-
rich regions in the carboxyl-terminal CK domains and amino-terminal D3 domains, respectively. The 
main physiological ligands of VWF as well as the ADAMTS13 cleavage site are indicated below the 
domains with which they interact.	
 
The platelet-tethering function of VWF is determined by its multimeric composition and its 
ability to undergo structural transitions. As each monomer contains the essential elements for 
platelet binding, the process of multimerization markedly enhances the activity of VWF.31,32 
Experimental evidence showed that both the binding capacity for GPIb and GPIIb/IIIa, and 
the platelet aggregating activity under high shear conditions increases with the degree of 
multimerization of VWF.33,34 These effects may be due to a higher number of binding sites in 
larger multimers and a higher binding affinity between HMW multimers and platelets, 
increasing platelet adhesion and aggregation.35 The circulating HMW VWF multimers are 
therefore the most functionally efficient, whereas MMW and LMW VWF multimers are less 
functionally efficient.36 Interestingly, no VWF-platelet interactions are observed in 
circulation under normal conditions. 
In a normal situation, the majority of plasma VWF circulates in a globular, latent 
conformation.37 In globular VWF, the collagen-binding site within the A3 domain is exposed, 
whereas the A1 domain is inaccessible for platelet binding enabling VWF to examine the 
blood vessel wall without unnecessary binding to platelets. In response to vascular injury, 
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however, the conformation of VWF rapidly alters. Via the exposed collagen-binding sites in 
the A3 domain, globular VWF is immobilized onto the collagen-rich subendothelial matrix. 
Shear forces in the blood then unfold the immobilized VWF into an elongated conformation 
thereby exposing the previously hidden platelet-binding sites within the A1 domains (Figure 
7A). The subsequent interactions between VWF and different platelet receptors facilitate 
stable adhesion of platelets and the formation of a primary hemostatic plug at the site of 
injury, as described in section 1.1.1. 
 
 
Figure 7: Shear-induced unfolding of VWF and cleavage by ADAMTS13. (A) Effect of shear 
forces on the conformation of VWF. In the absence of shear stress, atomic force microscopy images 
VWF as a globular protein. When shear forces are applied, VWF extends in the direction of the shear 
field and adopts an elongated conformation. (B) Size regulation of VWF by ADAMTS13. Ultra-large 
VWF multimers may spontaneously unfold in circulation due to their increased responsiveness to 
shear forces. Shear-force induced elongation of VWF exposes the ADAMTS13-cleavage site within 
the A2 domain of VWF enabling ADAMTS13 to cleave VWF multimers in smaller fragments. 
Figures adapted from (A) Siedlecki et al.38 and (B) Stockschlaeder et al.36  
 
Shear-induced unfolding of VWF does not only expose cryptic platelet-binding sites but also 
reveals the cryptic cleavage site for the VWF-cleaving protease, ADAMTS13. ADAMTS13 
cleaves the Tyr1605-Met1606 scissile bond within the A2 domain of VWF thereby reducing the 
multimer size, and hence its hemostatic activity (Figure 7B). Although this metalloprotease is 
constitutively active, it only cleaves VWF in response to shear since the ADAMTS13-
cleavage site is shielded and resistant to proteolysis in the globular conformation. Regulation 
of the VWF multimer size is necessary to prevent the accumulation of highly adhesive and 
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hyperresponsive UL-VWF multimers in circulation. More details on how ADAMTS13 and 
VWF interact will be discussed in section 1.3.2. 
 
In circulation, 1-2% of the available VWF monomers circulate as a tight non-covalent 
complex with 95-98% of FVIII in plasma (a ratio of 1 FVIII molecule to 50 VWF 
monomers).39,40 At the site of vascular injury, FVIII is locally activated by thrombin and 
released from the VWF D’/D3 domains making it available as an effective procoagulant 
cofactor in the coagulation cascade (as described in section 1.1.2.). The VWF-FVIII 
interaction protects FVIII against proteolytic inactivation by plasma proteases thereby 
prolonging its plasma half-life from 1-2 to 12 hours. The extremely low FVIII levels and 
hemophilia A-like bleeding phenotype associated with the complete lack of plasma VWF 
illustrate the clinical importance of the VWF-FVIII interaction.41 Additionally, the VWF-
FVIII complex formation also plays a role in FVIII function, immunogenicity, and 
clearance.42 
 
Abnormalities in either the quantity or quality of VWF multimers, especially the HMW VWF 
multimers, may cause a bleeding diathesis called von Willebrand disease, which will be 
described in section 1.2.4. 
 
1.2.3. Clearance of VWF  
In addition to its biosynthesis, clearance of VWF contributes to the steady-state levels of 
VWF in plasma. In the last decade, some factors and mechanisms affecting clearance kinetics 
and VWF survival have been identified.19,43 Studies in humans revealed that the glycosylation 
pattern of VWF44,45 and specific mutations within the VWF gene46,47 affect plasma VWF 
levels by influencing its clearance rate. For instance, normal subjects with the O blood group 
or subjects with the heterozygous AA substitution R1205H within the VWF gene have a 
reduced VWF survival and lower plasma VWF levels compared to normal subjects with the 
non-O blood group or without mutations.44,46  
The mechanism, by which VWF is cleared, has been partly elucidated. Recent studies have 
demonstrated that the basal clearance of VWF predominantly occurs in the liver, more 
specifically by macrophages that bind VWF through the low-density lipoprotein receptor-
related protein-1 (LRP1).48-50 The importance of macrophage LRP1 in VWF clearance is 
illustrated by the increased survival of VWF and the increased VWF antigen levels in 
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macrophage-specific LRP1-deficient mice.50 In addition to LRP1, several other carbohydrate 
receptors such as the asialoglycoprotein receptor51, Siglec-552, and CLEC4M53 are identified 
as clearance receptors that are able to bind and internalize VWF. 
In search for other determinants involved in the catabolic pathway of VWF, ADAMTS13 has 
also been proposed as a potential candidate.54 However, several studies have demonstrated 
that removal of VWF from the circulation occurs independent of ADAMTS13.55-57 Whether 
other proteases contribute to VWF clearance kinetics requires further investigation. 
 
1.2.4. Von Willebrand disease 
The average plasma concentration of VWF is 10 µg/ml58, although variability within the 
population is broad59. Deficient or dysfunctional VWF results in von Willebrand disease 
(VWD), an inherited autosomal bleeding disorder first described by Erik von Willebrand in 
1926. VWD is the most common bleeding disorder with prevalence up to 1% based on low 
VWF levels.60,61 The incidence of bleeding requiring treatment, however, varies from 0.01% 
to 0.002%.62-64 Characteristic bleeding symptoms associated with VWD include easy 
bruising, mucosal hemorrhages (especially epistaxis and menorrhagia), excessive bleeding 
from superficial wounds, bleeding from the oral cavity or gastrointestinal tract, prolonged 
bleeding during or after surgery, and less commonly, hemarthroses and soft tissue 
hematomas. The bleeding tendency is usually directly related to the extent of the deficiency 
or defect, although most VWD patients appear to have a mild phenotype.65 
 
1.2.4.1. Congenital VWD 
Congenital VWD is caused by mutations within the VWF gene and classified into three main 
categories based on quantitative (type 1 and type 3 VWD) or qualitative (type 2) 
abnormalities in VWF (Table 1).66,67 Type 1 VWD accounts for 65 to 80% of all cases of 
VWD and is characterized by a mild to moderate reduction in plasma VWF levels and 
parallel decreases in FVIII levels. Epidemiological studies have indicated that 2/3 of type 1 
VWD patients have identifiable VWF mutations, of which 70% appear to be missense 
mutations spread throughout the entire VWF gene.67 The majority of the mutations lead to 
reduced expression or reduced intracellular transport of dimeric pro-VWF68, or faster 
clearance of the protein from the circulation47. Patients present with a wide spectrum of 
symptoms, from asymptomatic to severe bleeding episodes, depending on the severity of the 
VWF and FVIII deficiency.  
CHAPTER 1 
 
 15 
Table 1: Classification of VWD  
VWD 
type 
Inheritance 
pattern 
Location mutation Pathophysiologic mechanism Phenotype 
1 
autosomal-
dominant 
Throughout VWF 
gene 
Partial deficiency in VWF:Ag 
and/or FVIII 
mild to 
moderately 
severe 
2A 
autosomal-
dominant 
VWF A2 domain; 
VWF D1, D2, D’ 
and D3 domains; 
VWF CK domains 
ê platelet-dependent VWF 
function, ê HMW multimers 
moderately 
severe 
2B 
autosomal-
dominant 
VWF A1 domain é platelet-dependent VWF 
function, ê HMW multimers 
moderately 
severe 
2M 
autosomal-
dominant 
VWF A1 and A3 
domains 
ê platelet-dependent VWF 
function, normal multimer 
pattern 
moderately 
severe 
2N 
autosomal-
recessive 
VWF D’ and D3 
domains 
ê binding to FVIII, normal 
multimer pattern 
moderately 
severe 
3 
autosomal-
recessive 
Throughout VWF 
gene 
Severe/complete deficiency in 
VWF:Ag and severe decrease 
in FVIII 
severe 
 
Type 3 VWD is characterized by very low to undetectable levels of VWF and associated low 
levels of FVIII due to mutations that disrupt normal VWF expression from both alleles. 
Despite its low prevalence (ranging from 0.5 to 5 cases per million), more than 110 
mutations, primarily point mutations (missense or null) and deletions scattered over the entire 
VWF gene, have already been identified. Type 3 is the most severe form of VWD and is often 
associated with the occurrence of hemophilia A-like symptoms, such as soft tissue 
hematomas and joint bleeding, given the low levels of FVIII.  
Type 2 VWD affects 20-35% of the patients and is associated with normal VWF levels but 
abnormal structure or function of VWF. Bleeding symptoms in patients with type 2 VWD are 
generally more severe than for type 1 VWD.69 Based on the underlying defect, i.e. a mutation 
in one of the functional domains of VWF, type 2 VWD is divided in 4 different subtypes: A, 
B, M and N. (I) Subtype 2A VWD is the most common qualitative variant that is 
characterized by a decreased platelet-dependent function of VWF caused by the loss of 
HMW (and MMW) VWF multimers. Genetic defects include mutations in either VWFpp or 
CK domain that lead to defective multimer assembly, and mutations in the A2 domain that 
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increase the susceptibility to proteolysis by ADAMTS13. In addition, some genetic VWF 
variants are intracellular retained or degraded, or show loss of regulated storage.70 (II) 
Subtype 2B VWD, is associated with increased and often spontaneous binding of VWF to 
platelet GPIb. This gain-of-function phenotype is caused by molecular defects residing within 
the A1 domain of VWF. HMW VWF multimers are lost from plasma as spontaneous binding 
of platelets to VWF facilitates proteolysis by ADAMTS1371,72 and also results in faster 
clearance of the VWF-platelet complexes73. (III) In subtype 2M VWD, VWF has a decreased 
function despite (near-) normal multimeric distribution. The majority of mutations cause 
impaired binding of the A1 domain to GPIb. Defective binding to collagen (due to mutations 
in the VWF A3 domain) has also been reported. (IV) Finally, subtype 2N VWD is 
characterized by a decrease in the affinity of VWF for FVIII, caused by homozygous or 
compound heterozygous mutations in the VWF D’ or D3 FVIII binding domain. FVIII levels 
are disproportional compared to VWF and vary between 5% and 40%.74 Due to this severe 
reduction in plasma FVIII, the clinical phenotype is comparable to mild hemophilia A, 
characterized by joint and muscle hematomas.75 
 
1.2.4.2. Acquired von Willebrand syndrome 
Acquired von Willebrand syndrome (aVWS) is a rare clinical bleeding disorder that mimics 
inherited VWD. Although aVWS patients present without a personal or familial history of 
bleeding diathesis and mostly synthesize normal amounts of VWF, they characteristically 
exhibit prolonged bleeding and low VWF and FVIII levels. This hemorrhagic condition is 
associated with a number of underlying disorders such as cardiovascular diseases, 
autoimmune diseases, and lympho- and myeloproliferative disorders.76 The pathogenic 
mechanism depends on the underlying disorder: (I) binding of VWF to (non-) specific 
autoantibodies forming immune complexes that are removed by specific immunological 
cells77; (II) adsorption of VWF onto malignant cells leading to increased clearance78,79; and 
(III) increased susceptibility for proteolysis by ADAMTS13 under conditions of high shear 
stress.80,81 Although the underlying conditions may be heterogeneous, the main feature 
causing bleeding is the accelerated removal of the hemostatically active VWF multimers 
from the circulation. 
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1.2.4.3. Current and future treatment options 
	
Current treatment 
Current management of VWD focuses on increasing the concentration of circulating VWF in 
VWD patients.82 The therapeutic approaches that are used to control and prevent bleeding 
depend on the type of VWD and involve the release of endogenous VWF from endothelial 
WPBs or the administration of exogenous VWF, whether or not in combination with adjuvant 
therapy. 
Desmopressin (1-desamino-8-D-arginine vasopressin; DDAVP), a synthetic derivative of 
vasopressin, induces the secretion of endogenous VWF from WPBs resulting in a 2- to 5-fold 
increase in VWF levels within one hour in patients that adequately respond.83,84 DDAVP is 
the treatment of choice in VWD patients expressing low levels of functionally intact VWF, 
i.e. the majority of type 1 VWD patients and some patients with type 2A and 2M, whereas it 
is ineffective in type 3 patients, and even contraindicated in type 2B patients. Treatment with 
DDAVP is recommended as first-line therapy for minor surgery and bleeding.  
When DDAVP is ineffective, inadequate, or contraindicated, VWD patients require the 
administration of exogenous VWF/FVIII concentrates. This includes all patients with type 3 
VWD, and most with type 2 and severe type 1 VWD. Replacement therapy is recommended 
for on-demand treatment of clinically significant bleeding events or for prevention of 
excessive bleeding in VWD patients undergoing major surgery. In addition, prophylactic use 
of VWF/FVIII concentrates prevents severe bleeding among the most affected VWD patients 
and improves quality of life.85,86  
The use of DDAVP or VWF/FVIII concentrates is often combined with the administration of 
antifibrinolytic or topical agents. Whereas antifibrinolytic agents (such as aminocaproic acid) 
inhibit the natural process of thrombus dissolution by decreasing plasmin activity, topical 
agents (such as recombinant human thrombin) enhance thrombus formation at sites of 
application. However, both agents are considered adjunctive therapies that have been most 
effective with increased VWF levels.87  
 
Future treatment 
To overcome the hurdles associated with the use of blood as source of VWF, researchers 
have developed a highly pure (>99% purity) recombinant VWF (rVWF) protein by in vitro 
cell culture.88 The major characteristic of rVWF is its homogenous and intact VWF multimer 
distribution, including a portion of UL-VWF multimers, which may predict a greater 
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hemostatic efficacy than plasma-derived VWF (Figure 8).88,89 In a recent phase 3 clinical 
trial, it was demonstrated that only a single infusion of rVWF together with recombinant 
FVIII resolved most bleeding events in severe VWD patients without eliciting thrombotic or 
serious adverse events.90 These clinical data demonstrate that use of rVWF is safe, well 
tolerated, and hemostatically effective in severe VWD, making it at present the most 
appealing alternative for current treatment.  
	
 
Figure 8: Electrophoretic analysis of recombinant von Willebrand factor versus plasma-derived 
von Willebrand factor. Multimers in recombinant von Willebrand factor (rVWF) and plasma-
derived von Willebrand factor (pdVWF) were separated using a low resolution SDS-agarose gel 
electrophoresis and stained with a polyclonal anti-VWF antibody. Preparations of rVWF contain a 
high portion of ultra large (UL-) VWF multimers, whereas this portion is absent in pdVWF. Figure 
adapted from Turecek et al.89 
 
Recently, the option of gene therapy for treatment of VWD has gained interest. Rather than 
relying on repetitive on-demand therapy, correction of the genetic defect would ideally cure 
the disease and therefore offer a long-term, possible lifelong, treatment improving the 
patient’s quality of life. VWD is a good candidate for gene therapy: it is a monogenetic 
disease and as VWF is secreted into the circulation, the need for tissue- and organ-specific 
targeting is obviated. In 2006, our group first described the feasibility of gene therapy for 
type 3 VWD.91,92 Since then, we and others have tested various gene therapeutic approaches 
targeting the liver using both viral93 and non-viral gene transfer techniques94-96 in VWD mice, 
albeit with limited success. Future studies that will focus on EC-targeting and long-term 
expression using non-viral integrating approaches will provide more insight into the 
therapeutic value of VWD gene therapy. 
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1.2.5. Differences in plasma VWF and platelet-derived VWF 
Biosynthesis of VWF is restricted to ECs and megakaryocytes after which it is present in 
plasma, the subendothelial space, and platelets. Although EC-derived VWF, and in particular 
plasma VWF, and platelet-derived VWF are products from the same gene, a number of 
structural and functional differences have been described.97 First, Williams et al. described 
differences in the capacity to support platelet-vessel wall interactions as platelet VWF binds 
more efficiently to GPIIb/IIIa and heparin, whereas it is less capable of binding to GPIb in 
comparison with plasma VWF.98 Second, analysis of the carbohydrate composition revealed 
substantial posttranslational differences. Platelet-derived VWF exists as a distinct glycoform, 
with different N- and O-linked glycosylation patterns, reduced sialic acid and galactose 
content, and absent expression of AB blood group determinants compared to plasma 
VWF.98,99 This divergent glycosylation profile renders platelet-derived VWF more resistant 
to proteolysis by ADAMTS13100,101 and may also mediate the differences in functional 
properties98. A third important difference between platelet-derived VWF and plasma VWF is 
the difference in multimeric organization. Whereas VWF in plasma is distributed as a range 
of multimers, VWF in platelets is enriched in hemostatically active multimers.102-104 
Altogether, these differences support the idea that VWF function is determined in part by its 
compartimentalization. Therefore, it is of interest to unravel the relative contribution of EC-
derived VWF, in particular plasma VWF, and platelet-derived VWF to hemostasis. To date, 
research groups have already used various animal models for VWD to gain better insights 
into the compartimental role of VWF. These animal models include pigs105, dogs106, and 
genetically modified mice107. Similar to human type 3 VWD, no VWF is detectable in 
plasma, platelets, and ECs of these VWD animals. In addition, VWD animals have low levels 
of circulating FVIII and exhibit prolonged bleeding times upon experimental injury. 
Since 10-20% of the total VWF content is present in platelets and very little is thought to be 
released in a constitutive manner, it is generally believed that EC-derived, and in particular 
plasma VWF, plays a major role in hemostasis. Evidence for this role stems from 
experiments of crossed bone marrow transplantations (BMT) carried out in normal and VWD 
pigs. In normal animals transplanted with VWD bone marrow that produced EC-derived 
VWF but lack platelet VWF, the bleeding time was partially corrected.108 In line with these 
observations, VWD pigs or VWD dogs in which plasma VWF was reconstituted by means of 
infusion of VWF concentrate also showed, respectively, partial or full correction of the 
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bleeding phenotype.109,110 In addition, more recent data obtained in mice also point towards a 
crucial role of EC-derived VWF, and in particular plasma VWF, in hemostasis. 
Transplantation of VWD bone marrow in normal mice or restoration of plasma VWF via 
hydrodynamic injection of VWF-expressing plasmid DNA in VWF deficient mice resulted in 
normal bleeding times upon experimental injury.96,111 All together, these data suggest that 
plasma VWF is necessary although not always sufficient to completely correct the bleeding 
phenotype. 
Indeed, there is a vast body of evidence suggesting a role of platelet-derived VWF in primary 
hemostasis. For example, by performing in vitro perfusion studies, it has been shown that 
when normal platelets are resuspended in VWD plasma, platelet deposition on collagen was 
significantly higher than when VWD platelets are resuspended in VWD plasma.111,112 
Additional evidence is derived from crossed BMT carried out in normal and VWD pigs or 
VWD mice demonstrating that the bleeding time in some, but not all, chimeric animals that 
have platelet VWF but lack EC-derived VWF was partially corrected.110,111,113 These data are 
consistent with the slightly increased bleeding time that was observed in chimeric pigs 
expressing only EC-derived VWF upon experimental injury.108 Interestingly, clinical 
observations from type 1 VWD patients further contribute to the idea that platelet VWF is 
necessary for normal hemostasis. Whereas type 1 VWD patients with normal platelet VWF 
levels have almost normal bleeding times, prolonged bleeding times are found in patients 
with low platelet VWF.114 In addition, not only in VWD patients, but also in healthy 
individuals an inverse relationship between platelet VWF and bleeding time has been 
demonstrated indicating that platelet VWF is major determinant of primary hemostasis. 
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1.3. ADAMTS13 
In normal circulation, the size, and hence hemostatic activity, of newly secreted VWF or 
VWF free in circulation is modulated by the VWF-cleaving protease called ADAMTS13.  
 
1.3.1. Biosynthesis and secretion 
The ADAMTS13 gene is located on chromosome 9 and spans 29 exons encompassing 
approximately 37 kb.115 The transcript of full-length ADAMTS13 is approximately 5 kb and 
encodes a 1427 AA protein. ADAMTS13 is primarily synthesized and released from hepatic 
stellate cells that reside in the interstitial area of the liver.116,117 Synthesis of ADAMTS13 has 
also been observed in vascular ECs.118,119 Although ECs only produce trace amounts of 
ADAMTS13 in vitro, the constitutive release from these cells may be an important source of 
circulating plasma ADAMTS13 considering their vast number throughout the vasculature. In 
addition, variable expression of ADAMTS13 has been found in megakaryocytes and 
platelets120,121, glomerular podocytes122, and glial cells123. It is secreted into the circulation as 
an active, glycosylated multidomain protease that is divided into an N- and a C-terminal part 
(Figure 9).124  
 
1.3.2. Structure-function relationship 
Similar to other proteases belonging to the ADAMTS family, the N-terminal part consists of 
a metalloprotease (M) domain, a disintegrin-like (D) domain, the first thrombospondin type 1 
repeat (T), a cysteine-rich (C) domain, and a spacer (S) domain (MDTCS part). The C-
terminal regions are more variable within the ADAMTS family. In case of ADAMTS13, the 
C-terminal part comprises 7 additional thrombospondin type 1 repeats (T2-T8) and 2 
Complement component C1r/C1s, Urinary epidermal growth factor and Bone morphogenetic 
protein-1 (CUB) domains (T2-C2 part) (Figure 9). 
Plasma ADAMTS13 circulates as a constitutive active enzyme that binds and cleaves the 
Tyr1605-Met1606 bond within the A2 domain of VWF thereby regulating the size of VWF 
multimers in circulation. This cleavage, however, is the result of a multistep process in which 
both N- and C-terminal portions are involved: Whereas the N-terminus contributes to the 
recognition and productive cleavage of VWF, the C-terminus is involved in initial docking to 
VWF and the regulation of ADAMTS13 activity. 
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Figure 9:	 Domain structure of ADAMTS13. Full-length human ADAMTS13 consists of a 
metalloprotease (M) domain, a disintegrin-like (D) domain, the first thrombospondin type-1 repeat 
(T1), a cysteine-rich (C) domain, a spacer (S) domain, 7 additional thrombospondin type-1 repeats 
(T2-T8), and 2 Complement component C1r/C1s, Urinary epidermal growth factor and Bone 
morphogenetic protein-1 (CUB) domains. The M, D, T, C, and S domains are part of the amino (N)-
terminal portion of ADAMTS13, whereas T2-T8 and the 2 CUB domains belong to the carboxyl (C)-
terminal portion.	
 
1.3.2.1. The amino-terminal portion of ADAMTS13  
The M domain contains the proteolytic site that cleaves the Tyr1605-Met1606 bond in the VWF 
A2 domain. The M domain is characterised by the presence of zinc- and calcium-binding 
sequences that ensure the enzymatic activity and structural integrity of the catalytic site.125 
The M domain alone, however, has little or no specific catalytic activity towards VWF 
substrates.126,127 Kinetic studies using recombinant ADAMTS13 proteins revealed that the 
addition of other non-catalytic domains within the N-terminal portion of ADAMTS13 
increases the cleavage specificity and efficiency.126,127 It is currently known that VWF-
binding exosites within the DTCS-region of ADAMTS13 work in concert and extensively 
interact with exosites in the A2 domain of VWF thereby positioning the Tyr1605-Met1606 bond 
into the cleavage cleft (Figure 10).128 Despite the coherent actions of the proximal domains, 
ADAMTS13-mediated cleavage only occurs when the VWF A2 domain is unfolded. In 
contrast with globular VWF in which the ADAMTS13-cleavage site is shielded and highly 
resistant to proteolysis, shear stress-induced unfolding of the A2 domain exposes the Tyr1605-
Met1606 bond. Subsequently, further unravelling exposes new regions within the C-terminal 
region of the VWF A2 domain that are engaged by complementary exosites present in the 
DTCS-region of ADAMTS13.129-131 Finally, the scissile bond is docked into subsites of the 
M domain of ADAMTS13 and positioned for cleavage.132 
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Figure 10: VWF-ADAMTS13 exosite interactions. (A) The secondary structure of the folded and 
unfolded VWF A2 domain. In absence of shear, the ADAMTS13-cleavage site (Y1605-M1606) is 
buried and resistant to proteolysis. When shear stress is applied, the A2 domain unfolds and 
subsequently exposes both the scissile bond and exosite-binding regions. (B) VWF-MDTCS binding 
model. The surface of the amino-terminal portion, MDTCS, is shown in grey. Zinc ions, shown in 
yellow, are bound in the catalytic cleft that is indicated by a yellow dotted ellipsoid. The red dotted 
ellipsoids represent the exosites within MDTCS that engage complementary binding sites in the VWF 
A2 domain that is indicated as a green dotted line. Figure is adapted from Akiyama et al.129 
 
1.3.2.2. The carboxyl-terminal portion of ADAMTS13 
To date, much less is known about the role of T2-T8 and the 2 CUB domains. Whereas some 
studies have shown that T2-C2 is dispensable for protease function under both static126 and 
flow133 conditions, other studies have demonstrated that distinct functions may be attributed 
to these domains. In 2009, our group and others found that the C-terminal ADAMTS13 
domains T5-C2 are able to interact with the surface-exposed D4CK domain in soluble 
(globular) VWF.134,135 Because the nature of this interaction was different to the binding that 
is required for proteolysis, the authors suggested that these distal domains probably serve as a 
docking site for VWF and participate as the initial step in a multistep reaction finally leading 
to proteolysis. This idea is in line with the in vitro observations that both the thrombospondin 
type 1 repeats (T2-T8) and 2 CUB domains cooperate to recognize VWF under flow.133,136 
The physiological relevance was supported by observations made in murine studies. Banno et 
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al. demonstrated that thrombus growth in mice lacking the 2 C-terminal thrombospondin type 
1 repeats (T7-T8) and 2 CUB domains was accelerated compared to mice encoding full-
length ADAMTS13.137 In addition, our group showed that removal of the CUB domains in 
murine ADAMTS13 abolished the processing of VWF strings on stimulated endothelium.138 
These data suggest that the C-terminal portion of ADAMTS13 positively regulates VWF 
processing and subsequent thrombus formation under flow. 
In addition, recent evidence has demonstrated that the C-terminal domains of ADAMTS13, 
and in particular the CUB domains, may negatively regulate the function of ADAMTS13. 
Data from our and other groups revealed that the addition of specific monoclonal antibodies 
targeting the CUB domains to human ADAMTS13 enhanced its proteolytic activity and 
revealed cryptic epitopes within the S domain under static conditions.139-141 Based on these 
initial data, it is now proposed that ADAMTS13, similar to VWF, undergoes conformational 
changes regulating its activity. In a normal situation, the CUB domains interact with the 
central S domain, an interaction that results in the folding of ADAMTS13. In this globular, 
folded conformation, critical VWF A2 domain-binding exosites within the S domain are 
shielded and unable to support efficient binding to VWF. Interestingly, ADAMTS13 unfolds 
upon docking of the CUB domains to VWF D4CK. In this unfolded conformation, the 
exosites within the S domain are able to directly engage the complementary binding sites 
within VWF A2 thereby enhancing the cleavage process.   
 
In conclusion, these data demonstrate that ADAMTS13-mediated cleavage of VWF is a 
multi-step process (Figure 11A). This process is initiated by the docking of the C-terminal 
domains within ADAMTS13 to VWF D4CK. Whereas binding of the distal ADAMTS13 
domains to VWF D4CK in globular VWF is unproductive, binding to D4CK in elongated 
VWF triggers new interactions as the unfolded VWF A2 domain exposes high affinity 
binding sites for the proximal ADAMTS13 domains. High affinity binding of the 
ADAMTS13 S domain is followed by additional interactions between the remaining DTCS 
domains and exosites within VWF A2. Altogether, these interactions position the catalytic 
site of the M domain towards the scissile bond, Tyr1605-Met1606, which results in VWF 
proteolysis.  
 
CHAPTER 1 
 
 25 
 
Figure 11: ADAMTS13-mediated cleavage of VWF. (A) Schematic representation of the 
interaction between full-length ADAMTS13 and VWF leading to VWF proteolysis. 1) Docking of the 
distal ADAMTS13 domains to VWF D4CK enables binding of ADAMTS13 to VWF. 2) Unfolding 
of the VWF A2 domain facilitates binding of the ADAMTS13 spacer domain to the VWF A2 domain. 
3) High affinity binding of the spacer domain unfolds ADAMTS13 enabling the proximal 
ADAMTS13 domains within the DTCS region to interact with additional exosites within VWF A2. 
Following these interactions, the catalytic site of ADAMTS13 within the metalloprotease domain is 
positioned to engage and cleave the Tyr1605-Met1606 scissile bond. (B) Schematic representation of the 
location of ADAMTS13-mediated cleavage of VWF. 1) Upon exocytosis from Weibel-Palade bodies 
(WPBs), UL-VWF can be directly secreted in the circulation, whereas a portion can remain attached 
to the endothelium. Endothelial-bound VWF becomes stretched in response to shear forces in the 
circulation that facilitates cleavage by ADAMTS13. The resulting smaller multimers are released in 
CHAPTER 1 
 
 26 
circulation and adopt a globular, latent conformation. 2) Shear-induced unfolding of globular VWF 
may occur during passage through microvessels. Spontaneous unravelling of UL-VWF exposes the 
scissile bond that is cleaved by ADAMTS13 under normal conditions. Smaller multimers are less 
responsive to shear forces and maintain the globular conformation. 3) At sites of vascular injury, 
plasma VWF binds to exposed collagen, unfolds, and recruits platelets. Whereas ADAMTS13 is 
locally inactivated, it may process bound VWF multimers downstream of injury site thereby 
regulating platelet aggregation. Figures adapted from Crawley et al.142 
 
ADAMTS13 is constitutively active with no specific inhibitor found in plasma. The 
importance of conformational changes within the VWF A2 domain implies that the activity 
of ADAMTS13 is regulated at the substrate level. Indeed, ADAMTS13 becomes functionally 
relevant when shear stress induces VWF stretching, a situation that seems to occur at 3 
distinct locations in the circulation (Figure 11B): (I) when VWF is tethered to the endothelial 
surface upon secretion143, (II) when VWF circulates free in plasma144, or when VWF binds 
downstream of the site of injury142. Regardless of the location, the scissile bond and exosites 
are more easily exposed in the highly adhesive UL-VWF multimers due their increased 
responsiveness to shear stress. By cleaving UL-VWF when it is partially unfolded by shear 
stress, ADAMTS13 helps to maintain VWF in smaller, less reactive forms that experience 
less shear and adopt a quiescent, globular conformation. 
 
Regulating the VWF multimer size by ADAMTS13 is crucial for normal hemostasis. 
Increased susceptibility for ADAMTS13 cleavage results in the loss of circulating HMW 
VWF multimers and bleeding episodes (type 2A VWD; see section 1.2.4.1.), whereas lack of 
ADAMTS13 activity results in the persistence of circulating UL-VWF multimers and 
increases the risk for thrombotic events (see section 1.4). 
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1.4. THROMBOTIC THROMBOCYTOPENIC PURPURA 
Modulation of the VWF multimer size by ADAMTS13 is crucial in maintaining hemostasis. 
If left unchecked, thrombosis instead of hemostasis may occur. Thrombotic 
thrombocytopenic purpura (TTP) is a life-threatening disease caused by a deficiency in 
ADAMTS13 that is either the result of mutations in the ADAMTS13 gene (congenital or 
hereditary TTP) or the presence of anti-ADAMTS13 antibodies (acquired TTP). Severely 
deficient ADAMTS13 function results in the presence and persistence of highly adhesive 
UL-VWF multimers in circulation (Figure 12) which can unfold and expose cryptic platelet-
binding sites in the absence of vascular injury.145 The spontaneous tethering of platelets to 
unfolded circulating VWF leads to the formation of circulating platelet aggregates which in 
turn can occlude microvessels (Figure 13). Consequently, widespread microvascular 
thrombosis in various organs may lead to ischemic organ failure and ultimately death if left 
untreated. 
 
 
Figure 12: Presence of UL-VWF multimers in patients with a severe deficiency of ADAMTS13 
activity. The distribution of VWF multimers in plasma of normal individuals (NHP) and a patient 
with no ADAMTS13 activity (TTP) was analyzed by SDS-agarose gel electrophoresis. Whereas no 
UL-VWF multimers are found in NHP, UL-VWF multimers do appear in plasma when ADAMTS13 
activity is absent (TTP). The dotted line indicates the area of UL-VWF multimers. Adapted from 
Veyradier et al.146  
 
TTP is a rare thrombotic disorder with an estimated annual incidence of 6 cases per million 
per year in the UK.147 Based on the primary mechanism causing a deficiency in ADAMTS13 
activity, TTP can be clinically classified into 2 major forms, congenital or acquired TTP. 
 
CHAPTER 1 
 
 28 
 
Figure 13: Pathophysiology of TTP. Severe ADAMTS13 deficiency, either the result of mutations 
in the ADAMTS13 gene or of autoantibodies directed against the circulating protease, leads to the 
persistence of ultra large (UL-) VWF multimers at the endothelial surface or in circulation. In areas of 
high shear stress (such as in arterioles or capillaries) these highly adhesive molecules may unfold and 
spontaneously recruit platelets. In turn, the resulting circulating VWF-rich platelet aggregates may 
obstruct the microvasculature causing tissue ischemia and organ failure. 
 
1.4.1. Congenital TTP 
Congenital (or hereditary) TTP, also known as Upshaw-Schulman syndrome, is a rare 
recessively inherited disease that accounts for ≤5% of all TTP cases.115,148 To date, more than 
140 mutations distributed throughout the ADAMTS13 gene have been identified. The 
majority of these mutations are single amino acid missense substitutions while the remaining 
part include deletions, insertions, nonsense mutations, and intronic splice site mutations.149 
Whereas heterozygous carriers have half-normal ADAMTS13 activity in plasma (40-70% of 
normal values) and are generally asymptomatic, individuals with homozygous or compound 
heterozygous mutations have a severe ADAMTS13 deficiency (<10% of normal value) and 
most certainly develop TTP.150 Via site-directed mutagenesis and expression studies in vitro 
it has been demonstrated that ADAMTS13 mutations are associated with impaired synthesis, 
catalytic activity, or secretion.151,152 The genetic heterogeneity is reflected in the variable 
clinical presentation of congenital TTP patients in terms of disease onset and severity. This 
variability could at least be partly explained by the residual ADAMTS13 activity found in the 
patient’s plasma which is influenced by the ADAMTS13 genotype.153 However, it is generally 
accepted that additional factors besides ADAMTS13 mutations also contribute to the 
unpredictable nature of congenital TTP. Other genetic defects, such as mutations in 
complement factor H gene, have been suggested.154 On the other hand, 
environmental/external triggers are known to influence the phenotype as patients often 
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encounter a first bout of TTP in situations that are associated with VWF release and elevated 
VWF levels, such as pregnancy or infection.155-157 
 
1.4.2. Acquired TTP 
In acquired TTP, which accounts for the majority of the TTP cases (95%), a severe 
deficiency in ADAMTS13 function is caused by autoantibodies directed against the 
circulating protease.149 In most acquired TTP patients the antibody-mediated ADAMTS13 
deficiency is not associated with an underlying clinical condition (‘idiopathic’ TTP). Epitope 
analysis revealed that most TTP patients harbour type G immunoglobulins that target 
multiple domains of ADAMTS13.158 Antibodies against the N-terminal part of the protease 
are found in more than 90% of the acquired TTP patients, while antibodies directed against 
the C-terminal domains are present in 30-50% of the patients.149 Pathogenic autoantibodies 
can contribute to severe ADAMTS13 deficiency (<10% of normal activity) through direct 
inhibition of ADAMTS13. It has been shown that the majority of these inhibitory 
autoantibodies primarily target antigenic sites within the spacer domain, which plays a 
critical role in substrate recognition.131,159,160 Direct inhibition of ADAMTS13, however, is 
not the only pathogenic mechanism responsible for ADAMTS13 deficiency. Scheiflinger et 
al. reported a patient with confirmed TTP who presented with high titer anti-ADAMTS13 
antibodies that did not neutralize the protease activity.161 In a more recent cohort study 
Thomas et al. demonstrated that acquired TTP patients lacking detectable inhibitory 
antibodies often have very low ADAMTS13 antigen levels.160 These data suggest that 
antibody-mediated clearance of ADAMTS13 antigen is a major cause of loss of ADAMTS13 
activity in acquired TTP patients. 
 
1.4.3. Clinical presentation and diagnosis 
The onset of disease is usually acute, although flu-like symptoms may manifest during the 
preceding days. The clinical presentation is characterized by thrombocytopenia, 
microangiopathic hemolytic anemia, and widespread microvascular thrombosis with 
consequent clinical manifestations. Thrombocytopenia can be explained by the consumption 
and incorporation of platelets in VWF-rich microthrombi, while hemolytic anemia, 
characterized by the presence of schistocytes (fragmented red blood cells) in peripheral blood 
smears, is due to the mechanical rupture of RBCs in the obstructed microvasculature (Figure 
14). The widespread presence of thrombi in terminal arterioles and capillaries is associated 
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with tissue ischemia and organ injury.162,163 In most cases, this results in cerebral (e.g. 
confusion, seizures, and coma), renal (e.g. hematuria and proteinuria), and cardiac 
manifestations (e.g. congestive heart failure, infarction, and arrhythmias).164 After onset, the 
disease rapidly progresses and runs a fatal course as the majority of patients die when not 
properly treated. 
 
 
Figure 14: VWF-rich microthrombi and hemolytic anemia in acute TTP. (Left and middle panel) 
Immunohistopathology of TTP. Severe ADAMTS13 deficiency may lead to spontaneous recruitment 
of platelets by UL-VWF multimers resulting in the dissemination of VWF-rich (brown) microthrombi 
in arterioles and capillaries of multiple organs such as the heart (left) and brain (middle). (Right 
panel) Peripheral blood smear from a TTP patient showing numerous fragmented red blood cells, also 
known as schistocytes, which suggest the occurrence of haemolytic anemia. A few schistocytes are 
indicated with an arrow. Adapted from Tsai et al.163 (left and middle panel) and www.ezio.com.br 
(right panel) 
 
A definitive diagnosis based on the initial clinical assessment, however, is difficult as not all 
TTP patients present with these clinical features and clinical presentation may overlap with 
other thrombotic microangiopathies (TMA), such as hemolytic uremic syndrome and 
malignancy-associated TMA.165 Therefore, measuring the plasma ADAMTS13 activity is 
helpful to confirm clinical diagnosis.166,167 Although multiple methodologies exist, a 
fluorescent resonance energy transfer technique using a short 73 amino acid VWF peptide 
containing the ADAMTS13-cleavage site to detect cleavage is frequently performed in 
clinical laboratories.168,169 Whereas other TMAs are associated with normal or mildly reduced 
plasma ADAMTS13 activity, TTP is most often characterised by a severe ADAMTS13 
deficiency. Once low activities have been demonstrated, detection of anti-ADAMTS13 
autoantibodies is required to confirm the diagnosis of acquired TTP. If no autoantibodies are 
found, sequencing of the ADAMTS13 gene may confirm the suspicion of congenital TTP. 
Additional, routine testing includes blood films, liver function tests, and pregnancy testing.149 
CHAPTER 1 
 
 31 
1.4.4. Treatment 
 
1.4.4.1. Current treatment options 
Acute TTP episodes require prompt treatment in specialized centers. For more than 20 years, 
the use of plasma exchange (PEX) or plasma infusion has been crucial in the management of 
TTP episodes, reducing mortality rates from 90% to 10-20%.170,171 PEX not only replaces the 
deficient or inhibited ADAMTS13 by active ADAMTS13 from donor plasma, but also 
removes potential disease-causing factors such as autoantibodies or bacterial toxins from the 
circulation. In contrast, plasma infusion only replenishes ADAMTS13 activity in acquired 
TTP patient’s plasma. PEX is superior to plasma infusion for acquired TTP and should be 
initiated once a presumptive diagnosis is made.170 When the initiation of plasma exchange is 
delayed, plasma infusion can provide temporary benefit.172,173 The number of PEX required 
to achieve remission (i.e. normalization of platelet count) depends on the severity of initial 
disease or progression of the symptoms during admission. In general, patients with acquired 
TTP require a higher number of PEX and longer treatment to normalize platelet counts 
compared to congenital TTP patients. 
In patients with acquired TTP, immunosuppressive drugs are used as adjuvant therapy to 
PEX. Immunosuppressive agents tone down the immune response and suppress the 
production of new autoantibodies. Consistent use of corticosteroids in addition to PEX seems 
to further increase survival and to reduce the frequency of relapses, especially in patients with 
severe acquired ADAMTS13 deficiency.174 Recently, rituximab, a humanized anti-CD20 
monoclonal antibody, has been shown to be a safe and effective adjunct to PEX, especially in 
patients with refractory or relapsing TTP.174,175 Standard intravenous rituximab treatment 
(375 mg/m2 weekly for 4 weeks) results in B-cell depletion, reduced anti-ADAMTS13 
antibody titers and increased plasma ADAMTS13 activity in most patients.174 Early 
administration, preferably within the first 3 days, is associated with faster attainment of 
remission, fewer number of PEX, shorter hospitalization, and a reduced relapsing risk.176 
These benefits have stimulated the use of rituximab as prophylactic therapy in patients with a 
history of TTP and deficient ADAMTS13 activity in remission. Although preventive 
rituximab infusions maintained a sustained remission in these patients, concerns regarding 
overtreatment and increased susceptibility for infections are raised.177 Therefore, a 
risk/benefit ratio on an individual patient level has yet to be made. 
Patients with known congenital TTP usually respond well to plasma infusion when admitted 
to the hospital. Once in remission, prophylactic plasma infusions alone are generally 
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sufficient to prevent TTP relapses for many years.178 The frequency of prophylactic treatment 
is empirically determined, although residual plasma ADAMTS13 activity has been identified 
as a useful biomarker.153 Patients having low residual activity and/or suffering from frequent 
recurrences require intermittent plasma infusions every 3-4 weeks in order to prevent 
symptomatic TTP episodes, while patients with higher residual activity only require 
prophylaxis in context of eliciting triggers (e.g. pregnancy or infection).153 
 
1.4.4.2. Animal models for TTP 
Since the introduction of PEX in clinical practice, survival rates did not further increase 
during the last 20 years. In addition, safer and more accessible alternatives for PEX are also 
highly warranted. The use of animal models is indispensable to validate novel treatment 
strategies. During the last ten years, several animal models for both congenital and acquired 
TTP have been established.179 
 
Animal models for congenital TTP 
In 2005, two independent research groups generated ADAMTS13 deficient (Adamts13-/-) 
mice on a 129/Sv genetic background180 and a mixed C57BL/6J x 129X1/SvJ genetic 
background181 by disrupting the Adamts13 gene through the insertion of a neomycin 
resistance cassette. Despite the complete lack of ADAMTS13 activity and the accumulation 
of UL-VWF multimers in plasma, Adamts13-/- mice did not spontaneously develop 
TTP.180,181 Elevation of the plasma VWF antigen levels by backcrossing to the CASA/Rk 
genetic background (which is associated with 5-10 fold higher VWF levels182) into mixed 
C57BL/6J x 129X1/SvJ Adamts13-/- mice increased the frequency of TTP symptoms.181 
These observations indicated that the etiology of TTP cannot be explained by a defect in the 
Adamts13 gene alone and secondary triggers may promote pathological thrombus formation, 
which is in accordance with clinical observations in humans.183 
Given the need for a second hit, external triggers have been evaluated in Adamts13-/- mice. So 
far, administration of large amounts of exogenous rVWF (either human or murine 
VWF)184,185 or Escherichia coli-derived shigatoxin181, have been shown to successfully elicit 
TTP symptoms that resemble human TTP. With respect to the shigatoxin-induced TTP 
model, it has been demonstrated that EC activation and subsequent release of EC-derived 
VWF upon infusion of shigatoxin, are an absolute requirement to trigger TTP symptoms in 
this model.186,187 Although these models suggest that external triggers associated with 
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increased levels of circulating VWF are sufficient to induce TTP symptoms in Adamts13-/- 
mice, also other factors (e.g. genetic factors) appear to determine the TTP phenotype.181,186  
 
 
Figure 15: Clinical signs of acquired TTP in baboons (Papio Ursinus). Systemic inhibition of 
ADAMTS13 activity in subject animals was achieved following intravenous administration of 2 
boluses of the inhibitory anti-ADAMTS13 antibody, 3H9 (600 µg/kg), over the course of 2 days. 
Control animals were treated with a non-inhibitory anti-ADAMTS13 antibody, 5C11. (A) Severe 
thrombocytopenia was observed within 24 hours in subject animals whereas normal platelet counts 
were observed in control animals. (B) Microangiopathic hemolytic anemia was evidenced by the 
continuous increase in the number of schistocytes in peripheral blood smears of subject animals. (C) 
Widespread microvascular thrombosis was confirmed by histopathologic analysis demonstrating 
deposition of VWF- and platelet (CD61)-rich aggregates in various organs of subject animals. Figures 
adapted from Feys et al.188  
 
Animal models for acquired TTP 
To date, acquired TTP models have been established in mice185,189, rats190, and baboons188. In 
mice, two research groups achieved acquired ADAMTS13 deficiency following 
administration of cross-reacting human monoclonal anti-ADAMTS13 antibody fragments 
derived from acquired TTP patients.185,189 In rats and baboons, our group employed 
polyclonal goat anti-ADAMTS13 antibodies190 or murine monoclonal antibodies188, 
respectively, to inhibit ADAMTS13 activity. Whereas full inhibition of ADAMTS13 in non-
CHAPTER 1 
 
 34 
human primates resulted in symptoms that were representative for the early stages of 
acquired TTP188 (Figure 15), no TTP symptoms were observed when an acquired deficiency 
was induced in rodents as observed for Adamts13-/- mice185,189,190. In rats and mice, the 
administration of an additional trigger such as rVWF or shigatoxin was needed to elicit TTP 
symptoms in a dose-dependent manner. 
 
1.4.4.3. Future treatment options 
In patients that still die, the formation of VWF-rich thrombi is probably disrupted not fast 
enough. Therefore, new agents that interfere with the binding of VWF to platelets or that 
process the highly adhesive UL-VWF multimers (thereby restoring the normal VWF 
multimer distribution) are being explored: 
 
Blocking the VWF-GPIb interaction 
One novel strategy encompasses the blockade of the VWF-GPIb interaction, thereby 
preventing the formation of VWF-rich platelet thrombi. By using agents that target the VWF 
A1 domain, our group and others provided proof of principle for this approach in the non-
human primate model for acquired TTP.191-193 Recently, a single-variable domain 
immunoglobulin (nanobody), called Caplacizumab, was tested in a multicentre phase II 
randomized, placebo-controlled trial, in which acquired TTP patients were given 
Caplacizumab as an adjunct to daily PEX.194,195 Caplacizumab-treated patients achieved 
faster platelet normalization and developed less recurrent thrombocytopenia that required 
initiation of PEX <30 days after the last PEX therapy.195 Interestingly, only minor bleeding 
episodes and manageable side effects were observed in patients in the active drug treatment 
arm. These data, together with data obtained from a less comprehensive clinical trial196, 
suggest that by preventing the interaction between VWF and platelets, the standard of care of 
TTP patients might improve. 
 
Recombinant ADAMTS13 
Another promising future therapy is the use of recombinant ADAMTS13 (rADAMTS13) as a 
safer and simpler substitute for human plasma. Preclinical animal studies have demonstrated 
that administration of rADAMTS13 before or after induction of TTP in Adamts13-/-	 mice 
reduced the incidence of severe thrombocytopenia and organ damage.184 A phase I clinical 
trial was recently initiated to assess rADAMTS13 in the treatment and prophylaxis of 
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congenital TTP. Although the approach seems more applicable to congenital TTP patients, 
our group and others have shown that rADAMTS13 is able to restore ADAMTS13 activity in 
the context of acquired TTP.190,197 An elegant way to circumvent autoantibody inhibition of 
rADAMTS13 may be the administration of autoantibody-resistant ADAMTS13 variants159 or 
platelet-delivered rADAMTS13185.  
 
Reduction of the VWF multimer size 
Chen and colleagues demonstrated that VWF multimer size can be pharmacologically 
decreased with N-acetylcysteine (NAC), a drug that has long been used to treat 
acetaminophen toxicity and chronic obstructive lung disease.198 Since administration of NAC 
in Adamts13-/-	 mice reduced the size of circulating UL-VWF multimers by reducing 
intrachain disulfide bonds, it is believed that NAC can reduce the size of UL-VWF multimers 
in TTP patients.198 Human case reports on TTP treatment with NAC however demonstrated 
varying outcomes and a clinical trial is currently ongoing to test its efficacy under controlled 
conditions.199-202 Another new treatment strategy that recently gained interest is the activation 
of plasminogen using thrombolytic agents. Plasmin indeed was shown to cleave VWF 
resulting in a reduction of TTP symptoms in a mouse model of congenital TTP.203 
 
1.4.5. Gene replacement therapy 
Survivors of an acute TTP episode suffer from various comorbidities, such as cognitive 
impairment and depression, and experience a decreased quality of life, suggesting that TTP 
may be more of a chronic disorder.204,205 These long-term observations emphasize the need 
for prophylactic treatment. Taking the welfare of the patients into account, safer, more 
simple, and efficient alternatives to prophylactic plasma infusions are of great importance.  
In case of congenital TTP, the therapeutic delivery of a functional copy of the ADAMTS13 
gene would ideally cure the underlying genetic defect and offer lifelong protection from TTP. 
Congenital ADAMTS13 deficiency is a good candidate for gene therapy as it is a 
monogenetic disease. Moreover, ADAMTS13 is secreted in the circulation; hence, cell- or 
tissue-specific targeting is not required. However, a prerequisite for successful gene therapy 
is the safe and effective delivery of the therapeutic gene. Current gene delivery vehicles, 
called vectors, are divided in 2 classes: viral and non-viral vectors. 
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1.4.5.1. Viral vector-mediated gene therapy 
Viruses have evolved to efficiently deliver their genomes to mammalian cells. By replacing 
the viral genes that are responsible for replication and retaining signal sequences that are 
essential for packaging, viruses were transformed into non-replicative gene delivery vehicles. 
To date, these modified viruses have been used in approximately 70% of the gene therapy 
clinical trials so far. Gammaretroviral, lentiviral, adenoviral, and adeno-associated viral 
(AAV) vectors are the most widely used viral vectors in current gene therapy studies.  
 
In case of congenital TTP, different viral vector-based gene therapeutic approaches have 
already been tested in Adamts13-/- mice. Lentiviral vectors encoding full-length ADAMTS13 
have been used in 2 different gene transfer strategies. Laje et al. explored an ex vivo gene 
therapy in the setting of autologous hematopoietic progenitor cell transplantation206, while 
Niiya et al. investigated the feasibility of in utero gene transfer207. Both strategies resulted in 
the expression and secretion of transgene enzyme into the murine plasma of Adamts13-/- mice 
for several months. Interestingly, the secreted ADAMTS13 was able to normalize the 
abnormal VWF multimer distribution indicating that newly released UL-VWF was 
adequately processed in vivo.206,207 An adenoviral gene transfer strategy has also been tested 
in Adamts13-/- mice.208 Systemic administration of an adenoviral vector encoding full-length 
ADAMTS13 efficiently transduced liver, kidney, lung, heart, and spleen, resulting in the 
secretion of ADAMTS13 into plasma. Transgene ADAMTS13 that was released into the 
blood stream was biologically active as it was able to reduce the formation of platelet thrombi 
on immobilized collagen under flow.208 The occurrence of hepatotoxicity in response to 
adenoviral injection and the formation of anti-adenoviral and inhibitory anti-ADAMTS13 
antibodies were a major drawback in this study.208 Since the use of lentiviral and adenoviral 
vectors is associated with several safety concerns, Jin and colleagues tested the efficacy of an 
AAV8-mediated gene therapeutic approach.209 Because of the low packaging capacity of 
AAV vectors (<4.3kb), the authors were forced to express the truncated murine ADAMTS13 
variant MDTCS (truncated at the spacer domain). Intravenous infusion of ≥2.6 X 1011 vector 
genomes per kilogram resulted in therapeutic activity levels that were sufficient to reduce 
circulating UL-VWF in Adamts13-/- mice.209 Moreover, stable transgene expression of this 
ADAMTS13 variant prevented the development of severe thrombocytopenia and reduced 
mortality when treated mice were challenged with shigatoxin 2 weeks after gene transfer.209 
Whereas no data about the protective role in TTP were available in both lentiviral and 
adenoviral vector-mediated gene therapy studies, the findings of Jin et al. provide proof-of-
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concept to support the development of a gene-therapeutic approach for the treatment of 
hereditary TTP. 
 
Since the beginning of gene therapy clinical trials in 1990, viral vectors have substantially 
contributed to this emerging field. Moreover, viral vector-mediated therapies are progressing 
from investigational agents to approved products. In 2012, a muscle-directed AAV1-based 
gene therapy for the treatment of a rare form of familial dyslipidaemia (also known as 
Glybera®) was the first gene therapy to be commercially approved in Europe.210 Despite 
vigorous efforts to improve the production and safety of viral vectors, high costs211 and safety 
concerns, such as insertional mutagenesis212 and immunotoxicity213,214 remain major 
limitations. However, many of these limitations may be addressed by using non-viral gene 
therapy. 
 
1.4.5.2. Non-viral vector-mediated gene therapy  
Non-viral, plasmid-based gene therapy relies upon the use of a physical source or synthetic 
chemical compounds in order to force the cell to take up plasmid DNA (pDNA) carrying the 
therapeutic expression cassette. In contrast with viral vectors, non-viral delivery systems 
generally have an enhanced safety profile, are less immunogenic and easier to synthesize, and 
have the potential to carry a larger genetic cargo. Although the application of non-viral 
vectors in gene therapy clinical trials has increased during the last ten years, non-viral vectors 
were neglected for a long time due to their low delivery efficiency relative to viral vectors.  
A variety of physical and chemical methods have been developed to successfully deliver 
therapeutic genes in vivo. Physical methods are based on making transient pores in the cell 
membrane by applying mechanical, electrical215, hydrodynamic216,217, or ultrasonic energy218 
to facilitate the entrance of nucleic acids. Unfortunately, these techniques are less applicable 
in humans. Chemical (synthetic) delivery methods are more common and are based on the 
compaction of negatively charged nucleic acids by cationic liposomes or cationic polymers 
(such as polyethylenimine (PEI)).219 These nanoparticle carriers provide protection against 
degradation by endonucleases (improving its half-life) and improve cellular uptake and 
endosomal escape of pDNA. An important feature of both physical and chemical methods is 
the localisation of the delivered therapeutic gene in the nucleus of the target cell to allow 
access to the transcriptional machinery. Plasmids that are routinely used are non-integrating 
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and episomal which dramatically reduces the risk of insertional mutagenesis, making non-
viral, plasmid-based gene therapy a safer alternative to viral vectors. 
Transgene expression and production of the therapeutic protein are crucial for its function. In 
many cases, high level of transgene product is achieved within the first days after non-viral, 
plasmid-based gene transfer. Within a few weeks, however, expression falls to low levels 
even when vector DNA is still present within the target cell.220 The short duration of 
expression, due to the lack of integration and epigenetic responses (i.e. transcriptional 
silencing), is a major obstacle in terms of developing plasmid-based gene therapy for the 
treatment of human diseases. Interestingly, this problem can be overcome by the use of 
transposable elements, a technology that combines the advantages of integrating viral vectors 
(i.e. prolonged expression) with those of non-viral delivery systems (i.e. lower 
immunogenicity, enhanced safety profile, and reduced costs). 
 
1.4.5.3. The ‘Sleeping Beauty’ transposon system 
Transposable elements or transposons are discrete DNA sequences with the ability to jump 
from one location within the genome to another (also known as ‘jumping genes’). Although it 
is estimated that transposons make up approximately 45% of the human genome221,222, these 
were originally dismissed as ‘junk’ or useless DNA. However, it is now generally believed 
that transposons might carry out some biological function, most likely a regulatory function, 
and contribute to genetic diversity.223  
DNA transposons are a particular class of transposable elements that constitutes 2-3% of the 
human genome. DNA transposons can move on their own in a process called transposition; 
these autonomous transposable elements can excise themselves from the genome, move as 
DNA, and insert themselves into new genomic sites by means of a so-called ‘cut-and-paste’ 
mechanism. DNA transposons exist as single units containing the transposase gene flanked 
by terminal inverted repeats (TIRs) carrying the transposase binding sites (Figure 16A). 
Although these elements were active during primate evolution, they are currently no longer 
active in the human genome due to the accumulation of several mutations.222  
Researchers have found that DNA transposons can been converted into a bi-component gene 
delivery system: by placing a gene of interest between the TIRs and supplying a source of 
active transposase in trans, virtually any DNA sequence could be transferred (Figure 16B). 
Unfortunately, many transposons are non-functional outside their hosts, making the use of 
invertebrate transposons systems in vertebrates not efficient.224 Interestingly, in 1997, Ivics 
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and co-workers awakened an active transposase gene from a long evolutionary ‘sleep’, hence 
the name ‘Sleeping Beauty’ (SB).225 By reverse engineering defective copies of an ancient 
Tc1/mariner-like transposon found in salmonid fish, they engineered the first DNA-based 
transposon sequence that allowed transposition-mediated gene transfer in higher vertebrate 
species via a ‘cut-and-paste’ mechanism (Figure 16C).225 Indeed, this resurrected 
transposable element was shown to successfully integrate foreign genes into the 
chromosomes of cultured vertebrate cell lines, including murine and human cells.225 The first 
in vivo proof-of-principle for the use of SB in human gene therapy was provided by Yant et 
al. who reported somatic integration of naked DNA into mouse chromosomes and long-term 
expression of therapeutic serum levels of human FIX after hydrodynamic delivery of the SB 
system in FIX deficient mice.226 
Additional engineering of the transposase gene increased its activity, resulting in integration 
efficiencies 100-fold greater than that achieved by random integration227,228, and making SB 
an interesting non-viral gene transfer strategy in various animal models of monogenetic229-232 
and acquired human diseases233,234. In addition to SB, other transposon-based vectors, such as 
Frog Prince235 and piggyBac236, have been developed to deliver therapeutic genes in 
vertebrate cells. Although these systems transpose genes via a similar ‘cut-and-paste’ 
mechanism as SB, they differ in their efficiency of gene insertion, cargo capacity, integration 
site preference, and effects on chromosomal stability.237 
 
 
Figure 16: The ‘Sleeping Beauty’ transposon toolbox. (A) In nature, DNA transposons (e.g. Tc-
1/mariner-like transposable elements) consists of a single open reading frame encoding a transposase 
enzyme that is flanked by terminal inverted repeats (TIR; black arrow), which contain the transposase 
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binding sites. (B) Under laboratory conditions, DNA transposons can be used as a bi-component 
system to perform gene transfer. While one plasmid vector carries the gene of interest between the 
TIRs, the other component is a transposase expression plasmid, in which the black arrow represents 
the promoter driving its expression. (C) Co-delivery of both components results in genomic 
integration via a ‘cut-and-paste’ mechanism. Binding of the transposase results in the excision of the 
gene of interest from the donor plasmid and the subsequent integration in the genome of the host cell. 
Adapted from Ivics et al.238  
 
During the process of transposition, the gene of interest is excised from the delivered pDNA 
and integrated into a genomic location (Figure 16C). At the primary DNA sequence level, SB 
transposons display specificity in target site selection in that they exclusively target their 
integration into TA dinucleotides that are duplicated upon transposition.225 At genomic scale, 
insertion site analysis revealed that integration is fairly random. Whereas integration by 
retroviral vectors strongly favours active genes239,240, SB transposons have no or little 
preference for transcriptionally active genes240-242. Insertion that occurs in genes is 
predominantly located in introns.243 Moreover, the TIRs flanking the gene of interest do not 
have enhancer elements and therefore should be less likely to cause insertional activation of 
proto-oncogenes. 
Despite its favourable insertion site preference, however, some safety concerns with respect 
to clinical application need to be addressed. First, integration and continued expression of a 
gene encoding SB transposase could lead to remobilization of the inserted transposon (a 
process called ‘rehopping’), with risk of genotoxicity. A safer alternative would be the use of 
in vitro-transcribed mRNA as a transient source of transposase.244 Second, with any vector 
that integrates into chromosomes comes the potential risk of insertional mutagenesis. 
Strategies that target integration into genomic safe ‘harbours’ could prevent these hazardous 
effects. Such strategies include the fusion of SB transposase with a heterologous DNA-
binding domain that will tether the transposase to selected sites in the genome.241,245 
 
Delivery of the SB transposon system is of crucial importance since transposition is 
dependent on the efficiency of uptake of the introduced plasmids into the cell nuclei. The SB 
transposon system can be administered either ex vivo or in vivo.  
In ex vivo gene delivery, a selected cell population is derived from the host, treated, and then 
infused back into the same patient. SB vectors are frequently introduced into isolated cell 
populations by means of nucleofection, an electroporation-based technique that transfers 
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nucleic acids directly to the nucleus. In this way, SB-mediated transposition has already been 
demonstrated in human CD34+ hematopoietic progenitor cells228,246, primary T-cells247, and 
embryonic stem cells248. The feasibility and robustness of this procedure in terms of human 
application holds much promise.249  
Using in vivo gene delivery, the SB vectors are directly introduced into the organ or tissue 
where expression is desired. The most effective method for in vivo SB-mediated gene transfer 
is hydrodynamic injection (Figure 17).250 This gene transfer technique is well established in 
mice and involves the injection of a large volume of DNA/saline solution (equivalent to 10% 
of the body weight) through the tail vein within 5-8 seconds.216,217 The resulting 
hydrodynamic pressure expands the liver, enlarges the fenestrae of the endothelium, and 
forces invagination of the cellular membranes of hepatocytes allowing the uptake of DNA 
into about 10-40% of the hepatocytes.251,252 Although hydrodynamic gene delivery is very 
efficient in small animal models, systemic application in larger animal models such as dogs 
and pigs is impractical and unsafe. 
 
 
Figure 17:  Schematic representation of the mechanisms leading to liver-directed transgene 
expression following hydrodynamic tail vein injection in mice. (A) A large volume of DNA 
solution goes directly to the heart and increases the intravascular pressure in the inferior vena cava 
upon rapid tail vein injection. (B) The DNA solution stretches myocardial fibres beyond their optimal 
length for contraction thereby inducing cardiac congestion. (C) Cardiac congestion generates a 
backflow to the organs that are connected to the inferior vena cava, in which the liver absorbs most of 
the solution and expands. (D) The intra-hepatic pressure increases the permeability of cellular 
membranes of hepatocytes and forces the DNA solution out of the endothelium into these cells. 
Adapted from Kamimura et al.253  
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In large animal models direct infusion of pDNA in the liver or other specific organs is the 
preferred route. By combining image-guided catheter insertion with the newly developed 
computer-controlled injection devices, site-specific gene delivery has been performed in 
liver254,255 and skeletal muscle256 of pigs (Figure 18). While this procedure is considered a 
safe, reproducible, and viable approach for clinical gene therapy253,257, obtaining high levels 
of gene transfer and persistent gene expression remains challenging.258 In addition to 
hydrodynamic injection, alternative strategies for the delivery of SB vectors have been 
investigated. These strategies include the cell or tissue type-specific gene delivery of SB 
vectors using PEI-DNA conjugates259-261, nanocapsules262, and adenoviral hybrid-vector 
systems263. Up-scaling and further improving these systems may pave the way towards 
clinical applications. 
 
 
Figure 18: Schematic representation of regional gene delivery using image-guided, computer-
assisted hydrodynamic injection. A balloon catheter (with injector) is inserted into the jugular vein, 
passed through the inferior vena cava, and placed at one of the lobular hepatic veins (for liver-directed 
gene transfer) or femoral veins (for muscle-directed gene transfer). A small amount of phase contrast 
medium is injected to confirm site-specific insertion after which the balloon is inflated to block 
backflow of the injected DNA solution. The vascular pressure that is measured at the distal tip of the 
catheter is transmitted to a computer and serves as the start/stop signal for hydrodynamic injection. 
Depending on the desired level of intravascular pressure that one wants to achieve, the computer starts 
an electric motor-driven injector that self-adjusts the injection power and reproduces preloaded 
pressure-time curves that are installed into the computer prior to injection. Figure adapted from 
Kamimura et al.253  
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Due to its reduced immunogenicity, its close-to-random integration profile, its ability to 
mobilize DNA up to 10kb in length, and its large-scale, affordable manufacture compared 
with viral vectors, the SB transposon technology holds much promise. Indeed, the first 
human clinical application of the SB system was launched in 2008 in the United States.249 In 
these phase I trials, SB was used to incorporate a CD19-specific chimeric antigen receptor 
transcript into the genome of patient- or donor-derived T cells, rendering T-cells cytotoxic 
toward CD19+ B-lineage tumours.264 These genetically modified CD19-specific T cells were 
administered to patients with advanced-stage CD19+ B-cell malignancies in an adjuvant 
setting following autologous or allogeneic hematopoietic stem cell transplantation. The 
procedure was considered safe and feasible, as clinicians did not observe acute toxicity 
(cytokine storm) or increased rates of infection or graft-versus-host disease. Interestingly, 
both overall and progression free survival rates appeared improved indicating that the 
procedure is an effective approach to augment disease control and to maintain remission in 
patients at a high risk of relapse.264 More clinical trials involving CAR-T cells (e.g. 
NCT01492036, NCT02529813, and NCT01653717) to treat B-lymphoid malignancies are 
currently ongoing in the United States. In Europe, a SB transposon-based, targeted ex vivo 
gene therapy to treat age-related macular degeneration (TargetAMD; 
http://www.targetamd.eu/) is also moving toward clinical trials. The results obtained from 
these clinical trials are important to bring visibility to the clinical use of the SB transposon 
technology. 
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1.5. DISTURBED BALANCE BETWEEN VWF and ADAMTS13 
The accumulation of UL-VWF multimers due to absent or low ADAMTS activity is 
associated with enhanced VWF-GPIbα binding and an increased risk of developing 
widespread microvascular thrombosis, as described earlier (section 1.4.). However, it has 
become clear that a dysregulated balance between VWF and ADAMTS13 is not exclusively 
restricted to TMAs but may also contribute to the pathogenesis of other diseases. Indeed, an 
imbalance between an overwhelming VWF release and a reduced VWF-cleaving capacity is 
thought to play a causal role in a variety of other disorders, of which most are known to be 
associated with an increased thrombotic tendency.265,266 In this chapter we will focus on the 
clinical relevance of changes in the VWF/ADAMTS13 axis in ischemic stroke and malaria.  
 
1.5.1. Ischemic stroke 
Stroke is the fourth-leading cause of death and the leading cause of long-term rehabilitation 
in the Western world.267 Approximately 87% of all strokes are caused by a blood clot 
occluding a cerebral blood vessel, often the middle cerebral artery (MCA) or one of its side 
branches. Such occlusions impair blood flow in particular areas of the brain (i.e. ischemic 
stroke). The remaining 13% of strokes are the result of hemorrhagic events due to vessel 
rupture (i.e. hemorrhagic stroke).267 In ischemic stroke, urgent recanalization of the occluded 
blood vessel and restoration of the blood flow are considered important therapeutic steps in 
order to reduce morbidity and mortality. Rapid reperfusion can be achieved either via 
pharmacological thrombolysis using t-PA, or via endovascular thrombectomy (mechanical 
removal of the clot). Surprisingly, despite restoration of blood flow and reoxygenation, 
progressive stroke still develops in many patients, which has led to the concept of reperfusion 
injury. This phenomenon is a complex process that involves both thrombotic and 
inflammatory pathways, aggravating tissue injury that was produced by ischemia alone.268,269 
In recent years, clinical and preclinical evidence has emerged that support the crucial 
involvement of the VWF/ADAMTS13 axis in stroke-associated ischemia/reperfusion injury. 
 
1.5.1.1. VWF and ADAMTS13 in clinical stroke studies 
Several clinical cohort studies demonstrated that high VWF levels270-273 and/or low 
ADAMTS13 levels271,274,275 are associated with an increased risk of ischemic stroke. 
Although meta-analyses confirmed significant association276, it remained debatable whether 
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high VWF and/or low ADAMTS13 levels were a cause or consequence of stroke since levels 
can be biased by poststroke changes. Fortunately, more definite conclusions were drawn from 
prospective, longitudinal cohort studies among subjects free from cerebrovascular disease. 
These large population-based studies have identified high levels of VWF277-279 and low levels 
of ADAMTS13 activity280 as strong predictors of the risk of ischemic stroke. The association 
between high VWF levels and/or low ADAMTS13 activity and ischemic stroke is likely to be 
explained by less cleavage of an excess amount of HMW VWF multimers, i.e. the most 
thrombogenic forms, leading to a procoagulant state.  
 
1.5.1.2. VWF and ADAMTS13 in experimental stroke studies 
In parallel with clinical studies, the pathophysiologic involvement of the VWF/ADAMTS13 
axis has been extensively studied in murine ischemic stroke models mimicking transient 
occlusion of the MCA. The most frequently used mouse model is the so-called filament or 
suture model in which a silicon-coated nylon suture is advanced from the internal carotid 
artery to the origin of the MCA in order to occlude the blood vessel and induce tissue 
ischemia (Figure 19). The intra-luminal model is used to study permanent or transient 
ischemia by leaving the suture in place, or by withdrawing the filament at a fixed time point, 
respectively. In case of transient MCA occlusion (tMCAO), removal of the filament allows 
reperfusion to occur which initiates secondary infarct growth comprising the ipsilateral 
parietal neocortex as well as the basal ganglia within the first 24 hours.  
Our group and others have demonstrated the crucial role of VWF and ADAMTS13 in stroke 
in Vwf-/- and Adamts13-/- mice, respectively (Figure 20). Whereas absence of VWF protected 
mice from ischemic stroke281,282, lack of ADAMTS13 aggravated ischemic brain damage283. 
Indeed, one day after tMCAO, deficiency of VWF resulted in a functionally relevant 
reduction of the cerebral infarct size compared to WT controls (Figure 20A).281,282 In 
contrast, ADAMTS13 deficiency caused a progressive decline in post-ischemic cerebral 
blood flow that resulted in larger cerebral lesions and a worse clinical outcome (Figure 
20B).283 
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Figure 19: Transient middle cerebral artery occlusion. A silicon-coated filament is advanced from 
the internal carotid artery (ICA) to the origin of the middle cerebral artery (MCA) in mice. Occlusion 
of the MCA origin causes severe reduction of blood flow in the basal ganglia, and gradual reduction 
in blood flow in the cerebral cortex. Prolonged obstruction of the cerebral blood flow in the MCA 
territory causes irreversible damage (ischemic lesion, black) in the basal ganglia, i.e. the core, and 
reversible damage in the cortical area at risk, i.e. the area surrounding the core. Removal of the 
filament after a certain interval restores cerebral blood flow in previously hypoperfused regions 
resulting in the occurrence of thrombo-inflammatory processes, including secondary 
microthrombosis. This causes a reduction in blood flow, secondary ischemia, and infarct growth, a 
phenomenon also known as ‘reperfusion’ injury (solid line). Inhibition of secondary microthrombosis 
(dashed line), e.g. by blocking VWF-GPIbα interactions or by administration of recombinant 
ADAMTS13, reduces ischemic lesion size following transient MCA occlusion (tMCAO). Figures 
adapted from Lee et al.284 and Gauberti et al.285  
 
Additionally, indirect evidence for the involvement of the VWF/ADAMTS13 axis in 
transient ischemic stroke is provided by studies showing that blocking the interaction 
between VWF and its main ligand, platelet GPIbα286-288, or administration of recombinant 
ADAMTS13282,289 protected the brain from severe ischemia-reperfusion injury. Data from 
our and other groups have demonstrated that similar strategies may also promote lysis of 
already existing thrombi.290,291 Altogether, these experimental studies have led to the concept 
that initial VWF-mediated platelet attachment and activation plays an important role in stroke 
pathogenesis and that ADAMTS13 has a neuroprotective effect, probably by cleaving UL-
VWF multimers that are secreted from the endothelium by ischemia, and by cleaving VWF 
multimers on the surface of thrombi formed on ischemic ECs. 
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Although it is evident that pathological thrombus formation plays an important role in stroke, 
there is evidence indicating that also VWF-mediated inflammatory responses may contribute 
to ischemic brain damage. Following tMCAO, Khan et al. showed that the aggravated brain 
injury observed in Adamts13-/- mice was associated with an increased inflammatory cell 
infiltration in the damaged tissue compared with WT controls.292 Further experiments 
revealed that the enhanced inflammation was VWF-dependent since mice deficient in VWF 
or both VWF and ADAMTS13 exhibited an identical reduction in inflammatory cell 
infiltration compared to WT controls.292 These observations are in line with studies showing 
that VWF and GPIbα are involved in various inflammatory processes, such as leukocyte 
adhesion, rolling, and extravasation.293-295 
 
 
Figure 20: The pathophysiological relevance of the VWF/ADAMTS13 axis in ischemic stroke in 
mice. Effects of Vwf and Adamts13 gene deletion on infarct size following tMCAO in mice are 
shown. Transient cerebral ischemia was induced by (A) 60 or (B) 30 minutes occlusion of the right 
middle cerebral artery, followed by 23 or 23.5 hours of reperfusion, respectively. Infarct sizes were 
assessed by sectioning the brain in consecutive sections and staining these with 2,3,5-
triphenyltetrazolium chloride, an indicator that is used to differentiate between metabolically active 
and inactive tissue. Red areas represent vital brain tissue, whereas white areas represent infarcted 
brain tissue. (A) Deficiency of VWF protected mice from ischemic stroke, underlining the important 
pathophysiological role of VWF during ischemic stroke. (B) Lack of ADAMTS13 aggravated 
ischemic brain damage, demonstrating the neuroprotective effect of the VWF-cleaving protease in 
ischemic stroke. Figures adapted from (A) Kleinschnitz et al.281 and (B) Fujioka et al.283 
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In summary, accumulating evidence from both clinical and preclinical studies indicate that a 
disturbed balance between VWF and ADAMTS13 (i.e. elevated VWF levels/activity and 
reduced ADAMTS13 levels/activity) predisposes individuals to a higher risk of stroke and 
contributes to both the acute phase of cerebral blood vessel obstruction and the subsequent 
reperfusion phase after re-opening of the artery. Therefore, interfering with the 
VWF/ADAMTS13 axis could become a promising novel approach in the treatment of 
ischemic stroke. 
 
1.5.2. Malaria 
Malaria is the most important parasitic disease in humans. According to the annual World 
Malaria Report of the World Health Organization, an estimated 214 million people were 
clinically affected in 2015, and approximately 438 000 people died of the disease, most of 
whom are children in sub-Saharan Africa (World Malaria Report 2016, Geneva, World 
Health Organization 2016). Malaria is a protozoan disease caused by species of the genus 
Plasmodium and transmitted by female Anopheles mosquitoes (Figure 21). Five species are 
known to infect humans: P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi, of 
which P. falciparum is the most deadly one. Most infections usually result in a mild, 
uncomplicated febrile disease, characterized by intermittent episodes of fever and peaks of 
parasitemia, reflecting the ability of adaptive immunity to prevent disease. In non-immune 
individuals, however, complications may arise suddenly and cause severe, life-threatening 
malaria syndromes. In infants and young children life-threatening disease typically 
encompasses metabolic acidosis (leading to respiratory distress), cerebral malaria (CM) 
associated with coma, and severe malarial anemia. Primary infection in adults frequently 
involves other disturbances such as pulmonary edema, renal failure, and shock. Current 
antimalarial treatments, e.g. chloroquine and artemisinin derivatives, target the asexual blood 
stage of the infection thereby reducing parasite loads, disease symptoms and the risk of 
disease progression. Besides frontline artemisinin therapy, severe malaria necessitates 
intensive nursing and supportive care management. 
 
Although the global mortality rate due to malaria has decreased by 60% between 2000 and 
2015, it still remains high (10-20% in children). Moreover, increased mortality and morbidity 
due to the development of parasite resistance to chloroquine and artemisinin therapy has been 
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observed. Therefore, efforts are made to develop new fast acting antimalarial drugs and to 
investigate new adjuvant therapies to better manage the clinical manifestations of severe 
malarial disease. To achieve this, a better understanding of the pathogenesis of malaria-
associated manifestations is of great importance. 
 
 
Figure 21: Life cycle of the malaria parasite. The life cycle of the malaria parasite involves 2 hosts. 
Human infection starts with a blood meal of an infected female Anopheles mosquito inoculating 
sporozoites into the human host. Sporozoites infect liver cells and mature in schizonts which in turn 
rupture and release merozoites into the circulation. Merozoites invade RBCs and begin an asexual life 
cycle: merozoites develop into ring-stage throphozoites that mature in schizonts releasing new 
merozoites upon rupture. This cycle of invasion and rupture is repeated every 1-3 days (depending on 
the Plasmodium species) resulting in thousands of parasitized RBCs and leading to illness and 
malaria-associated complications. Some parasites differentiate into male and female gametocytes that 
are ingested by a feeding mosquito. In the mosquito, the parasite reproduces sexually resulting in the 
formation of new sporozoites. Picture adapted from White.296  
 
1.5.2.1. Pathogenesis 
It is generally believed that P. falciparum malaria-related syndromes arise from the 
intersection of 2 different processes, i.e. (I) the sequestration of infected red blood cells 
(iRBCs) among target organs followed by (II) a dysregulated inflammatory anti-parasitic 
immune response.297 
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(I) Site-specific sequestration of P. falciparum-iRBCs is caused by the interaction between a 
family of cell-surface proteins, known as P. falciparum erythrocyte membrane protein-1, and 
multiple receptors expressed on ECs, such as intercellular adhesion molecule-1, vascular cell-
adhesion molecule-1, thrombospondin, and CD36. While cytoadhesion of iRBCs is an 
important mechanism to evade clearance by the spleen, massive sequestration in different 
microvascular beds results in mechanical obstruction of the capillary blood flow, reduced 
perfusion, and decreased removal of waste products.298 Intense sequestration of iRBCs has 
been observed in capillaries and post-capillary venules of lungs and brains in patients who 
died from malaria-associated acute respiratory distress syndrome (MA-ARDS)299 or CM300-
302, respectively. In patients with severe falciparum malaria, the proportion of blocked 
capillaries is associated with disease severity.298 However, parasite sequestration occurs in 
every P. falciparum infection, even in patients with uncomplicated malaria, indicating that 
the mere presence of parasites in peripheral blood and tissues is not enough to attribute a 
specific syndrome or death solely to mechanical obstruction.  
(II) Besides mechanical obstruction of the capillary blood flow, a disproportional activation 
of pro-inflammatory immune mechanisms may contribute to clinical outcome as well.297,303 
Upon infection, both innate and adaptive immune mechanisms are required to clear the 
infection from the circulation. When this immune response is mounted early during infection 
and timely down-regulated, disease is absent or mild. An inefficient anti-parasitic response, 
however, favours excessive parasite replication, sequestration, and the release of parasite 
virulence factors (e.g hemozoin and glycophosphatidylinositol) into the blood, which may 
result in excessive endothelial activation and inflammation causing severe pathology (Figure 
22). Indeed, late-stage P. falciparum-iRBCs are known to activate inflammatory pathways in 
ECs in vitro304, while the released parasite virulence factors are known to bind receptors of 
the innate immune system and activate monocytes to secrete pro-inflammatory cytokines, 
such as tumor necrosis factor.305-307 Moreover, widespread endothelial activation and 
sequestration of immune cells in brain microvasculature are evident in patients with CM.  
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Figure 22: Pleiotropic effects on endothelium following P. falciparum infection. Malaria 
pathophysiology is complex and involves multiple balances that determine clinical outcome. Beyond 
mechanically obstructing microvessels, cytoadherence of infected RBCs initiates endothelial cell 
signalling pathways that promote adhesion, thrombosis, inflammation, and endothelial dysfunction, 
and impair vasoregulation. Figure adapted from Miller et al.308 
 
1.5.2.2. VWF and ADAMTS13 levels in clinical and experimental studies 
Recent findings have suggested that hematological abnormalities in terms of VWF and 
ADAMTS13 may play a role in malaria-associated pathology as well 309. A series of clinical 
studies have demonstrated that either severe falciparum or vivax malaria is associated with 
elevated levels of both VWF and VWFpp (a useful marker for acute EC activation) in 
children310-312 and adults313,314. For example, Phiri and co-workers showed that both plasma 
VWF and VWFpp levels upon admission were significantly higher in children with both 
cerebral and mild malaria when compared with the non-malarial control groups.312 Increased 
levels of VWF and VWFpp are already observed early after onset of the blood-stage 
infection.315 In addition, by using a nanobody that detects ‘active’ VWF (i.e. VWF that 
exposes the GPIbα platelet-binding domain)37, De Mast et al. found that increased levels of 
activated VWF were present in plasma of P. falciparum patients315, which corroborates the 
accumulation of UL-VWF multimers during malaria311,316. In line with these studies, a severe 
decrease in both ADAMTS13 antigen and activity levels has been identified in malaria-
infected patients.311,313,314,316 Whether these abnormalities constitute epiphenomena, or 
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whether they play direct roles in mediating the pathophysiology of the condition remains 
unclear. 
Independent observations suggest that elevated levels of VWF with enhanced GPIbα-binding 
activity, whether or not in combination with low ADAMTS13 activity, may play a direct role 
in malaria pathogenesis. First, plasma VWFpp and VWF levels were correlated with disease 
severity312, and both VWF and activated VWF levels were inversely correlated with platelet 
count315. These correlations support the idea that elevated levels of activated VWF may cause 
intravascular platelet adhesion and clumping resulting in thrombocytopenia (a common 
finding in malaria infection) and mechanical obstruction of blood flow in microvessels. 
Second, Bridges et al. demonstrated that mature P. falciparum-iRBCs were able to bind to 
platelet-decorated VWF strings on cultured ECs stimulated with histamine (Figure 23).317 
Further characterization of the binding revealed that pretreatment of the activated 
endothelium with rADAMTS13 or antibodies selectively blocking the VWF A1 domain 
dose-dependently decreased the number of iRBCs-bound VWF strings. These in vitro data 
support the hypothesis that the VWF/ADAMTS13 axis plays a role in the cytoadherence of 
iRBCs to vascular endothelium suggesting that VWF is not just a marker of malaria disease 
severity but instead actively contributes to malaria pathogenesis. Further investigation 
regarding its pathogenic involvement is highly warranted, preferably in vivo.  
 
 
Figure 23: Binding of P. falciparum-infected RBCs to platelet-decorated VWF strings. (A) 
Human umbilical vein endothelial cells were stimulated with histamine before successive additions of 
platelets and RBCs infected with fluorescently labelled P. falciparum throphozoites (indicated with 
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white triangle). RBCs containing the mature, adhesive form of the parasite were able to interact with 
platelet-decorated VWF strings (indicated with black arrow; IE (troph)) in a CD36-dependent matter. 
No binding was observed in the presence of uninfected RBCs (RBC) or RBCs infected with 
immature, non-adhesive throphozoites (IE (ring)). (B) Schematic representation of VWF-mediated 
sequestration of infected RBCs. Endothelial cell-derived VWF, bound to the surface of ECs, elongates 
in the direction of the flow and recruits platelets in a GPIbα-dependent manner. Specific erythrocyte 
membrane proteins that are expressed on the surface of P. falciparum-infected RBCs may bind the 
platelet surface receptor CD36 thereby establishing the sequestration of infected RBCs in vascular 
beds. Figures adapted from (A) Bridges et al.317 and (B) De Ceunynck et al.318  
 
The most common animal model to study the pathobiology of malaria is the mouse model. 
Various models have been developed to study lethal and non-lethal malaria, which usually 
involves the infection of inbred mouse strains with rodent-specific Plasmodium species: P. 
berghei, P. vinckei, P. chabaudi, and P. yoelii. The characteristics of both infection and 
disease differ in the four species, and for each of the species in various mouse strains.319 
Unfortunately, no single mouse model mimics all the various clinical manifestations of 
severe malaria in humans. Therefore, by combining each of the species for rodent malaria 
with different mouse strains, different malaria syndromes can be mimicked. For example, 
C57BL/6J mice infected with P. berghei ANKA exhibit neurological symptoms such as 
ataxia, convulsions, and/or paralysis, and typically die between days 6 to 8 post-infection, 
making it the most widely used model to study CM.320 On the other hand, infection of the 
same mouse strain with P. berghei NK65 is used to study lethal MA-ARDS, without 
occurrence of cerebral complications.321 To date, only one study has investigated the direct 
role of VWF in a mouse model of experimental CM.322 In this recent study, infection of 
C57BL/6J WT mice with P. berghei ANKA activated ECs resulting in increased plasma VWF 
levels, including the pathological UL-VWF multimers. To investigate whether VWF was 
directly involved in experimental CM pathogenesis, P. berghei ANKA infection was 
investigated in Vwf-/- mice. Interestingly, a prolonged survival of Vwf-/- mice was observed 
while parasitemia and platelet count were identical to controls, suggesting that VWF is an 
important regulator of malaria disease. The underlying mechanisms defining its role in 
disease pathology are not yet unravelled. 
 
In summary, clinical and preclinical studies indicate that malaria infection is associated with 
acute EC activation, the accumulation of highly adhesive UL-VWF multimers, and a 
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significant reduction in ADAMTS13. Although the question whether these alterations are the 
‘effect’ or ‘cause’ of decreased malaria resistance still requires further investigation, 
preclinical findings point towards a direct role of the VWF/ADAMTS13 axis in malaria 
pathogenesis. If true indeed, it will be of great importance to clarify the mechanisms linking 
these alterations and disease progression, and to explore new therapeutic strategies. 
Therefore, future studies using different mouse models for malaria are needed to provide 
more insight into these topics. 
 
The unifying pathophysiological mechanism linking the above-mentioned disorders 
(ischemic stroke and malaria) is a dysfunctional activation of ECs resulting in the release of 
substantial amounts of highly adhesive UL-VWF multimers that may compromise the 
microcirculation, especially in context of reduced ADAMTS13 activity. Whether VWF-
directed therapy can be translated into therapeutic practice and improve clinical outcome 
remains unclear and requires further investigation.  
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AIMS of the STUDY 
 
The general aim of this PhD thesis was to study different aspects of VWF and ADAMTS13 
in stroke, thrombotic thrombocytopenic purpura, and malaria. More specifically, we wanted 
(I) to gain more insight in the relative importance of plasma VWF and platelet-derived VWF 
in hemostatic and thrombotic processes, (II) to develop a non-viral gene therapy for 
congenital TTP, and (III) to unravel the contribution of the VWF/ADAMTS13 axis in 
malaria disease using a murine model of malaria-associated acute respiratory distress 
syndrome.  
 
AIM I: To gain more insight in the relative importance of plasma VWF and platelet-
derived VWF in hemostasis and thrombosis. 
VWF is a multimeric plasma glycoprotein that plays a crucial role in hemostasis. At sites of 
vascular injury, VWF acts as a bridge between the exposed subendothelium and the 
circulating platelets, thereby promoting the formation of a platelet plug that prevents 
excessive blood loss. VWF circulates in the blood either in plasma or in platelets. Even 
though plasma VWF and platelet-derived VWF are products of the same gene with a similar 
protein backbone, experimental studies have described a number of biochemical and in vitro 
functional differences. While it is generally assumed that plasma VWF is the major 
contributor in maintaining normal hemostasis, a limited number of preclinical and clinical 
studies have demonstrated a significant contribution of platelet VWF as well. Given the 
distinctive features of platelet VWF, and variable platelet VWF antigen and activity levels 
between VWD patients, it is important to elucidate and understand the biological activity of 
this specific pool of VWF. 
To reach this aim we will perform crossed bone marrow transplantations between Vwf-/- and 
WT mice, generating chimeric mice specifically lacking platelet VWF or with VWF only in 
platelets. Three to four weeks after transplantation, full chimerism will be evaluated by 
measuring the relative amount of VWF-positive platelets in blood using flow cytometry. To 
assess whether platelets constitutively secrete VWF in circulation, plasma VWF levels and 
FVIII activity levels will be determined using ELISA. To evaluate the role of platelet VWF 
in hemostasis, we will use the chimeric mice in a tail clip bleeding time assay. To address the 
question whether platelet VWF contributes to thrombotic processes, we will first perform a 
FeCl3-induced carotid artery thrombosis model and assess the time that is needed to form an 
occlusive thrombus. Second, we will explore the specific contribution of platelet VWF in a 
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murine model of ischemic stroke. Twenty-four hours after induction of transient cerebral 
ischemia, we will evaluate brain infarct sizes and measure fibrin(ogen) deposition in brain 
lysates using Western Blot followed by densitometric analysis. The results obtained from this 
study will further clarify the specific role of platelet VWF in hemostasis and shed new light 
on the specific activity of platelet VWF in different thrombotic processes, such as ischemic 
stroke.  
 
AIM II: To develop a non-viral gene therapeutic approach that offers long-term 
protection against TTP in mice. 
The platelet-binding capacity of VWF is determined by its multimeric size, ranging from low 
reactive dimers to hyper-reactive UL-VWF multimers. In normal circulation, the multimer 
size is regulated by the VWF-cleaving protease, ADAMTS13, which processes unusually 
large multimers into smaller, less reactive fragments. In case of a congenital deficiency in 
ADAMTS13, however, these highly adhesive UL-VWF multimers persist in circulation and 
may cause the life-threatening thrombotic disorder TTP (congenital TTP).  
Despite appropriate treatment, 10-20% of all patients still die following an acute TTP 
episode, while survivors may relapse. In congenital TTP patients, prophylactic plasma 
infusions are generally sufficient to prevent disease relapse. Lifelong plasma therapy, 
however, is stressful and has a negative impact on the patient’s quality of life. In addition, 
adverse events following the administration of plasma products have been observed. Novel 
therapeutic strategies that improve clinical outcome are highly warranted. Correction of the 
underlying genetic defect using gene therapy has been considered an appealing alternative 
that may offer long-term protection against TTP. 
To accomplish this aim we will use the ‘Sleeping Beauty’ transposon system (SB100X) to 
deliver and express a functional copy of the Adamts13 gene in ADAMTS13 knockout 
(Adamts13-/-) mice. In this study the SB100X transposon system will consist of a transposon 
plasmid containing a murine ADAMTS13 expression cassette (i.e. the murine Adamts13 gene 
under transcriptional control of a liver-specific promotor) and a transposase plasmid encoding 
a hyperactive version of the transposase. To obtain stable murine ADAMTS13 expression, 
both SB100X plasmids will be delivered by hydrodynamic injection. Injection of the single 
transposon plasmid will be used as a control. Transgene expression of murine ADAMTS13 in 
plasma will be measured using ELISA. Its proteolytic activity will be assessed by analysis of 
the plasma VWF multimer distribution using SDS agarose gel electrophoresis. Different 
groups of Adamts13-/- mice treated with SB100X will be challenged with human rVWF at 
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different time points to induce TTP symptoms. The TTP phenotype will be evaluated by 
measuring platelet counts, plasma lactate dehydrogenase levels, hemoglobin levels, and 
weight loss. Adamts13-/- mice hydrodynamically injected with saline solution and triggered 
with rVWF will be used as a control group for each different time point. 
The results obtained from this study will provide proof-of-concept supporting the 
development of an SB100X-mediated gene therapeutic approach as an alternative treatment 
option for congenital TTP in humans. 
 
AIM III: To unravel the role of the VWF/ADAMTS13 axis in a murine model of 
malaria-associated acute respiratory distress syndrome. 
An excess of (UL-) VWF along with a reduction in ADAMTS13 activity has been observed 
in various life-threatening conditions. Recent clinical findings have demonstrated that human 
malaria infection is associated with increased levels of hyper-reactive VWF multimers and 
marked ADAMTS13 inhibition. Although it has been proposed to use VWF solely as a 
marker for disease severity, it is reasonable to assume that a dysregulated balance between 
VWF and ADAMTS13 may contribute to malarial microangiopathic organ damage. To date, 
only a few preclinical studies that tried to dissect the direct role of VWF in malaria disease 
have supported this hypothesis. However, future studies using different animal models for 
experimental malaria are required to unravel the mechanisms linking alterations in the 
VWF/ADAMTS13 axis and malaria disease, and to explore novel therapeutic avenues. 
To reach this aim, we will induce malaria-associated acute respiratory distress syndrome 
(MA-ARDS) in WT mice on a C57BL/6J background via intraperitoneal injection of 
Plasmodium berghei NK65-infected red blood cells. To evaluate hemostatic alterations in 
terms of VWF and ADAMTS13, we will take blood samples at regular time points following 
infection. We will assess plasma VWF and ADAMTS13 levels by using ELISA. The 
distribution of plasma VWF multimers will be assessed using SDS agarose gel 
electrophoresis, while the activity of ADAMTS13 will be measured using the FRETS-
VWF73 assay. Daily Giemsa-stained blood smears will be prepared to measure peripheral 
blood parasitemia levels. To investigate the direct role of VWF, we will infect Vwf-/- mice 
and compare survival rates, peripheral parasitemia levels, platelet counts, and lung pathology 
with infected WT mice. Lung pathology will be assessed by measuring protein levels in the 
broncho-alveolar lavage fluid.  
The results obtained from this study will demonstrate whether changes in plasma VWF levels 
and ADAMTS13 activity in a murine model of MA-ARDS are in accordance with human 
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malaria infection or other murine malaria models. These results will also shed more light on 
the potential role of VWF as primary player in malaria pathogenesis and whether VWF-
directed therapy may offer novel therapeutic opportunities. 
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2.1. ABSTRACT 
 
Von Willebrand factor (VWF) is a key hemostatic protein synthesized in both endothelial 
cells and megakaryocytes. Megakaryocyte-derived VWF is stored in α-granules of platelets 
and is enriched in hyperactive ‘ultra-large’ VWF multimers. To elucidate the specific 
contribution of platelet VWF in hemostasis and thrombosis we performed crossed bone 
marrow transplantations between C57BL/6J and Vwf-/- mice to generate chimeric mice. 
Chimeric mice specifically lacking platelet VWF showed normal tail bleeding and carotid 
artery thrombosis, similar to wild type mice. Chimeric mice with VWF present only in 
platelets were not able to support normal thrombosis and hemostasis. However, using a 
mouse model of transient middle cerebral artery occlusion, we observed that cerebral infarct 
sizes and fibrin(ogen) deposition in chimeric mice with only platelet VWF were significantly 
increased compared with Vwf-/- mice (p < 0.01). Blocking of the platelet VWF-GPIb 
interaction abrogated this platelet VWF-mediated injury. These data suggest that whereas 
platelet-derived VWF does not play a crucial role in hemostasis and arterial thrombosis, it 
aggravates thrombo-inflammatory diseases such as stroke via a GPIb-dependent mechanism. 
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2.2. INTRODUCTION 
 
Von Willebrand factor (VWF) is an adhesive multimeric glycoprotein that is crucial for 
normal hemostasis. The best-known functions of VWF are facilitating platelet adhesion at 
sites of vascular injury and protecting clotting factor VIII against early degradation in the 
circulation. Consequently, absence or dysfunction of VWF results in bleeding symptoms as 
observed in patients with von Willebrand disease (VWD).1 Intriguingly, it has become clear 
that VWF is also implicated in various non-hemostatic processes, such as tumor metastasis, 
inflammation and angiogenesis.2 In particular, the pathophysiological role of VWF in 
ischemic stroke has recently gained increased attention.3-7 
Biosynthesis of VWF is restricted to endothelial cells (ECs) and megakaryocytes. Endothelial 
VWF is constitutively secreted into plasma and subendothelium or stored as ‘ultra-large’ 
VWF (UL-VWF) multimers in Weibel-Palade bodies. VWF produced in megakaryocytes 
ends up as UL-VWF in the α-granules of platelets. VWF present in endothelial and platelet 
storage organelles is secreted in a regulated process in response to stimulation by 
secretagogues. Platelets contain a significant amount of VWF, accounting for 15-20% of the 
total amount of circulating VWF. Interestingly, an increasing body of evidence shows that 
platelet VWF differs in various biochemical aspects from endothelial VWF.8 Williams et al. 
showed that, in comparison with plasma VWF, platelet VWF binds more efficiently to 
glycoprotein (GP)IIb/IIIa and heparin whereas it is less capable of binding to GPIb.9 
Divergent glycosylation profiles could explain these differences. Indeed, platelet VWF exists 
as a distinct glycoform, characterized by a significantly reduced degree of N-linked 
sialylation and by the absence of expression of AB blood group determinants.8,10 This 
differential glycosylation also renders platelet VWF more resistant to ADAMTS13 
proteolysis.10 With platelet VWF being enriched in UL-VWF, this resistance to ADAMTS13 
cleavage could become particularly relevant in settings where local accumulation of UL-
VWF is detrimental, like cerebral or myocardial ischemia/reperfusion injury.6,11,12 Given 
variable platelet VWF antigen and activity levels between individuals, it is important to 
understand the biological activity of this specific pool of VWF. Only a few studies have tried 
to dissect the different (patho)physiological roles of platelet and plasma VWF. Although 
experimental evidence shows that platelet VWF indeed contributes to initial platelet adhesion 
to collagen at sites of vascular injury13-15 in vivo data on the role of platelet VWF in 
thrombosis is limited. The role of VWF from platelets in ischemic stroke has never been 
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investigated. In the present study, we found that plasma VWF but not platelet VWF is needed 
for normal hemostasis and carotid artery thrombus formation whereas platelet VWF by itself 
is able to mediate ischemic brain injury via a GPIb-dependent mechanism, shedding new 
light on the role of platelet VWF in thrombo-inflammatory disease. 
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2.3. METHODS 
 
2.3.1. Mice 
Male and female Vwf-/- (VWF KO)16 and littermate wild-type (WT) C57BL/6J mice were 
used. All animal experiments were performed in accordance with protocols approved by the 
Institutional Animal Care and Use Committee of the KU Leuven (Belgium). 
 
2.3.2. Bone marrow transplantation 
Bone marrow cells were collected from the femur and tibia of six to ten week old donor mice. 
The mononuclear cell population (MNC) was isolated using ficoll gradient centrifugation 
(Ficoll-PaqueTM Premium 1.084; GE Healthcare, Waukesha, IL). Six to eight week old 
recipient VWF KO and WT mice were conditioned for cellular transplantation with a single 
lethal dose of 1100 cGy total body irradiation using a dual linear energy accelerator (Clinac 
DHX, 6MV; Varian Medical Systems, CA). Twenty-four hours after irradiation, 10 x 106 
MNC dissolved in 250µl sterile phosphate buffered saline (PBS) were infused by intravenous 
injection in irradiated recipient mice. Three to four weeks after transplantation full chimerism 
was confirmed via flow cytometry.  
 
2.3.3. Blood collection   
Animals were anesthetized using 5% isoflurane (Nicholas Piramal Limited, London, UK) in 
100% O2. Blood was collected by retro-orbital puncture on 0.5M EDTA (1 volume to 40 
volumes of blood) or 3.8% trisodium citrate (1 volume to 6 volumes of blood). EDTA-treated 
blood was used to determine platelet counts using the Hemavet 950FS Multi-species 
Hematology system (Drew Scientific, Oxford, CT). Platelet-rich plasma (PRP) was prepared 
from citrated blood by centrifugation at 325g for 5 minutes at room temperature (RT) and 
immediately used for flow cytometric analysis. Platelet-poor plasma (PPP) was prepared 
from citrated blood by centrifugation at 4300g for 6 minutes at 4°C and stored at -20°C for 
further analysis.  
 
2.3.4. Flow cytometry 
Three to four weeks after transplantation, citrated PRP was prepared from chimeric and 
control mice. After fixation with 2% formaldehyde in Hepes Tyrode (HT) buffer for 20 
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minutes, 10 x 106 platelets were washed with HT buffer containing 0.35% bovine serum 
albumin (BSA) (HT + 0.35% BSA). Resuspended platelets were permeabilized with 2.5% 
Triton X-100 in HT + 0.35% BSA for 5 minutes, rinsed with HT + 0.35% BSA and 
subsequently incubated for 15 minutes at RT with polyclonal anti-human VWF antibody 
(1:100; Dako, Glostrup, Denmark). Following a washing step, FITC-conjugated swine anti-
rabbit antibody (1:40; Dako) was added for 15 minutes at RT. After washing, platelets were 
fixated and stored at 4°C for further analysis. To quantify the relative amount of VWF-
positive platelets, a standard curve (0%, 25%, 50%, 75%, and 100% VWF-positive platelets) 
was made by combining PRP from WT and VWF KO mice. Results were expressed as 
percentage of WT values. To identify the platelet population, platelets were stained with rat 
anti-mouse CD41 antibody conjugated with PE (1:50; eBioscience, San Diego, CA). 
Expression of CD41 and intracellular platelet VWF was determined using a Beckman Coulter 
EPICS XL-MCL flow cytometer and analysed with the WinMDI 2.9 free FACS analysis 
software. 
 
2.3.5. VWF and FVIII analysis 
VWF antigen levels in plasma were determined using an in-house developed enzyme-linked 
immunosorbent assay (ELISA). VWF was captured by polyclonal anti-human VWF 
antibodies (1/1000; Dako) coated on a microtiter plate. After blocking the wells with 3% milk 
powder solution, test PPP, as well as plasma pool samples (in duplicate), were applied at 1:10 
to 1:640 dilutions. The captured VWF from plasma was detected using a mixture of in-house 
generated biotinylated anti-murine VWF monoclonal antibodies (15H2 and 2C12; 1 µg/ml) 
followed by incubation with horseradish peroxidase-labeled streptavidin (Roche, Mannheim, 
Germany). After addition of ortho-phenylenediamine (Sigma-Aldrich, St Louis, MO) the 
coloring reaction was stopped with 4 M H2SO4. The absorbance was determined at 490 nm. 
FVIII activity (FVIII:C) in mouse plasma was determined using the COATEST® SP4 FVIII 
(Chromogenix, Molndal, Sweden) according to the manufacturer’s protocol. Pooled plasma 
from 10 to 20 WT mice was used as a reference (100%) and results were expressed as 
percentage of WT values. 
  
2.3.6. Tail clip bleeding time assay 
Tail clip bleeding times were assessed as described.17 Five to six weeks after transplantation, 
mice were anesthetized with intraperitoneal injection of pentobarbital (60 mg/ml; Nembutal, 
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Ceva Santé Animale, Brussels, Belgium). Immediately after removing 5 mm of the tail tip 
using a surgical scalpel, the tail was immersed in 0.9% NaCl pre-warmed at 37°C. The time 
until blood loss ceased was monitored. The experiment was stopped when bleeding did not 
stop within 600 seconds. 
 
2.3.7. FeCl3-induced carotid artery thrombosis model 
Eight to ten weeks after transplantation, mice were anesthetized using 2.5% isoflurane in 
100% O2. The right carotid artery was subsequently exposed and a doppler flow probe 
(Transonic TS420 perivascular flow meter module; AD Instruments, Oxford, UK) was 
positioned around the artery to monitor blood flow via a laser doppler perfusion monitor 
(PeriFlux System 5000; Perimed AB, Järfälla-Stockholm, Sweden) coupled to a PowerLab 
8/35 data acquisition unit (AD Instruments) using LabChart v8.0.5 software (AD 
Instruments). Arterial thrombosis was induced by applying a piece of WhatmanTM filter paper 
(1 x 1 mm; GE Healthcare) saturated in 12% FeCl3 solution, for 3 minutes downstream of the 
flow probe. The time to occlusion was recorded. If the time to occlusion exceeded 50 
minutes, the experiment was ended. 
 
2.3.8. Transient middle cerebral artery occlusion 
Focal cerebral ischemia was induced 8 to 10 weeks after transplantation by 60 minutes 
transient middle cerebral artery occlusion (tMCAO) as described.5 Mice were anesthetized 
with 2.5% isoflurane in 100% O2. Following a midline skin incision in the neck, the proximal 
right common carotid artery and the external carotid artery were ligated, and a standardized 
silicon rubber-coated 6.0 nylon monofilament (6021; Doccol Corp., Redlands, CA) was 
advanced through the right internal carotid artery to occlude the origin of the right MCA. The 
intraluminal suture was left in situ for 60 minutes, after which the animals were re-
anesthetized and the occluding monofilament was withdrawn to allow reperfusion. This 
model typically results in a reduction of blood flow in the MCA territory by 90% during 
occlusion. Upon removal of the filament, blood flow is restored to approximately 80% of 
baseline.3,18 To block the VWF-GPIb interaction, 100 µg rat anti-mouse GPIbα (p0p/B) Fab19 
or rat IgG Fab control was injected intravenously 5 minutes after inducing reperfusion of the 
right middle cerebral artery. All stroke experiments were conducted according to the 
recommendations for research in experimental stroke studies and the current ARRIVE 
guidelines (http://www.nc3rs.org/ARRIVE). Animals were randomly assigned to the 
CHAPTER 2 
 
 92 
operators by independent persons not involved in data acquisition and analysis. Surgeries and 
evaluation of all readout parameters were performed while being blinded to the experimental 
groups. 
 
2.3.9. Determination of infarct size 
Assessment of infarct size was performed 24 hours after induction of cerebral ischemia as 
described.5 After sacrificing the animal, the brain was removed and sectioned in three 
consecutive 2 mm thick sections. Sections were stained with 2% 2,3,5-triphenyltetrazolium 
chloride (TTC; Sigma-Aldrich) in PBS and fixated. Pictures were taken and the infarct 
volume was calculated via planimetry (ImageJ Software, National Institutes of Health, USA). 
 
2.3.10. Western blot analysis 
Western blot for fibrin/fibrinogen was performed as previously described.5 Three TTC-
stained coronal brain sections of 1 mouse were separated in ipsi- and contralateral parts, 
pooled, and homogenized in RIPA buffer (25 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40) 
containing 0.1% sodium dodecylsulfate (SDS) and a proteinase inhibitor cocktail (cOmplete, 
EDTA-free; Roche Applied Science, Penzberg, Germany). After sonication of the samples 
for 10 seconds, tissue lysates were centrifuged at 15,000 g for 30 minutes at 4°C and 
supernatants were used for Bradford protein assay and subsequent Western blot analysis.  
For Western blot analysis, equal amounts (determined via Bradford protein assay) of the 
supernatant of ipsi- and contralateral homogenates were run on SDS-PAGE (10% running 
and 4% stacking gel) under reducing conditions and blotted to AmershamTM HybondTM C 
extra membranes (Amersham Bioscience, Piscataway, NJ). After blocking for 30 minutes 
with blocking buffer (5% non-fat dry milk, 50 mM Tris–HCl pH 7.5, 0.05% Tween-20) 
membranes were incubated with primary rat anti-fibrin(ogen) (1:500; Acris Antibodies 
GmbH, Herford, Germany) and murine anti-actin (1:500; Merck Millipore, Darmstadt, 
Germany) antibodies overnight at 4°C. After washing with tris buffered saline (50 mM Tris–
HCl pH 7.5, 0.05% Tween-20), membranes were incubated for 1 hour with horse radish 
peroxidase-conjugated goat anti-rabbit IgG (for fibrin(ogen); at a dilution of 1:5000) or goat 
anti-mouse IgG (for actin; at a dilution of 1:50 000) and were finally developed using 
Supersignal® West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL). The 
amount of fibrin(ogen) was quantified by densitometry from scanned (LAS-4000 Imager, 
Fujifilm, Tokyo, Japan) Western blots normalized to the actin signal, using ImageJ software. 
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The ratio of the normalized ipsilateral fibrin(ogen) band density relative to the normalized 
band density of contralateral fibrin(ogen) served as a measurement for relative fibrin 
deposition. 
 
2.3.11. Statistics 
Data are expressed as mean ± SEM. For statistical analysis, the Prism Version 6.0 software 
(GraphPad Software; La Jolla, CA) was used. Statistical analysis was conducted using one-
way ANOVA followed by the Tukey’s multiple comparison post hoc test to assess variance 
between FVIII:C levels, cerebral infarct sizes and fibrinogen deposition in different 
experimental groups. The Kruskal-Wallis test followed by Dunn’s multiple comparison post 
hoc test was used to compare plasma VWF antigen levels, tail clip bleeding times and arterial 
occlusion times. P values less than .05 were considered statistically significant. 
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2.4. RESULTS 
 
2.4.1. Generation of chimeric mice expressing VWF only in megakaryocytes or 
endothelial cells 
To determine the contribution of platelet VWF in hemostasis and thrombosis, we generated 
chimeric mice that produce VWF only in megakaryocytes or endothelial cells, respectively. 
MNCs were isolated from WT donor mice and transplanted into lethally irradiated VWF KO 
acceptor mice, resulting in chimeric mice with only platelet VWF (VWF PLT, Figure 1A). 
By transplanting VWF KO MNCs into WT acceptor mice, chimeric mice that specifically 
lack VWF in platelets were obtained (VWF EC, figure 1B). No difference in platelet count 
between chimeric mice and VWF KO and WT mice was observed (data not shown). To 
confirm successful transplantation, the relative amount of VWF-containing platelets was 
determined via flow cytometry (Figure 1C). As in VWF KO mice, no VWF-positive platelets 
were detected in VWF EC chimeric mice. On the other hand, the relative amount of VWF-
positive platelets in VWF PLT chimeric mice (98.44 ± 1.87%, n = 18) was similar to WT 
mice (99.94 ± 1.31%, n = 12) (Figure 1C).  
Absence of VWF-positive platelets in VWF EC chimeric mice confirms previous findings 
that endocytosis of VWF from plasma to platelet α-granules does not occur.15,19 As expected, 
platelets do not seem to release significant amounts of VWF into the circulation under normal 
conditions (Figure 1D). Indeed, normal plasma levels of VWF antigen were found in WT 
mice (99.9 ± 7.1%, n = 16) and VWF EC chimeric mice (106.3 ± 9.3%, n = 8) whereas no 
detectable levels of VWF were observed in plasma of VWF KO mice (n = 14) and most 
VWF PLT chimeric mice (n = 21). However, in some (7 out 21) VWF PLT chimeric mice 
trace amounts of VWF were observed, which could account for the slightly (but non-
significantly) increased FVIII activity (14.3 ± 1%, n = 16) compared to VWF KO mice (6.3 ± 
0.4%, n = 12) (Figure 1E). FVIII activity levels in the VWF EC chimeric mice (83.6 ± 3.1%, 
n = 10) were slightly decreased when compared to WT mice (100 ± 4.6%, n = 12) but 
remained in the normal range (Figure 1E). These data further confirm the notion that plasma 
VWF mainly originates from endothelial cells and that no platelet VWF is constitutively 
secreted into the circulation under normal circumstances.  
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Figure 1: Generation and characterization of chimeric mice that lack VWF in either 
megakaryocytes or endothelial cells. Mononuclear cells (MNC), isolated from donor WT (black) or 
VWF KO mice (white), were transplanted into lethally irradiated VWF KO or WT acceptor mice to 
generate (A) chimeric mice that have VWF only in platelets (VWF PLT) or (B) chimeric mice that 
specifically lack VWF in their platelets (VWF EC), respectively. (C) Relative amount of VWF-
positive platelets detected in WT (n = 17), VWF KO  (n = 12), VWF PLT chimeric (n = 18) and VWF 
EC chimeric (n = 14) mice. (D) VWF antigen levels (VWF:Ag) were determined in plasma samples 
from WT (n = 16), VWF KO (n =14), VWF PLT chimeric (n = 21), and VWF EC chimeric (n = 8) 
mice. (E) FVIII activity (FVIII:C) was determined in plasma samples from WT (n = 12), VWF KO (n 
=12), VWF PLT  chimeric (n = 16), and VWF EC chimeric (n = 10) mice. Results are expressed as 
percentage of WT values. ***, P < 0.001; ns, not statistically significant. 
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2.4.2. Plasma but not platelet VWF is the major determinant for normal 
hemostasis 
To unravel the specific role of platelet VWF in hemostasis, we used our chimeric mice in a 
tail clip bleeding assay. After removing 5 mm of the tip of the tail, the time needed to stop 
bleeding was recorded (Figure 2). As expected, most WT animals stopped bleeding within 3 
min (100.9 ± 18.7 s, n = 15) while VWF KO mice were not able to control the bleeding 
within 10 min (> 600 s, n = 14). Interestingly, most of the VWF PLT chimeric mice also bled 
longer than 10 min (528.2 ± 38.9 s, n = 16). Bleeding stopped spontaneously in 3 out of 16 
mice (19%). In chimeric mice that only produce endothelial VWF (VWF EC), bleeding times 
were comparable to those of WT mice (101.1 ± 17.3 s, n = 9). These data suggest that platelet 
VWF alone is not able to support normal hemostasis and that lack of platelet VWF does not 
affect bleeding in this model.  
 
 
Figure 2:	Plasma VWF is the major determinant to control bleeding in a tail clip bleeding assay. 
Five mm of the tail of WT (n = 15), VWF KO (n = 14), VWF PLT chimeric (n = 16), and VWF EC 
chimeric (n = 9) mice was removed. Subsequent tail bleeding in pre-warmed saline was monitored 
and the time needed to stop the bleeding was recorded. If bleeding did not end within the first 10 min, 
the experiment was ended with a recorded bleeding time of 600 s. ***, P < 0.001; ****, P < 0.0001; 
ns, not statistically significant.	
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2.4.3. Plasma but not platelet VWF regulates arterial thrombus formation 
Ex vivo flow chamber studies have previously shown that platelet-derived VWF plays a role 
in platelet adhesion to collagen.13-15 However, the exact role of platelet VWF in in vivo 
thrombus formation in mice has never been studied. To address this question, we performed a 
FeCl3-induced carotid artery thrombosis model (Figure 3). In WT mice, an occlusive 
thrombus was consistently formed within 10 min (9.2 ± 0.5 min, n = 8). In contrast, no 
occlusive thrombus was formed within the first 50 min in VWF KO mice (n = 5). 
Interestingly, arterial occlusion times in VWF EC chimeric mice (10.6 ± 0.4 min, n = 6) were 
similar to WT mice while no occlusive thrombi were formed in VWF PLT chimeric mice (n 
= 8). These results indicate that on the one hand platelet-derived VWF alone is not able to 
support normal thrombus formation in this model, and that on the other hand lack of VWF in 
platelets does not affect normal arterial thrombosis. 
 
 
Figure 3: (A) The carotid artery of WT (n = 8), VWF KO (n = 5), VWF PLT chimeric (n = 8), and 
VWF EC chimeric (n = 6) mice was exposed and a local injury was generated by topical application 
of a filter paper saturated with 12% FeCl3. Carotid artery blood flow was monitored and the time 
needed to form an occlusive thrombus was recorded. If no occlusion occurred within 50 min, the 
experiment was ended (time to occlusion of 50 min). (B) Carotid artery (CA) blood flow profiles of 
WT (black; n = 8), VWF KO (grey; n = 5), VWF PLT chimeric (dashed grey; n = 8), and VWF EC 
chimeric (dashed black; n = 6) mice were recorded using a laser doppler flow monitor. **, P < 0.01; 
***, P < 0.001; ns, not statistically significant. 
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2.4.4. Both endothelial cell- and platelet-derived VWF alone are able to mediate 
ischemic brain injury 
We and others showed that VWF plays a crucial role in ischemic stroke most probably by 
recruiting platelets and leukocytes in the reperfused tissue.3-5 Interestingly, absence of 
ADAMTS13 further aggravates ischemic brain damage, suggesting a specific contribution of 
UL-VWF multimers in the pathophysiology of stroke.4,12,20 Given the abundance of UL-VWF 
multimers in α-granules of platelets, we explored the specific contribution of platelet VWF in 
ischemic brain injury. After 60 minutes of focal cerebral ischemia, blood flow in the middle 
cerebral artery was restored to allow reperfusion of the ischemic territory. Twenty-four hours 
after induction of ischemia, cerebral infarction sizes were determined (Figure 4). In 
accordance with our previous studies,3,5 cerebral infarct sizes observed in VWF KO mice 
(34.4 ± 5.2 mm3, n = 12) were significantly reduced compared to WT mice (78.9 ± 10.2 mm3, 
n = 10). As expected, VWF EC chimeric mice developed infarcts that were similar in size to 
WT animals (76.7 ± 8.4 mm3, n = 9). Surprisingly however, VWF PLT chimeric mice 
expressing VWF only in platelets also showed infarct sizes that were similar to WT mice 
(79.6 ± 8.1 mm3, n = 16). Because cranial irradiation may induce persistent 
neuroinflammation in C57BL/6J mouse brain21,22 we tested lethally irradiated VWF KO mice 
transplanted with VWF KO MNCs to exclude any potential effect of irradiation on cerebral 
injury in our model (Figure 4C). In this separate set of experiments, infarct sizes were still 
small (18.71 ± 4.31 mm3, n = 7) and comparable with those observed in VWF KO mice 
(19.43 ± 5.49 mm3, n = 7). Hence, the irradiation procedure had no effect on infarct size in 
VWF KO animals. Together, these data show that the presence of either platelet VWF or 
plasma VWF alone is sufficient to cause VWF-mediated ischemic stroke injury.  
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Figure 4: Platelet-derived VWF alone mediates ischemic stroke injury. Transient focal cerebral 
ischemia was induced by 60 min occlusion of the right middle cerebral artery, followed by 23 hours 
of reperfusion in WT (n = 12), VWF KO (n = 10), VWF PLT chimeric (n = 16), and VWF EC 
chimeric (n = 9) mice. (A) Representative TTC staining of 3 consecutive coronal brain sections 24 
hours after induction of transient middle cerebral artery occlusion (tMCAO) are shown. White color 
indicates infarcted area, whereas a pink color shows unaffected brain tissue. (B) Brain infarct volumes 
as quantified by planimetric analysis 24 hours after tMCAO. (C) To exclude potential irradiation-
mediated effects on cerebral injury, transient focal cerebral ischemia was induced in irradiated VWF 
KO mice transplanted with MNCs derived from VWF KO mice (VWF KO + VWF KO PLTs). 
Planimetric analysis of brain infarct volumes 24 hours after tMCAO in WT (n = 5), VWF KO (n = 7), 
and VWF KO + VWF KO PLTs chimeric mice (n = 7). *, P < 0.05; **, P < 0.01; ns, not statistically 
significant. 
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2.4.5. Platelet VWF-mediated ischemic brain injury is GPIbα-dependent. 
We next wanted to further elucidate the mechanism by which platelet VWF exacerbates 
ischemic stroke. The main interactions of VWF in platelet adhesion and thrombus formation 
are binding to platelet GPIb, collagen and platelet GPIIb/IIIa. Interestingly however, 
Williams and colleagues have shown that platelet-derived VWF binds GPIbα with lower 
affinity than plasma VWF.9 To test whether binding of platelet VWF to GPIb is important in 
ischemic stroke, we blocked the VWF-GPIbα axis using an anti-GPIbα (p0p/B) Fab fragment 
(Figure 5).23 Interestingly, administration of p0p/B significantly reduced cerebral infarct 
development in VWF PLT chimeric mice (44.8 ± 10.19 mm3, n = 8) to levels as observed in 
VWF KO mice (43.38 ± 10.02 mm3, n = 5). These were half the size of those observed in 
non-treated WT mice (92.19 ± 11.52 mm3, n = 6) or VWF PLT chimeric mice that received 
IgG control Fab (83.07 ± 3.7 mm3, n = 12). These data suggest that the detrimental effect of 
platelet VWF in ischemic stroke is mediated by a platelet GPIbα-dependent mechanism. It is 
interesting to note that no cerebral hemorrhagic events were observed in all experimental 
groups after macroscopic analysis of whole brains and of 2-mm brain sections (data not 
shown), which is in line with our previous studies.3,5,23 
 
 
Figure 5: Blockade of platelet GPIbα reduces platelet VWF-mediated ischemic stroke injury. 
Transient focal cerebral ischemia was induced by 60 min occlusion of the right middle cerebral artery, 
followed by 23 hours of reperfusion in non-treated WT (n = 6) and VWF KO (n = 5) mice, and VWF 
PLT chimeric mice treated with 100 µg anti-GPIbα Fab (+ p0p/B; n = 8) or rat IgG Fab control (+ IgG 
Fab; n = 12). (A) Representative TTC stainings of 3 consecutive coronal brain sections 24 hours after 
tMCAO. White color indicates infarcted area, whereas a pink color shows unaffected brain tissue. (B) 
Brain infarct volumes as quantified by planimetric analysis 24 hours after tMCAO. **, P < 0.01; ns, 
not statistically significant.	
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2.4.6. Platelet-derived VWF exacerbates ischemic brain injury by promoting 
intracerebral thrombosis 
To gain further insight on how platelet VWF promotes cerebral injury, we measured 
fibrin(ogen) deposition in the brain after stroke (Figure 6). In WT mice, the ischemic 
hemisphere contained almost four times more fibrin(ogen) than the contralateral hemisphere 
(ratio ipsilateral/contralateral of 3.69 ± 0.37, n = 9) 24 hours after stroke, suggesting 
thrombotic events occurring during the ischemia/reperfusion phase. In VWF KO mice, 
significantly less fibrin(ogen) was found in the ipsilateral hemisphere (only a 1.44 ± 0.17-fold 
increase of contralateral, n = 8). Reconstitution of the platelet VWF compartment in VWF 
KO mice (VWF PLT) again significantly increased cerebral fibrin(ogen) deposition in the 
affected hemisphere (ratio ipsilateral/contralateral of 2.99 ± 0.56, n = 7). Interestingly, when 
VWF PLT chimeric mice were treated with anti-GPIbα Fab, fibrin(ogen) in the ipsilateral 
hemispheres was reduced (ratio ipsilateral/contralateral of 1.28 ± 0.10, n = 5). Administration 
of control IgG Fab to VWF PLT chimeric mice did not alter fibrin(ogen) deposition in the 
brain (ratio ipsilateral/contralateral of 3.75 ± 0.34, n = 6). These data suggest a significant 
contribution of platelet-derived VWF in intracerebral fibrin(ogen) deposition during ischemic 
stroke that depends on VWF binding to GPIbα. 
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Figure 6: Platelet-derived VWF contributes to ischemic brain injury by promoting 
intracerebral thrombosis. Transient focal cerebral ischemia was induced by 60 min occlusion of the 
right middle cerebral artery, followed by 23 hours of reperfusion in WT (n = 9), VWF KO (n = 8), 
non-treated VWF PLT chimeric (n = 7), anti-GPIbα Fab-treated VWF PLT chimeric (p0p/B, n = 5), 
and control IgG Fab-treated VWF PLT chimeric (IgG Fab; n = 6) mice. Twenty-four hours after 
induction of ischemia, the amount of fibrin(ogen) in both the contralateral and ipsilateral hemisphere 
was determined by semi-quantitative Western blot. (A) Representative immunoblot showing 
accumulation of fibrin(ogen) in ipsi- (I) and contralateral (C) hemispheres. (B) Band intensities from 
A were quantified by densitometry. Each fibrin(ogen) density signal was first normalized to the 
corresponding actin density signal. The ratio of the normalized ipsilateral fibrin(ogen) density relative 
to the normalized contralateral fibrin band served as a measurement for relative fibrin(ogen) 
deposition (ratio ipsilateral/contralateral). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not 
statistically significant. 
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2.5. DISCUSSION 
 
As a main finding of this study, we showed that platelet VWF is not essential for normal 
hemostasis and arterial thrombus formation but that this specific pool of VWF can contribute 
to ischemic brain injury via a GPIbα-dependent mechanism. 
 
Although normal plasma VWF levels were observed in VWF EC chimeric mice, no VWF 
was detected in their platelets. This observation confirms earlier transplantation studies 
performed in both mice15 and pigs19 and corroborates the absence of VWF in platelets of 
VWD type 3 patients after replacement therapy.24 Hence, our data further support the 
hypothesis that platelet VWF originates solely from megakaryocytes and is not taken up from 
plasma, in contrast to e.g. fibrinogen. Chimeric mice with VWF only in platelets did not 
show any significant amounts of VWF in plasma. In addition, no significant increase in 
circulating FVIII was observed. Similar observations were obtained in chimeric pigs.19 
Interestingly, Kanaji et al.15 showed trace amounts of circulating VWF in chimeric mice that 
only have VWF in platelets. One possible explanation of this discrepancy could be a 
difference in VWF ELISA detection sensitivities. Alternatively, slight platelet activation can 
result in the release of VWF in the plasma. 
 
The contribution of platelet-derived VWF in normal hemostasis is still not totally clear. Case 
studies in humans suggested that platelet-derived VWF is beneficial for normalization of 
bleeding.25-28 Our tail clip bleeding experiments show that endothelial cell-derived VWF is 
the major determinant in the process of normal hemostasis. This concept is further supported 
by earlier observations of defective hemostasis in mice15 and pigs29,30 with VWF only in 
platelets. Furthermore, hydrodynamic gene transfer experiments that target the liver for VWF 
expression also show that VWF present only in plasma can correct the bleeding diathesis of 
VWF KO mice17,31. Nevertheless, we observed that a small subset (19%) of mice expressing 
VWF only in platelets had partially corrected bleeding times, suggesting that in some cases 
platelet-derived VWF is more or less able to support hemostasis. Similar results were 
obtained by Kanaji and colleagues who showed that 38% of their VWF PLT mice also had a 
partially corrected bleeding time.15 Why bleeding stopped in some of our VWF PLT mice 
remains unclear. These mice did not show higher platelet counts nor did they have higher 
levels of plasma VWF or FVIII. Although less likely, differences in size and quantity of 
VWF in the platelet granules might contribute to these observations. More studies, preferably 
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using bleeding models that more closely mimic clinically relevant human hemorrhage, are 
needed to further clarify the specific function of platelet VWF in bleeding. 
  
Platelet VWF is important for initial in vitro platelet adhesion on collagen-coated 
surfaces.15,30 To test whether this is relevant for in vivo thrombus formation, we used a FeCl3-
induced carotid artery thrombosis model. Interestingly, mice having VWF only in platelets 
(VWF PLT) could not form occlusive thrombi, whereas chimeric mice with only endothelial 
cell-derived VWF (VWF EC) did so within 10 minutes. Thus, overall arterial thrombus 
formation does not seem to be largely dependent on VWF in platelets, which is in line with 
earlier thrombosis studies in chimeric pigs.29 In our model, we were not able to assess initial 
platelet adhesion rates after carotid artery injury but lack of VWF in platelets seemed to slow 
down the rate of blood flow reduction compared with WT mice, an effect that was however 
lost in the total kinetics of occlusive thrombus formation in the large carotid artery. Studies 
using other thrombosis models would be helpful to further explore the specific role of platelet 
VWF in thrombus formation. 
 
Increased platelet adhesion at sites of vascular injury could be important in thrombotic 
pathologies affecting the microcirculation such as ischemic stroke. We and others have 
shown that VWF KO mice are protected from stroke.3-5 Chimeric mice that lack VWF in 
platelets (VWF EC) developed the same cerebral infarctions as observed in WT animals, 
suggesting that plasma VWF alone can mediate the VWF-dependent ischemic brain injury. 
These findings are in agreement with the same large infarctions observed in VWF KO mice 
reconstituted with plasma VWF via hydrodynamic VWF gene transfer.5 Surprisingly, stroke 
lesions in VWF PLT chimeric mice were also similar to those seen in WT mice. Indeed, 
whereas VWF PLT chimeric mice display a phenotype similar to VWF KO animals in the 
tail-clipping bleeding and carotid artery thrombosis model, this is not the case in the stroke 
model. Hence, the contribution of VWF in platelets seems to be specifically relevant in the 
setting of cerebral ischemia. In addition, we observed an increased intracerebral deposition of 
fibrin(ogen) in VWF PLT chimeric mice compared with VWF KO mice indicating that local 
release of platelet VWF can promote intracerebral thrombosis. It is tempting to speculate that 
platelets adhere to activated endothelium (or subendothelium) in the area of 
ischemia/reperfusion and upon activation, secrete their granular contents, including large 
amounts of UL-VWF. This may result in the formation of platelet-derived VWF strings that 
may even be more resistant to ADAMTS13 proteolysis.10,32 Similar to endothelial-derived 
CHAPTER 2 
 
 105 
VWF strings, VWF strings from platelets could recruit new platelets and inflammatory cells 
resulting in platelet/leukocyte plugs that block the microvasculature and contribute to the no-
reflow phenomenon. Interestingly, such platelet derived-VWF strings have been shown in 
vitro.33 Future studies specifically addressing the inflammatory nature of platelet-derived 
VWF will definitely shed more light on its role in this thrombo-inflammatory process. 
 
Despite in vitro data showing that purified platelet VWF has a lower affinity for GPIbα than 
plasma VWF,9 we found that platelet VWF mediates ischemic brain injury via a GPIb-
dependent mechanism. This finding further supports the crucial importance of the VWF-
GPIb axis in stroke.5-7,23,34 Although p0p/B is not cytotoxic to platelets,23 we observed a small 
decrease in platelet count in p0p/B-treated mice compared with the control group (657.4 ± 
115.6 versus 895.7 ± 107.1, respectively; p < 0.01). This difference in platelet count can 
however not account for the observed difference in infarct size as 10% of normal platelet 
counts is already sufficient to induce full brain infarction following transient ischemic 
stroke.35  
 
In conclusion, our data shed an unexpected new light on the activity of platelet VWF and 
expand our insights on VWF-mediated mechanisms underlying ischemic stroke. This study 
further supports the idea that blocking the GPIb-VWF axis would be an interesting novel 
treatment strategy in stroke. 
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3.1. ABSTRACT 
 
Severe deficiency in the von Willebrand factor (VWF)-cleaving protease ADAMTS13 (A 
Disintegrin And Metalloproteinase with ThromboSpondin type-1 motif, member 13), due to 
mutations in the ADAMTS13 gene, can lead to acute episodes of congenital thrombotic 
thrombocytopenic purpura (TTP), requiring prompt treatment. In order to replenish plasma 
ADAMTS13 activity, current treatment consists of therapeutic or prophylactic infusions of 
fresh frozen plasma. However, lifelong treatment with plasma products is a stressful therapy 
for TTP patients. Here, we describe a gene therapeutic approach of using the ‘Sleeping 
Beauty’ (SB100X) transposon system to realize lifelong expression of ADAMTS13 that 
protects against congenital TTP. We demonstrate that hydrodynamic tail vein injection of the 
SB100X system expressing murine ADAMTS13 in Adamts13-/- mice resulted in long-term 
expression of supraphysiological levels of transgene ADAMTS13 over a period of 25 weeks. 
The stable expression of ADAMTS13 efficiently removed the prothrombotic ultra large VWF 
multimers present in the circulation of Adamts13-/- mice. Moreover, mice stably expressing 
ADAMTS13 were protected against TTP. The treated mice did not develop severe 
thrombocytopenia nor did organ damage occur when triggered with recombinant VWF, and 
this up to 20 weeks after gene transfer. These data demonstrate the feasibility of using 
SB100X-mediated gene therapy to achieve sustained expression of transgene ADAMTS13 
and long-term prophylaxis against TTP in Adamts13-/- mice. 
 
 
 
 
 
 
 
  
CHAPTER 3 
 
 113 
3.2. INTRODUCTION 
 
Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic disorder caused by 
deficiency in the von Willebrand factor (VWF)-cleaving protease ADAMTS13 (A 
Disintegrin And Metalloproteinase with ThromboSpondin type 1 motif, member 13). In 
normal circulation, ADAMTS13 cleaves highly reactive ultra large VWF (UL-VWF) 
multimers into smaller, less prothrombotic multimers preventing spontaneous platelet 
aggregation. Severe ADAMTS13 deficiency, caused by mutations of the ADAMTS13 gene 
(congenital TTP) or autoantibodies against ADAMTS13 (acquired TTP), can result in the 
accumulation of UL-VWF multimers and intravascular deposition of VWF- and platelet-rich 
thrombi in the microcirculation.1-3 During an acute episode, TTP patients typically present 
with thrombocytopenia, hemolytic anemia and organ injury including cerebral, renal, and 
cardiac manifestations.4,5  
Acute TTP is a medical emergency with a mortality rate as high as 90% if left untreated. In 
patients with congenital TTP, infusion of fresh frozen plasma (FFP; 10-15mL/kg) replenishes 
the missing ADAMTS13 and ameliorates disease outcome.6,7 However, congenital TTP 
patients with low residual plasma ADAMTS13 activity have frequent disease recurrences 
necessitating prophylactic FFP infusions.8,9 Indeed, regular plasma infusions (every 2-3 
weeks) may prevent acute TTP episodes.8,10,11 Although the number of prophylactic infusions 
needed depends on the patient’s phenotype, lifelong plasma therapy is stressful and has a 
significant negative impact on the lifestyle and quality of life of TTP patients.12,13 In addition, 
administration of plasma products may result in fluid overload or elicit allergic reactions to 
plasma proteins. The risk of viral/prion transmission also remains a major concern. 
Given the severity of the disease and the limitations of FFP prophylaxis, gene therapy for 
congenital TTP would offer an attractive alternative, as correction of the underlying genetic 
defect would result in lifelong expression of ADAMTS13 avoiding the need for plasma 
infusions. Gene therapeutic approaches have been viewed as highly promising for both rare 
genetic diseases and more common complex disorders. The therapeutic potential of this 
strategy has recently been demonstrated in clinical trials for haemophilia B14, Leber’s 
congenital amaurosis15, X-linked severe combined immunodeficiency disorder16, and 
metachromatic leukodystrophy17. In the TTP model, an initial preclinical study demonstrated 
that viral vector-mediated expression of a truncated form of ADAMTS13 protected 
Adamts13-/- mice from developing TTP symptoms elicited by bacterial shigatoxin.18 
Although protection from TTP was only assessed 2 weeks after gene transfer, this study 
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provided evidence that supports the validity of a gene therapeutic approach. However, to 
successfully translate gene therapy into a clinical setting, a long-term expression of 
ADAMTS13 is required that guarantees lifelong protection of congenital TTP patients from 
acute TTP episodes. 
To achieve long-term prevention of congenital TTP, we use the non-viral ‘Sleeping Beauty’ 
(SB100X) transposon system to deliver and express a functional copy of the Adamts13 gene 
to Adamts13-/- mice in order to achieve stable, robust gene expression. This plasmid-based 
transposon system consists of a transposon DNA sequence and a transposase protein that 
excises the transposon from the donor plasmid and integrates it into the target genome 
(Figure 1).19,20 The SB100X system utilizes a hyperactive version of the transposase.20 The 
SB transposon system has already been used to successfully integrate therapeutic genes into 
the host cell genome resulting in long-term transgene expression and phenotypic correction 
of monogenetic diseases such as haemophilia20-22 and lysosomal storage disorders23,24 in 
preclinical animal studies. In this study, we report that delivery of the SB transposon, 
encoding the murine Adamts13 gene, along with a SB100X transposase to the liver of 
Adamts13-/- mice can mediate long-term expression of supraphysiological levels of plasma 
ADAMTS13 and long-term prevention of the onset of TTP symptoms in Adamts13-/- mice. 
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3.3. METHODS 
 
3.3.1. Plasmids 
The plasmid expressing the transposase (Figure 1), pCMV(CAT)T7-SB100 (referred as 
pCMV-SB100x in the text), contains the hyperactive transposase (SB100x) cDNA of which 
expression is driven from a cytomegalovirus (CMV) enhancer/promoter.20 The transposon 
plasmid, pT2/HCRHPi-ADAMTS13, was constructed using the In-Fusion® HD Cloning Kit 
(Clontech Laboratories, Mountain View, CA). The expression cassette containing a liver-
specific promoter (HCRHPi: apolipoprotein hepatic control locus region (ApoE-HCR) linked 
to a human α1-anti-trypsin promoter and a truncated 1.4 kb human factor IX) coupled to the 
murine Adamts13 cDNA was amplified from pBS-II-SK-HCHRPi-muADAMTS1325 using 
Phusion® High Fidelity DNA polymerase (New England Laboratories, Ipswich, MA) and 
primers flanking the desired region. In parallel, pT2/CAGGS-GFP20 was digested with 
ClaI/NotI-HF (New England Laboratories) thereby excising the CAGGS-GFP expression 
cassette. Subsequently, the HCRHPi-ADAMTS13 polymerase chain reaction product was 
ligated into the linearized pT2-vector backbone according to the In-Fusion cloning procedure 
for spin-column purified PCR fragments. The HCRHPi-ADAMTS13 cassette was sequenced 
to confirm the sequence (GATC Biotech AG, Konstanz, Germany). Plasmid DNA used for 
hydrodynamic tail vein injection was prepared using the Endofree® Plasmid Mega Kit 
(Qiagen, Venlo, The Netherlands). 
 
3.3.2. Mice 
Male and female ADAMTS13 knockout (Adamts13-/-) and wild-type (Adamts13+/+) mice 
were bred from heterozygous Adamts13+/- (with a mixed C57BL/6J-129X1/SvJ-CASA/Rk 
background).26 All animal experiments were performed in accordance with protocols 
approved by the Institutional Animal Care and Use Committee of the KU Leuven (License 
LA1300114, project number P163/2015, KU Leuven, Belgium).  
 
3.3.3. Hydrodynamic gene transfer 
Five to 7-week old Adamts13-/- mice (weighing 16-21 g) were injected with 5 µg transposon 
plasmid DNA and 0.2 µg transposase plasmid DNA via hydrodynamic tail vein injection.27-29 
Plasmid DNA was diluted in a saline solution (0.9% NaCl) equivalent to 10% of the body 
weight and administered via the lateral tail vein in 5-7 seconds. Adamts13-/- mice that were 
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hydrodynamically injected with only transposon plasmid DNA (no transposase) or with 
saline solution were used as controls. 
 
3.3.4. Blood collection 
Animals were anesthetized using 5% isoflurane (Nicholas Piramal Limited, London, UK) in 
100% O2. Whole blood was drawn from the retro-orbital plexus and collected on 0.5M 
EDTA (1 volume to 40 volumes of blood) or 3.8% sodium citrate (1 volume to 7 volumes of 
blood). Platelet-poor plasma was prepared from citrated blood by centrifugation at 4300 g for 
6 minutes at room temperature and stored at -80°C for further analysis. 
 
3.3.5. Induction of TTP 
To induce TTP symptoms, saline- or SB-treated Adamts13-/- mice were challenged with a 
single intravenous bolus injection of recombinant human VWF (rVWF; 2000 VWF:RCoU/kg 
body weight) in the lateral tail vein as described.30 Twenty-four hours after challenge, blood 
was collected to monitor TTP symptoms. Platelet count and hemoglobin levels were 
determined in EDTA-anticoagulated blood using the Hemavet 950FS Multi-species 
Hematology system (Drew Scientific Inc., Dallas, TX). Lactate dehydrogenase (LDH) 
activity was measured in citrated plasma using an LDH activity colorimetric assay kit 
(Biovision, Milpitas, CA) according to the manufacturer’s instructions. Body weight loss was 
determined by calculating the difference in body weight assessed before and 24h after 
challenge with rVWF. 
 
3.3.6. ADAMTS13 antigen analysis 
Transgene ADAMTS13 antigen levels in plasma were determined via an in-house developed 
enzyme-linked immunosorbent assay (ELISA) as described, with some minor 
modifications.25 A 96-well microtiter plate was coated overnight at 4°C with our anti-mouse 
ADAMTS13 monoclonal antibody 14H7B8 (5 µg/mL in phosphate buffered saline (PBS)). 
After blocking with a 3% skimmed milk solution, plasma samples (diluted in PBS containing 
0.3% (m/v) skimmed milk) were added and incubated for 90 minutes at 37°C. Captured 
ADAMTS13 was detected via our in-house developed polyclonal rabbit anti-mouse 
ADAMTS13 antibodies (5 µg/ml in PBS containing 0.3% skimmed milk) and polyclonal 
goat anti-rabbit antibodies labeled with horseradish peroxidase (HRP; Jackson 
ImmunoResearch Laboratories Inc., West Grove, PA) (1/10,000 in PBS containing 0.3% 
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skimmed milk). The colouring reaction was initiated after addition of ortho-
phenylenediamine (Sigma-Aldrich, St Louis, MO) and H2O2, and stopped with 4 M H2SO4. 
The ADAMTS13 antigen level in pooled plasma of more than 20 Adamts13+/+ mice was used 
as a reference (100%, normal murine plasma, NMP). 
 
3.3.7. Immunohistochemistry 
After sacrificing the animal, the left liver lobe was removed, embedded in Tissue-Tek® 
O.C.T.TM Compound (Sakura Finetek Europe B.V., Alphen aan den Rijn, The Netherlands), 
snap-frozen in liquid nitrogen and stored at -80°C. Liver lobes were cut in 10 µm thick 
cryosections using a Leica CM1950 Cryostat (Leica Biosystems, Richmond, IL) and stored at 
-20°C. Before use, sections were air-dried and fixed in 4% paraformaldehyde. Sections were 
then blocked and permeabilized with 5% normal goat serum in PBS containing 0.1% Triton 
X-100, 1% bovine serum albumin (BSA), and 0.1% Tween20 for 1 hour at room temperature 
followed by overnight incubation with our polyclonal rabbit anti-mouse ADAMTS13 
antibodies31 (10 µg/ml in PBS containing 1% BSA and 0.1% Tween20) at 4°C. After 
washing in PBS, endogenous peroxidase activity was blocked using 0.3% H2O2 in PBS for 15 
min at room temperature. Subsequently, sections were washed and incubated with HRP-
labeled goat anti-rabbit antibodies (1/500 in PBS containing 1% BSA and 0.1% Tween20; 
Jackson ImmunoResearch Laboratories Inc.) for 45 minutes at room temperature. After 
another washing step, ADAMTS13-positive liver cells were visualized with 3,3’-
diaminobenzidine (DAB; Dako, Glostrup, Denmark) followed by counterstaining with 
hematoxylin (Sigma-Aldrich) for 2 minutes. Sections were dehydrated and mounted in DPX 
(Fluka, Bornem, Belgium). Pictures were taken at 10x magnification using a Zeiss Primo Star 
microscope (Carl Zeiss Microscopy GmbH, Jena, Germany). 
 
3.3.8. Analysis of murine plasma VWF multimers 
Citrated plasma samples were 1/5 diluted in sample buffer (8 M urea, 5% (m/v) sodium 
dodecyl sulphate (SDS), 10 mM Tris, 1 mM EDTA, and 0.3% bromophenol blue; pH 8.0) 
and incubated at 60°C for 30 minutes. VWF multimers were separated on a low-resolution 
(1.2%) SDS isoelectric focusing agarose gel (GE Healthcare Europe GmbH, Diegem, 
Belgium), fixed on a GelBond® film (Lonza, San Diego, CA), by electrophoresis at 10-15 
mA in a multiphor II apparatus (GE Healthcare). Following electrophoresis, the gel was 
rinsed in distilled water, dried under cooled air and blocked in 5% skimmed milk in TBS 
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containing 0.05% Tween20. After overnight incubation with polyclonal anti-human VWF 
antibodies (1/750 diluted in TBS; Dako), in-house conjugated with alkaline phosphatase, and 
subsequent rinsing with TBS containing 0.05% Tween20, VWF multimers were visualized 
using an Alkaline Phosphate conjugate substrate kit (BioRad, Hercules, CA).29 Densitometric 
analysis was performed using Image J software (version 1.47, National Institute of Health, 
Bethesda, MD). The density-profile of each VWF multimer pattern was graphed. 
Distinguishable bands were divided into 3 subclasses: (1) 1-5 dimers were designated as low 
molecular weight VWF multimers (LMW), (2) 6-10 dimers as medium molecular weight 
VWF multimers (MMW), and (3) >10-dimers as high molecular weight VWF multimers 
(HMW; including UL-VWF multimers). UL-VWF multimers did not resolve in single bands 
but appeared as a smear that was included in the HMW subclass. The total density of each 
subclass was divided by the density of all multimer bands to calculate the relative abundance 
of all subclasses.29 
 
3.3.9. Statistical analysis 
Data are represented as mean ± SEM. For statistical analysis, Prism Version 6.0 software 
(GraphPad Software, La Jolla, CA) was used. One-way analysis of variance followed by 
Dunnett’s multiple comparisons post hoc test was conducted to assess the variance of the 
relative amounts of HMW multimers between Adamts13-/- mice and the different 
experimental groups. Unpaired t testing was used to compare saline- and SB-treated 
Adamts13-/- mice challenged with rVWF at different time points. A probability value < 0.05 
was considered as statistically significant. 
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3.4. RESULTS 
 
3.4.1. Long-term expression of supraphysiological levels of transgene murine 
ADAMTS13 in Adamts13-/- mice 
We aimed at obtaining long-term expression of transgene murine ADAMTS13 in Adamts13-/- 
mice by using the SB100X transposon system (Figure 1). We cloned an expression cassette 
consisting of murine Adamts13 cDNA under control of the liver-specific α1-antitrypsin 
promoter (HCRHPi)32 into the SB transposon vector to obtain pT2/HCRHPi-ADAMTS13. 
To integrate the Adamts13 transgene into the mouse genome, the plasmid containing the 
hyperactive variant of the original transposase under control of the ubiquitous CMV promoter 
was used (pCMV-SB100X).20 Plasmids were hydrodynamically injected in Adamts13-/- mice 
resulting in in vivo transfection of murine hepatocytes.27-29  
 
 
Figure 1: Schematic representation of ‘Sleeping Beauty’-transposon mediated gene transfer. The 
‘Sleeping Beauty’ (SB100X) transposon system is a two-component system consisting of a transposon 
plasmid comprised of inverted terminal repeats (ITR, white arrow) flanking the gene of interest 
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(GOI), and a transposase plasmid pCMV(CAT)T7-SB100X (pCMV-SB100X) encoding the 
hyperactive SB transposase (SB100X). Upon SB transposon-mediated gene transfer, the SB100X 
transposase (grey circles) will bind the inverted terminal repeats (ITR, white arrows), excise the 
engineered therapeutic gene (gene of interest, GOI) from the plasmid DNA, and integrate it into 
genomic TA dinucleotides of chromosomal DNA.   
 
In the first group of Adamts13-/- mice (n=7), both transposon (pT2/HCRHPi-ADAMTS13) 
and transposase (pCMV-SB100X) plasmids were hydrodynamically injected. In this group, 
the integration of the murine Adamts13 cDNA into the mouse genome was promoted by the 
transposase (gene therapy group). In the second group, Adamts13-/- mice (n = 7) were injected 
with a solution containing only the transposon (pT2/HCRHPi-ADAMTS13), but no 
transposase (control group). At 3 days post injection, levels of transgene ADAMTS13 were 
remarkably high in both groups of mice (368 ± 52% and 392 ± 91% in the gene therapy 
group and in the control group, respectively; Figure 2A). Notably, long-term follow up of 
transgene ADAMTS13 expression levels indicated that transgene expression was only 
transient in the control group, as ADAMTS13 antigen levels rapidly decreased over time 
(Figure 2A). On the contrary, transgene ADAMTS13 levels remained high in the gene 
therapy group up to 25 weeks after gene transfer, the time point at which the experiment was 
ended (184 ± 17% and 10 ± 2% in the gene therapy group and the control group, 
respectively; Figure 2A).  
Immunohistochemical analysis of liver sections confirmed the above results. Mice with long-
term and high-level expression of transgene ADAMTS13 (gene therapy group) had a high 
number of ADAMTS13-expressing hepatocytes at 25 weeks post injection (Figure 2B, right 
panel). In contrast, in mice with transient ADAMTS13 transgene expression (control group) 
only a few ADAMTS13-positive hepatocytes were found in liver sections at 25 weeks post 
injection (Figure 2B, middle panel). Finally, we addressed whether the treatment induced 
immune response. We observed no profound anti-ADAMTS13 antibody response in either 
group (data not shown).  
In conclusion, these data indicate that SB100X transposon-mediated gene delivery is a 
powerful technique to obtain long-term expression of supraphysiological levels of transgene 
ADAMTS13 in Adamts13-/- mice. 
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Figure 2: Long-term and stable expression of transgene ADAMTS13 in plasma and liver after 
‘Sleeping Beauty’ transposon-mediated gene transfer. Adamts13-/- mice were hydrodynamically 
injected with 5 µg pT2-HCRHPi-ADAMTS13 with (+SB100X, gene therapy group; n = 7) or without 
(-SB100X, control group; n = 7) 0.2 µg pCMV-SB100X. (A) Therapeutic ADAMTS13 antigen levels 
in plasma. Blood was collected at the indicated time points. Plasma ADAMTS13 antigen levels were 
determined by an in-house developed ELISA. Mean values ± SEM are expressed as percentage of 
normal murine plasma pool (% NMP). Dashed line indicates ADAMTS13 antigen level in NMP. (B) 
Transgene expression of ADAMTS13 in liver. A representative mouse of each group was sacrificed 
and liver sections were subjected to immunohistochemistry. ADAMTS13-positive liver cells were 
detected with polyclonal rabbit anti-ADAMTS13 antibodies and secondary HRP-labeled goat anti-
rabbit antibodies, and visualized using DAB (dark brown color). Sections were counterstained with 
hematoxylin. Representative images of stained liver sections of a non-treated Adamts13-/- mouse 
(plasma ADAMTS13 antigen level: 0% of NMP), an Adamts13-/- mouse expressing low levels of 
ADAMTS13 antigen (-SB100x; plasma ADAMTS13 antigen level: 9% of NMP), and an Adamts13-/- 
mouse expressing high levels of ADAMTS13 antigen (+SB100x; plasma ADAMTS13 antigen level: 
125% of NMP) at 25 weeks post injection are shown. ADAMTS13 antigen levels (%) are indicated 
below each image. Original magnifications, 10x; scale bar represents 50 µm.  
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3.4.2. Long-term expression of transgene ADAMTS13 prevents the accumulation 
of prothrombotic UL-VWF multimers in Adamts13-/- mice 
Previous studies have demonstrated that Adamts13-/- mice exhibit a prothrombotic phenotype. 
Due to the absence of ADAMTS13 activity, prothrombotic UL-VWF multimers accumulate 
in Adamts13-/- mice compared to wild-type littermates.26,33 Since these UL-VWF multimers 
are the major cause of TTP in humans, we assessed whether transgene ADAMTS13 was able 
to proteolyze UL-VWF multimers in Adamts13-/- mice. At day 3 post injection, when 
transgene ADAMTS13 levels were high in both groups (Figure 2A), UL-VWF multimers 
were absent (Figure 3). The percentage of HMW VWF multimers (including the UL-VWF 
multimers) in both the gene therapy group (29.9 ± 0.9%; n = 4) and the control group (30.7 ± 
2.2%; n = 5) was comparable to the percentage observed in Adamts13+/+ mice (36.0 ± 1.6%; n 
=7 ) showing that UL-VWF multimers were efficiently proteolyzed by transgene 
ADAMTS13 (Figure 3). At 25 weeks post injection however, the percentage of HMW VWF 
multimers (39.9 ± 1.2%; n = 5) in the control group increased again to values observed in 
Adamts13-/- mice (41.3 ± 1.4%; n = 8), indicating that the low levels of transgene 
ADAMTS13 were not sufficient to digest the UL-VWF multimers (Figure 3). In contrast, the 
relative amount of HMW VWF multimers was still normalized in the gene therapy group at 
25 weeks post injection (31.7 ± 1.3%; n = 4), which is in line with the high levels of 
transgene ADAMTS13 present in these mice (Figure 2A).  
In conclusion, SB transposon-mediated expression of the therapeutic ADAMTS13 gene leads 
to long-term normalization of the VWF multimer distribution in circulation and prevents 
accumulation of prothrombotic UL-VWF multimers in Adamts13-/- mice. 
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Figure 3: Long-term 'Sleeping Beauty' transposon-mediated expression of high levels of 
transgene ADAMTS13 reduces VWF multimer size in Adamts13-/- mice. Adamts13-/- mice were 
hydrodynamically injected with 5 µg pT2-HCRHPi-ADAMTS13 with (+SB100X, gene therapy 
group) or without (-SB100X, control group) 0.2 µg pCMV-SB100x. Plasma samples of non-treated 
Adamts13-/- and Adamts13+/+ mice were used as controls. (A) VWF multimer gel analysis was 
performed on plasma samples collected at 3 days and 25 weeks after gene transfer (GT). The relative 
abundance of high molecular weight (HMW) multimers, including the ultra-large VWF multimers, 
was determined by densitometric analysis. (B) Representative image of VWF multimer patterns and 
corresponding densitometric profiles of mice expressing low (-SB100X: 17% of NMP) or high 
(+SB100X: 125% of NMP) ADAMTS13 antigen levels at 25 weeks after gene transfer. 
Distinguishable bands were divided into 3 subclasses: 1-5 dimers were designated as low molecular 
weight (LMW) VWF multimers, 6-10 dimers as medium molecular weight (MMW) VWF multimers, 
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and >10-dimers as high molecular weight (HMW) and ultra-large VWF multimers. Ns, not 
significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared to Adamts13-/- mice. 
 
3.4.3. ‘Sleeping Beauty’ transposon-mediated gene therapy prevents the onset of 
TTP symptoms in Adamts13-/- mice up to 20 weeks following gene transfer 
It was previously shown that Adamts13-/- mice develop TTP symptoms when they are 
triggered with recombinant VWF (rVWF).30 We next investigated whether our SB100X-
mediated gene therapeutic strategy could be an effective prophylactic approach to prevent 
acute TTP in Adamts13-/- mice.  
We therefore hydrodynamically injected 3 groups of Adamts13-/- mice with the SB100X 
transposon system (gene therapy groups) to obtain long-term and high levels of transgene 
ADAMTS13 expression (as described in Figure 2A). To induce TTP symptoms, each group 
was challenged with a single dose of human rVWF (2000 VWF:RCoU/kg) at different time 
points (1, 4, or 10 weeks after gene transfer). In parallel, we hydrodynamically injected 3 
groups of Adamts13-/- mice with a saline solution to serve as non-expressing controls and also 
challenged these mice with rVWF at different time points (control groups). A single group of 
Adamts13-/- mice that was hydrodynamically injected with PBS and treated with PBS instead 
of challenged with rVWF was used as a healthy control group. Twenty-four hours following 
the challenge, platelet count, plasma LDH levels (marker for tissue damage), hemoglobin 
levels (marker for hemolytic anemia) and weight loss were determined in all groups to assess 
TTP-like symptoms (Figure 4). As expected, all mice in the control groups (no gene transfer) 
developed TTP at all time points of rVWF challenge: platelet counts were dramatically 
decreased (>80%) (Figure 4A), plasma LDH levels were substantially elevated (Figure 4B), 
hemoglobin levels were decreased (Figure 4C), and a dramatic weight loss was observed 
(Figure 4D) when compared to values observed in healthy Adamts13-/- mice. Importantly and 
in stark contrast, regardless of the time point of the challenge, mice of the gene therapy 
groups did not develop TTP-like symptoms: they did not suffer from severe 
thrombocytopenia, (Figure 4A), their plasma LDH and hemoglobin levels remained within 
the normal range (Figure 4B and C) and they did not lose weight upon induction of TTP, 
reflecting a healthy state (Figure 4D). To further emphasize the long-term prophylactic 
efficacy of our gene therapeutic approach, an additional gene therapy group was challenged 
with rVWF at 20 weeks after gene transfer (Figure 4). Again, mice did not develop TTP as 
platelet counts, plasma LDH and hemoglobin levels remained within the normal range, nor 
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did these mice lose weight. Taken together, these results demonstrate that long-term SB 
transposon-mediated expression of ADAMTS13 results in long-lasting prophylaxis against 
TTP in this animal model.  
	
 
Figure 4: Long-term ‘Sleeping Beauty’ transposon-mediated expression of high levels of 
transgene ADAMTS13 prevents the onset of TTP symptoms in Adamts13-/- mice challenged with 
rVWF. Adamts13-/- mice were injected with saline solution (control group, no gene transfer) or with 
the plasmids coding for the SB100X system (gene therapy group) via hydrodynamic injection. Mice 
were subsequently challenged with a single dose of recombinant human VWF (rVWF; 2000 
VWF:RCoU/kg) at different weeks post hydrodynamic injection (wpi) (control group and gene 
therapy group). Another control group (no gene transfer) was hydrodynamically injected with saline 
and subsequently injected with PBS instead of challenged with rVWF (healthy control group). 
Twenty-four hours after challenge with rVWF, blood was collected and analysed. (A) 
Thrombocytopenia was assessed by measuring platelet counts in EDTA-treated blood using an 
automated cell counter. (B) Tissue damage was determined by measuring lactate dehydrogenase 
(LDH) activity in citrated plasma using a colorimetric assay kit. (C) Hemoglobin (Hb) levels were 
measured in EDTA-treated blood using an automated cell counter. (D) Weight loss was determined 
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by calculating the difference in weight before and 24 hours after challenge with rVWF. Mean 
ADAMTS13 antigen levels at the indicated time points are shown. Ns, not significant; *, P < 0.05; **, 
P < 0.01; ****, P < 0.0001. 
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3.5. DISCUSSION 
 
In this study, we developed a novel integrating, non-viral gene therapy strategy to prevent 
congenital TTP in a mouse model. We demonstrated that SB100X-mediated gene transfer of 
murine Adamts13 cDNA in Adamts13-/- mice results in long-term and high-level expression 
of the therapeutic protein, ADAMTS13. Importantly, this gene therapeutic strategy was able 
to prevent onset of acute TTP disease up to 20 weeks following gene transfer. 
 
The SB transposon-mediated technology allowed sustained expression of high levels of 
transgene ADAMTS13 (184 ± 17%) in Adamts13-/- mice for 25 weeks post injection (almost 
six months; the end of the study). Stable expression of high plasma ADAMTS13 antigen 
levels was associated with the presence of a high number of ADAMTS13-expressing 
hepatocytes. When the SB100X transposase was absent, transgene expression rapidly 
dropped below WT levels within 3 weeks post injection, resulting in a low number of 
ADAMTS13-expressing hepatocytes. Still, low-level transgene expression, associated with a 
low number of ADAMTS13-expressing hepatocytes persisted for 25 weeks post injection (10 
± 2%), indicating that not all non-integrated prokaryotic DNA was degraded or epigenetically 
silenced.32,34,35 
  
Notably, expressed ADAMTS13 was biologically active in vivo, as demonstrated by the 
normalization of the VWF multimer pattern in Adamts13-/- mice. Only mice expressing 
sustained high therapeutic ADAMTS13 levels were able to normalize the VWF multimer 
pattern for the whole 25-week period. These results indicate that the corresponding plasma 
ADAMTS13 activity was high enough to process newly secreted UL-VWF multimers. Furlan 
et al. showed that 5% plasma ADAMTS13 activity might be already sufficient to degrade the 
most adhesive VWF multimers into smaller forms that do not spontaneously recruit platelets 
in congenital TTP patients.36 In line with this observation, data obtained by Lotta et al. 
indicate that a small increase in residual plasma ADAMTS13 activity is sufficient to lower 
the risk of disease recurrence and the need for FFP prophylaxis in congenital TTP patients.9 
In contrast, in the present study we observed that the plasma ADAMTS13 activity associated 
with a mean antigen value of 10% (range 2-17%) was not yet sufficient to alter the VWF 
multimer distribution. Whether this can be explained by species-specific differences in 
threshold ADAMTS13 levels required to normalize the VWF multimer pattern or due to 
synthesis of the therapeutic enzyme in heterologous cells (hepatocytes), requires further 
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investigation. Nevertheless, our study shows that the SB100X transposon system results in 
expression levels of ADAMTS13 of 184 ± 17% in Adamts13-/- mice for up to six months 
after gene transfer. Thus, it might be reasonable to assume that the SB100X system could be 
a proper vector able to provide stable therapeutic ADAMTS13 levels of more than 10% in 
congenital TTP patients. 
  
In addition to studying expression levels, we next investigated whether SB transposon-
mediated gene therapy would be a potent strategy to protect Adamts13-/- mice from 
developing TTP. TTP was triggered with rVWF as previously described.30 As expected, 
severe thrombocytopenia, increased plasma LDH levels, decreased haemoglobin levels, and 
increased weight loss were observed in all Adamts13-/- mice that did not receive therapeutic 
gene transfer and hence did not express ADAMTS13. Intriguingly, treatment with the SB 
transposon system was a very effective prophylactic strategy. When Adamts13-/- mice 
expressing the therapeutic gene ADAMTS13, were triggered with rVWF at 1, 4 or 10 weeks 
after gene transfer, TTP symptoms did not appear. Even 20 weeks after gene transfer, 
expression levels of ADAMTS13 were still high enough to protect mice from developing 
TTP, as no profound thrombocytopenia, elevated LDH levels, decreased hemoglobin levels 
or increased weight loss were observed. These data demonstrate that the expression level of 
ADAMTS13 and its corresponding VWF-cleaving activity were high enough to process the 
large amounts of exogenous VWF, and prevent extensive organ damage and hemolysis. To 
our knowledge this is the first gene therapy-based preclinical study demonstrating long-term 
prophylaxis for congenital TTP using a non-viral gene therapeutic approach. 
 
The use of the SB transposon technology holds high promise as it combines low cost and 
simplicity of naked DNA with the efficiency of gene transfer associated with retroviral 
vectors. SB has proven successful as a therapeutic vector in various preclinical studies 
demonstrating long-term gene expression in a wide range of tissues and primary cells.37 
Moreover, SB technology reached clinical level as the first phase I clinical trials using SB 
transposons have recently been conducted for adjuvant treatment of patients with advanced 
B-cell malignancies.38 The results obtained from these trials are encouraging in terms of 
safety and patient’s outcome, and support further clinical development of this non-viral gene 
therapeutic approach. To transfer the SB transposon-mediated approach described in this 
preclinical study from bench to clinical setting, the issue of hydrodynamics-based delivery 
and safety must be addressed. First, while hydrodynamic tail vein injection may be an 
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efficient delivery system in rodent animal models, the procedure is not readily applicable to a 
human clinical setting. However, efforts are made to apply this method to clinical gene 
therapy. Image-guided, computer-assisted hydrodynamic gene delivery restricted to the liver 
has been shown to be safe and effective in dogs, pigs, and non-human primates.39 A second 
issue regarding to the clinical use of the SB transposon system is the safety of SB-mediated 
integration. It has been shown that SB-mediated transposition mediates integration into target 
dinucleotides without preference for transcriptionally active sites.19,40 In fact, the SB 
transposon system has the most random integration profile of all vectors used in gene 
therapeutic approaches.41,42 Although occurrence of insertional mutagenesis after SB-
mediated gene therapy cannot be excluded, attempts are made to minimize the risk of 
accidental transactivation of genes. Studies have shown that engineered fusion proteins 
comprised of zinc finger proteins and the SB transposase can be used to effectively redirect 
transposon insertion into specific sequences in the genome.43,44 
 
In conclusion, we successfully achieved long-term therapeutic expression of full-length 
ADAMTS13 in Adamts13-/- mice using the SB transposon system. This study is the first 
report demonstrating that a single administration of naked plasmid DNA can result in long-
term correction of ADAMTS13 deficiency and prophylaxis of TTP in Adamts13-/- mice. We 
believe that the present study may pave the way to a SB transposon-mediated gene therapy 
that will cure congenital TTP in humans. 
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4.1. ABSTRACT 
 
Malaria is a major cause of cause of morbidity and mortality in the developing world. 
Malaria-associated acute respiratory distress syndrome (MA-ARDS) is a common 
complication of malaria, with a mortality rate of up to 80%. Recent clinical studies have 
demonstrated that severe malaria infection is associated with high von Willebrand factor 
(VWF) and low ADAMTS13 activity levels. Whether this prothrombotic state constitutes an 
epiphenomenon, or whether this plays an active role in the pathophysiology of MA-ARDS is 
currently unknown. To address this issue, we used an established murine model of MA-
ARDS, in which C57BL/6J mice are infected with Plasmodium (P.) berghei NK65 parasites. 
Plasma VWF levels in infected wild-type (WT) mice significantly increased early after 
infection, but normalized afterwards. During the course of infection, VWF multimer patterns 
remained normal until end stage disease at which a marked decrease in high molecular 
weight VWF multimers was observed. This was accompanied by a significant reduction of 
the ADAMTS13 activity/antigen ratio and severe thrombocytopenia.	To	determine the direct 
role of VWF in MA-ARDS pathogenesis, we investigated P. berghei NK65 infection in VWF 
knockout (Vwf-/-) mice. Similar to WT mice, thrombocytopenia was also observed in the 
absence of VWF indicating that VWF does not contribute to malaria-associated 
thrombocytopenia. Overall mouse survival times were slightly but significantly shortened in 
Vwf-/- mice. Vwf-/- mice showed an increased number of infected red blood cells but reduced 
lung pathology compared to WT mice. Further studies are needed to unravel the biological 
mechanisms by which VWF might influence peripheral blood parasitemia levels and the 
development of lung pathology in MA-ARDS. 	
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4.2. INTRODUCTION 
 
Malaria remains a major global health burden with an estimated number of 214 million 
clinical cases and 438 000 deaths in 2015, of which most are caused by Plasmodium 
falciparum (World Malaria Report 2015, World Health Organization). The 
pathophysiological mechanisms of life-threatening P. falciparum-associated complications 
are multifactorial involving mechanical obstruction of organ microvasculature by sequestered 
P. falciparum-infected erythrocytes1,2 and the initiation of atypical inflammatory cascades in 
target organs3,4. Despite the availability of anti-malarial drugs, the lethality rate associated 
with severe complications remains high. Besides malarial anemia and cerebral malaria, 
malaria-associated acute respiratory distress syndrome (MA-ARDS) is a common 
complication with a mortality rate of up to 80%.5 All five malaria species able to infect 
humans have been reported to cause MA-ARDS, although clear differences exist between 
different species.6 MA-ARDS is often observed in association with other complications but 
also occurs as a single manifestation of otherwise uncomplicated malaria. No treatment is 
currently available and very little is known about its pathogenesis. Hence, better 
understanding of the mechanisms that mediate MA-ARDS will be crucial to develop novel 
treatment strategies for this often-lethal complication. Both thrombotic and inflammatory 
processes are known to be involved in malaria pathology and in recent years, the thrombo-
inflammatory molecule von Willebrand factor (VWF) has gained increased attention.7 
VWF is an adhesive multimeric glycoprotein that is synthesized by endothelial cells (ECs) 
and megakaryocytes. VWF is best known for its crucial role in primary hemostasis, where it 
participates in the adhesion of platelets to sites of vascular injury and the protection of 
clotting factor VIII against premature degradation in circulation. The hemostatic efficacy of 
VWF is determined by its multimeric composition, with ultra large (UL-) VWF multimers 
being the most active forms, capable of spontaneously binding, activating, and aggregating 
platelets.8 In ECs, these highly adhesive VWF multimers are stored within specific 
endothelial storage sites, called Weibel-Palade bodies (WPBs), from where they are released 
into the circulation upon EC activation. A number of case-control studies carried out in 
children and adults with naturally acquired P. falciparum infection have demonstrated that 
human malaria infection is associated with acute EC activation and WPB exocytosis resulting 
in elevated concentrations of plasma VWF9-13 and pathological accumulation of UL-VWF 
multimers11,14,15. In normal conditions, the VWF multimer size, and therefore VWF platelet-
binding potential, is regulated by the VWF-cleaving protease, ADAMTS13, which degrades 
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UL-VWF multimers in smaller, less thrombogenic forms before entering circulation.16 In 
malaria, however, ADAMTS13 activity is markedly reduced.11,14,17,18 Furthermore, in vitro 
studies have shown that released UL-VWF multimers can form platelet-decorated VWF 
strings that are able to bind multiple P. falciparum-infected red blood cells.19 All together, 
these data suggest that a dysregulated VWF balance, i.e. high VWF and low ADAMTS13 
activity, may play a direct role in the underlying pathophysiology of malaria-associated 
syndromes. 
So far, nothing is known on the potential involvement of the VWF/ADAMTS13 axis in MA-
ARDS. The goal of this study therefore was to elucidate the role of VWF and ADAMTS13 in 
severe malaria pathogenesis using a murine model of malaria-associated lung pathology.20  
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4.3. METHODS 
 
4.3.1. Mice  
Five to 8-week old male and female wild-type (WT) and VWF knockout (Vwf-/-)21 mice on a 
C57BL/6J background were bred and maintained in a conventional animal facility with water 
and food ad libitum. To ensure optimal parasite growth, drinking water was supplemented 
with 0.375 mg/ml 4-amino-benzoic acid (Sigma-Aldrich, Bornem, Belgium). Experimental 
groups were weight- and age-matched for each experiment. All animal experiments were 
performed in accordance with protocols approved by the Institutional Animal Care and Use 
Committee of the KU Leuven (License LA1300114, project number P173/2015, KU Leuven 
Belgium). 
 
4.3.2. Parasites 
Mice were inoculated with 104 P. berghei NK65 parasites via intraperitoneal injection.20 
Infected mice were monitored daily for the progression of malaria-associated lung pathology. 
Clinical parameters comprised loss in body weight, piloerection, spontaneous activity, body 
tone, limb grasping, and abnormal breathing. Mice suffering from severe disease were 
defined as ‘end-stage’ and sacrificed by cervical dislocation according to the ethical 
guidelines.  
 
4.3.3. Determination of parasitemia 
Peripheral blood parasitemia levels were monitored by examination of blood smears. A 
droplet of blood was collected from the tail tip and smeared on glass slides. After fixation in 
methanol, blood smears were stained with 10% Giemsa solution (Giemsa’s stain R66 solution 
Gurr®; VWR International, Lutterworth, UK) for 15-20 minutes. After washing and air-
drying, parasitemia was estimated by calculating the percentage of infected red blood cells 
after counting a minimum of 800 red blood cells. 
 
4.3.4. Blood collection   
Animals were anesthetized using 5% isoflurane (Nicholas Piramal Limited, London, UK) in 
100% O2. Blood was collected by retro-orbital puncture on 0.5M EDTA (1 volume to 40 
volumes of blood) or 3.8% trisodium citrate (1 volume to 6 volumes of blood). EDTA-treated 
blood was used to determine whole blood counts using the Hemavet 950FS Multi-species 
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Hematology system (Drew Scientific, Oxford, CT). Platelet-poor plasma (PPP) was prepared 
from citrated blood by centrifugation at 4300 g for 6 minutes at room temperature (RT), 
aliquoted, and stored at -80°C for further analysis. 
 
4.3.5. Determination of plasma VWF and ADAMTS13 levels 
VWF and ADAMTS13 antigen levels in plasma were determined using in-house developed 
enzyme-linked immunosorbent assays (ELISAs). Plasma VWF or ADAMTS13 was captured 
by either polyclonal anti-human VWF antibodies (1/1000 in phosphate buffered saline (PBS); 
Dako, Glostrup, Denmark) or the anti-mouse ADAMTS13 monoclonal antibody 14H7B8 (5 
µg/ml in PBS) immobilized on a 96-well microtiter plate, respectively. After blocking the 
wells with 3% skimmed milk in PBS, plasma samples were applied at 1:20 to 1:1480 
dilutions. Captured VWF from plasma was detected using a mixture of in-house generated 
biotinylated anti-murine VWF monoclonal antibodies (15H2 and 2C12; 1 µg/ml in PBS 
containing 0.3% skimmed milk) followed by incubation with horseradish peroxidase (HRP)-
labeled streptavidin (Roche, Mannheim, Germany). In the ADAMTS13 assay, bound 
ADAMTS13 was detected after addition of in-house generated polyclonal rabbit anti-mouse 
ADAMTS13 antibodies (5 µg/ml in PBS containing 0.3% skimmed milk) followed by 
incubation with polyclonal goat anti-rabbit antibodies labeled with HRP (1/10,000 in PBS 
containing 0.3% skimmed milk; Jackson ImmunoResearch Laboratories Inc., West Grove, 
PA). Washing steps with PBS + 0.1% Tween20 were performed between each step. The 
coloring reaction was initiated by addition of ortho-phenylenediamine (Sigma-Aldrich, St 
Louis, MO) and H2O2, and stopped with 4 M H2SO4. The absorbance was determined at 490 
nm using a FLUOstar OPTIMA ELISA reader (BMG Labtech GmbH, Offenburg, Germany). 
Plasma VWF and ADAMTS13 levels in infected mice were expressed as percentages of 
baseline levels that were determined in plasma collected 2 weeks before infection. 
 
4.3.6. Determination of plasma ADAMTS13 activity 
The proteolytic activity of ADAMTS13 was determined by fluorescent resonance energy 
transfer using a short fluorogenic 73 amino acid VWF peptide (FRETS-VWF73; Peptides 
International, Louisville, KY), as decribed previously.22 Briefly, plasma was incubated at 
37°C with 2 µM FRETS-VWF73 substrate in a HEPES-buffered saline solution (50 mM 
HEPES, 5 mM CaCl2, 1 mM ZnCl2, 150 mM NaCl; pH 7.4) containing 1 mg/ml bovine 
serum albumin (Sigma). Digestion of the FRETS-VWF73 substrate generated a fluorescent 
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signal that was measured using the FLUOstar OPTIMA ELISA reader during 40 cycli of 300 
seconds using excitation at 355 nm and emission at 460 nm. Fluorescence intensities were 
depicted in function of time and the slope of the resulting curve was used as a measure for 
activity. Plasma ADAMTS13 activity levels in infected mice were expressed as percentages 
of baseline levels observed in plasma from 2 weeks before infection. 
 
4.3.7. In vivo inhibition of ADAMTS13 
ADAMTS13 activity in WT mice was inhibited by retro-orbital injection of a mixture of in-
house developed inhibitory monoclonal anti-mouse ADAMTS13 inhibitory antibodies, 13B4 
and 14H7 (1.25 mg/kg of each).23 Injection of a non-functional anti-mouse ADAMTS13 
monoclonal antibody, 20A10 (2.5 mg/kg), was used as a negative control. 
 
4.3.8. Plasma VWF multimer analysis 
Plasma samples were diluted in sample buffer (8 M urea, 5% (m/v) sodium dodecyl sulphate 
(SDS), 10 mM Tris, 1 mM EDTA, and 0.3% bromophenol blue; pH 8.0) and denatured at 
60°C for 30 minutes. The denatured VWF was fractionated on a low-resolution (1.2%) SDS 
isoelectric focusing agarose gel (GE Healthcare Europe GmbH, Diegem, Belgium), fixed on 
a GelBond® film (Lonza, San Diego, CA), by electrophoresis at 10-15mA in a multiphor II 
apparatus (GE Healthcare). Following electrophoresis, the gel was rinsed in distilled water, 
air-dried, and blocked in 5% skimmed milk in tris buffered saline (TBS) solution containing 
0.05% Tween20 (TBST). After overnight incubation with alkaline phosphatase-conjugated 
polyclonal anti-human VWF antibodies (1/750 diluted in TBS; Dako) and subsequent rinsing 
with TBST, VWF multimers were visualized using an Alkaline Phosphate conjugate 
substrate kit (BioRad, Hercules, CA). To quantify differences in the VWF multimer 
composition, densitometric analysis of each VWF multimer pattern was performed using 
Image J software (version 1.47, National Institute of Health, Bethesda, MD). Distinguishable 
bands were divided into 3 subclasses: (1) 1-5 dimers were designated as low molecular 
weight VWF multimers (LMW), (2) 6-10 dimers as medium molecular weight VWF 
multimers (MMW), and (3) >10-dimers as high molecular weight VWF multimers (HMW; 
including UL-VWF multimers). The total density of each subclass was divided by the total 
density of all multimer bands to calculate the relative abundance of each subclass. The 
relative amount of LMW, MMW, and HMW VWF multimers in infected mice were 
expressed as percentages of baseline levels observed in plasma 2 weeks before infection. 
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4.3.9. Broncho-alveolar lavage 
To obtain broncho-alveolar lavage (BAL) fluid, mice were anesthetized by intraperitoneal 
injection of pentobarbital (60 mg/ml; Nembutal®, Ceva Santé Animale, Brussels, Belgium). 
Broncho-alveolar lavages were performed by intratracheal instillation of 0.75 mL PBS in 
both lungs for 30 seconds after which the PBS was slowly withdrawn. This procedure was 
performed twice and both lavages were combined. BAL fluid samples were centrifuged at 
335 g for 10 minutes at 4°C. Protein concentrations in supernatants were determined using a 
Bradford assay (BioRad, Hercules, CA) according to the manufacturer’s protocol. 
 
4.3.10. Statistical analysis 
Data are represented as mean ± SEM. For statistical analysis, the Prism Version 6.0 software 
(GraphPad Software, La Jolla, CA) was used. One-way analysis of variance followed by 
Dunnett’s multiple comparisons post hoc test was conducted to assess the variance of VWF 
levels, ADAMTS13 activity levels, and the relative amounts of HMW multimers between 
plasma samples before (pre) and at different time points during infection. Paired t testing was 
used to assess differences in ADAMTS13 levels and the ratio of ADAMTS13 activity to 
antigen between plasma samples before infection (pre) and at end-stage disease (end). 
Unpaired t testing was used to compare protein levels in BAL fluid of infected or non-
infected WT and Vwf-/- mice. A log-rank test was used to determine differences between 
Kaplan-Meier survival curves. Values of P < 0.05 were considered as statistically significant. 
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4.4. RESULTS 
 
4.4.1. Effect of P. berghei NK65 infection on circulating VWF and ADAMTS13 
levels 
Observational studies in malaria patients showed increased levels of VWF and decreased 
ADAMTS13 activities.11,14,17,18 How and when exactly parasite infection influences these 
parameters is however not well understood. We therefore used an established murine model 
of MA-ARDS, in which C57BL/6J mice are infected with P. berghei NK65.20,24 VWF 
antigen levels in plasma of P. berghei NK65-infected C57BL/6J mice doubled 3 days after 
infection (pre: 100 ± 4.1% versus day 3: 200.2 ± 7.1%; P < 0.0001) and remained increased 
during the development of malaria pathology (Figure 1A). At the end stage of the disease 
(day 8 or 9 after infection), however, VWF levels were again normalized. Remarkably, the 
early increase of VWF antigen occurred before a noticeable rise in peripheral blood 
parasitemia levels (Figure 1B), suggesting that P. berghei NK65 infection is associated with 
early EC activation. In non-infected control mice, VWF antigen levels remained within 
normal range (Figure 1A). Mean plasma ADAMTS13 activity levels stayed within the 
normal range during the initial course of infection, but markedly decreased from day 7 after 
infection (pre: 100 ± 7% versus day 7: 57.2 ± 6.3%; P < 0.01) (Figure 1C). No significant 
changes were observed in plasma of non-infected mice (Figure 1C). Interestingly, the 
decrease in ADAMTS13 activity in P. berghei NK65-infected mice near end-stage disease 
could not be attributed to reduced antigen levels, as ADAMTS13 antigen remained normal 
(Figure 1D) resulting in a significant reduction of the ADAMTS13 activity over antigen ratio 
(Figure 1E). These data suggest that P. berghei NK65-mediated MA-ARDS is associated 
with a significant reduction of ADAMTS13 activity during the later stages of disease. 
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Figure 1: Early increase in plasma VWF levels and late stage reduction in ADAMTS13 activity 
in MA-ARDS. C57BL/6J mice were injected with 104 P. berghei NK65 parasites (infected mice; 
solid line) or PBS (non-infected mice; dashed line). Blood samples were collected 2 weeks before 
infection (pre) and at indicated time points after infection. The final blood sample was withdrawn at 
end-stage disease (end), i.e. when mice were considered moribund (day 8 or 9 after infection). (A) 
Plasma VWF levels in infected (n = 12) and non-infected (n = 7) mice were measured by ELISA (n = 
12). (B) Peripheral blood parasitemia levels in infected mice (n = 12) were determined from Giemsa-
stained blood smears. (C) Plasma ADAMTS13 activity levels in infected (n = 5) and non-infected (n 
= 3) mice were measured using a FRETS-VWF73 assay. (D) Plasma ADAMTS13 antigen levels in 
infected mice (n = 6) were determined via ELISA at indicated time points. (E) Ratio of ADAMTS13 
activity to antigen in infected mice (n = 6) at indicated time points. Ns, not significant; *, P < 0.05; 
**, P < 0.01; ***, P < 0.001; ****, P < 0.0001. 
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4.4.2. Murine MA-ARDS is associated with loss of HMW VWF multimers  
Patient studies have reported that severe P. falciparum infection is associated with 
accumulation of abnormally HMW VWF multimers.11,14 We therefore analyzed the multimer 
distribution of plasma VWF at different time points after infection by P. berghei NK65 
(Figure 2). Prior to end-stage disease, VWF multimer patterns were (near-) normal (Figure 
2A-B). At end-stage disease, however, multimer distribution appeared abnormal, with a 
severe reduction in the relative amount of HMW VWF multimers (pre: 46.6 ± 1.7% vs end: 
19.8 ± 2.3%; P < 0.0001; Figure 2A-B).  
VWF multimer size is controlled through continuous proteolysis by ADAMTS13, and a 
decreased average size of plasma VWF multimers has been associated with an increased 
susceptibility of VWF for ADAMTS13-mediated cleavage.25 To investigate whether 
increased ADAMTS13-mediated proteolysis caused the loss of HMW VWF multimers at 
end-stage disease, we blocked endogenous ADAMTS13 activity in P. berghei NK65-infected 
mice. Inhibitory anti-ADAMTS13 antibodies were administered at day 5 after infection, prior 
to the observed drop in HMW VWF multimers. Injection of these inhibitory antibodies 
results in complete inhibition of plasma ADAMTS13 activity for up to 7 days.23 
Administration of a non-inhibitory monoclonal anti-ADAMTS13 antibody was used as 
control. Full inhibition of the proteolytic activity of plasma ADAMTS13 was indeed 
observed at day 7 after infection and end-stage disease, whereas in the group receiving non-
inhibitory monoclonal anti-ADAMTS13 antibodies, ADAMTS13 activity was not affected 
(data not shown).  Interestingly, we still found a severe reduction in the number of HMW 
VWF multimers in plasma of moribund mice with inhibited ADAMTS13 activity (pre: 41.4 ± 
2.0% versus end: 23.1 ± 2.8%; P < 0.05) (Figure 2C). This reduction was similar to the 
reduction observed in the control group (Figure 2C), indicating that loss of HMW VWF 
multimers was not attributable to an increased degradation by ADAMTS13. These data 
clearly demonstrate that infection of C57BL/6 mice with P. berghei NK65 parasites is not 
associated with a pathological accumulation of abnormal HMW VWF multimers, but instead 
is characterized by a pronounced loss of HMW VWF multimers at end-stage disease, which 
is in contrast with human findings. 
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Figure 2: Loss of HMW VWF multimers during end-stage P. berghei NK65 infection. C57BL/6J 
mice were injected with 104 P. berghei NK65 parasites (infected mice; n = 7) or PBS (non-infected 
mice; n = 4). Blood samples were collected 2 weeks before infection (pre), at indicated time points 
during infection, and at end-stage disease (day 8 or 9 after infection; end). Multimer composition of 
circulating plasma VWF was analyzed via 1.2% agarose gel electrophoresis and densitometry. (A) 
Representative VWF multimer patterns from infected and non-infected mice. Distinguishable bands 
were divided into 3 subclasses: 1-5 dimers were designated as low molecular weight (LMW) VWF 
multimers, 6-10 dimers as medium molecular weight (MMW) VWF multimers, and >10-dimers as 
high molecular weight (HMW) VWF multimers, including the ultra large VWF portion. (B) VWF 
multimer distribution (left) and the relative abundance of HMW VWF multimers (right) during the 
course of infection. (C) Effect of ADAMTS13 inhibition on VWF multimer composition during end-
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stage P. berghei NK65 infection. Activity of ADAMTS13 in infected mice was inhibited via 
intravenous administration of inhibitory anti-ADAMTS13 antibodies at day 5 after infection (n = 4). 
Infected mice treated with non-inhibitory anti-ADAMTS13 antibodies were used as a negative control 
(n = 3). Paired t-testing was used to assess differences the relative abundance of HMW VWF 
multimers between plasma samples before infection (pre) and plasma samples at end-stage disease 
(end). Ns, not significant *, P < 0.05; ****, P < 0.0001. 
 
4.4.3. VWF deficiency influences the course of P. berghei NK65 infection 
Several patient studies have suggested that elevated levels of VWF inversely correlate with 
clinical outcome, making VWF an informative biomarker of malarial disease 
severity.12,15,26,27 Increasing evidence, however, points towards a direct role of VWF in 
malaria pathogenesis, where for example, VWF is thought to facilitate adhesion of P. 
falciparum-infected red blood cells to endothelial cells in microvascular beds of various 
organs.19 To investigate whether VWF plays a direct role in MA-ARDS pathogenesis in 
mice, we studied P. berghei NK65 infection in Vwf-/- mice compared with WT mice. Median 
survival time in Vwf-/- mice (9 days) was slightly but significantly shorter than in WT mice 
(10 days, P < 0.05) (Figure 3A). Whereas 75% of Vwf-/- mice died within the first 9 days, 
only 30% of WT mice had died in the same period. Interestingly, we found that the overall 
course of peripheral blood parasitemia levels was significantly different between WT and 
Vwf-/- mice starting from day 6 after infection, with parasitemia levels being significantly 
higher in Vwf-/- mice (Figure 3B). 
 
 
Figure 3: Lack of VWF alters the course of P. berghei NK65 infection. WT (n = 20; solid line) and 
Vwf-/- (n = 20; dashed line) mice on a C57BL/6J background were inoculated with 104 P. berghei 
NK65 parasites. (A) Survival and (B) peripheral blood parasitemia levels were monitored daily. **, P 
< 0.01; ***, P < 0.001. 
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Infection of WT C57BL/6J mice with P. berghei NK65 parasites causes pulmonary 
complications characterized by pulmonary edema, vascular permeabilization, and leukocyte 
infiltration.20 To further elucidate the involvement of VWF in MA-ARDS in mice, we 
investigated pulmonary pathology in Vwf-/- mice compared with WT mice following P. 
berghei NK65 infection. We determined protein levels in BAL fluid, which is indicative for 
edema and alveolar leakage, to measure the extent of lung pathology. At day 8 after infection, 
protein levels in BAL fluid of WT and Vwf-/- mice were significantly elevated compared to 
non-infected controls (Figure 4A). However, protein concentrations were significantly lower 
in BAL fluid of P. berghei NK65-infected Vwf-/- mice compared to infected WT mice (Vwf-/-: 
1.79 ± 0.42 mg/ml versus WT: 3.58 ± 0.48 mg/ml; P < 0.001), indicating that edema and 
alveolar leakage were less pronounced in Vwf-/- mice. Altogether, these data demonstrate that 
lack of VWF in mice reduces pulmonary pathology following P. berghei NK65 infection but 
alters the course of infection by modulating peripheral blood parasitemia levels. 
 
 
Figure 4: Reduced edema and alveolar leakage in Vwf-/- mice following P. berghei NK65 
infection. WT and Vwf-/- mice on a C57BL/6J background were injected with 104 P. berghei NK65 
parasites (infected mice) or PBS (non-infected mice). Broncho-alveolar lavage fluid samples were 
collected from non-infected WT (n = 5) and Vwf-/- (n = 7) mice, and infected WT (n = 13) and Vwf-/- 
(n = 7) mice at day 8 following injection. After centrifugation, protein content of the supernatants was 
determined using Bradford assay. *, P < 0.05 
 
4.4.4. Malaria-related thrombocytopenia in MA-ARDS occurs independent of 
VWF 
Severe thrombocytopenia is a risk factor of adverse clinical outcome in children and adults 
following P. falciparum infection.28,29 The exact mechanism underlying this phenomenon 
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remains poorly understood although recent studies suggested that VWF might be implicated 
in malaria-related thrombocytopenia.10,30 To test this hypothesis, we measured platelet 
numbers in WT and Vwf-/- mice following P. berghei NK65 infection (Figure 5). In WT mice, 
platelet numbers started to decrease after day 5 post infection, indicating that 
thrombocytopenia constituted a hallmark also in this murine model. Within the following 2-3 
days, mean platelet counts had fallen by approximately 90%, resulting in a profound 
thrombocytopenia at end-stage disease (Figure 5). Interestingly, a similar reduction in platelet 
count was observed in P berghei NK65-infected Vwf-/- mice, demonstrating that VWF does 
not contribute to malaria-related thrombocytopenia in mice (Figure 5). 
 
 
Figure 5:	 Thrombocytopenia following P. berghei NK65 infection is not VWF-mediated. WT (n 
= 10; solid line) and Vwf-/- (n = 7; dashed line) mice were infected with 104 P. berghei NK65 
parasites. Blood was collected one day before injection (day -1) and at indicated time points during 
infection, until end-stage disease (day 8 or 9 after infection; end). Platelet counts were measured using 
an automated cell counter. 
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4.5. DISCUSSION 
 
In this study we wanted to unravel the direct role of VWF in malaria pathogenesis using a 
murine model for MA-ARDS. C57BL/6 mice infected with P. berghei NK65 develop severe 
pulmonary complications, of which the pathophysiological findings are in agreement with 
human MA-ARDS.20 Here, we demonstrated that P. berghei NK65 infection is associated 
with elevated plasma VWF levels, which resembles the activated EC phenotype observed in 
both uncomplicated and complicated human malaria infection.11,17,18,27 In parallel with human 
studies, VWF levels increased from a very early stage following infection, at the time that 
only a small percentage red blood cells were infected, indicating that early EC activation 
constitutes a hallmark of P. berghei NK65.10 To date, the trigger for this early activation 
remains unclear. Further studies are needed to define how exposure to malaria parasites 
modulates EC activation. 
 
VWF released following EC activation and subsequent exocytosis of WPBs consists of 
highly adhesive HMW VWF multimers that are rapidly cleaved by ADAMTS13 at the 
endothelial surface under normal conditions.16 Throughout most of the course of P. berghei 
NK65 infection, ADAMTS13 activity levels were within normal range and capable of 
properly processing secreted VWF as indicated by the appearance of (near) normal VWF 
multimer patterns. Near end-stage disease, however, ADAMTS13 activity levels were 
severely decreased. Surprisingly, the decrease in ADAMTS13 activity was not accompanied 
by a concomitant accumulation of UL-VWF multimers. Instead, we observed a loss of HMW 
VWF multimers at end-stage disease. The clinical relevance of this phenomenon remains 
unclear since these findings differ from severe P. falciparum malaria, where reduced 
ADAMTS13 activity results in the presence of circulating UL-VWF multimers.11,14 Whether 
loss of HMW VWF multimers could serve as a potential biomarker for end-stage disease 
remains to be studied. One potential explanation for the loss of HMW VWF multimers could 
be enhanced ADAMTS13-mediated cleavage of VWF in the hyperdynamic microcirculatory 
blood flow environment of P. berghei NK65-infected mice. Indeed, exposure of VWF to 
pathological shear stress can result in increased VWF proteolysis by ADAMTS13 and 
subsequent loss of HMW VWF multimers.25 Full inhibition of ADAMTS13 activity prior to 
the observed drop, however, did not alter the degree of VWF proteolysis indicating that 
excess VWF cleavage is not caused by ADAMTS13. This, however, does not rule out the 
possible involvement of other proteolytic enzymes, such as leukocyte-derived proteases31,32 
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and plasmin33. In addition to increased VWF proteolysis, other mechanisms, such as 
increased clearance or consumption of the larger VWF multimers, may explain the abnormal 
VWF multimer distribution at end-stage disease. Future studies are warranted to shed more 
light on the mechanisms and clinical relevance of this intruiging phenotype.  
 
Another interesting observation is the reduction of ADAMTS13 activity near end-stage 
disease, which is in line with the presence of reduced ADAMTS13 activity in patients with 
severe P. falciparum or P. vivax malaria.11,14,17,18 Here, we demonstrated that the reduced 
ADAMTS13 activity, however, was not caused by a decrease in antigen levels indicating that 
specific factors may regulate ADAMTS13 function during MA-ARDS. Several factors such 
as free hemoglobin and inflammatory cytokine interleukin-6 are known to reduce 
ADAMTS13 activity in vitro34,35. Although their levels are increased during malaria 
infection, their absolute concentrations do not approach the concentrations that were reported 
necessary to inhibit ADAMTS13 activity in vitro.14,17 Nevertheless, by performing mixing 
studies, Larkin and colleagues demonstrated the presence of an unidentified inhibitor that 
might explain the severe reduction in ADAMTS13 activity.14 In the near future mixing 
studies will be performed to find out whether reduced ADAMTS13 activity in near end-stage 
P. berghei NK65 infection is caused by the presence of an inhibitor.  
 
An increasing body of evidence suggests the direct involvement of high levels of VWF in the 
underlying pathophysiology of human malaria-associated disease syndromes. 
Thrombocytopenia is one of the most common hematological alterations in P. falciparum and 
P. vivax malaria and has occasionaly been associated with disease severity.28,36 The 
mechanism underlying the decrease in platelet count remains to be elucidated, although it is 
believed to be a multifactorial phenomenon.37 The pathogenic mechanisms include cell- and 
antibody-mediated immune mechanisms38,39, splenic alterations40, oxidative stress41, and 
platelet apoptosis42. Recently, independent research groups have demonstrated an inverse 
correlation between platelet numbers and VWF levels, suggesting that increased VWF levels, 
and in particular UL-VWF multimers, may be an important inducer of thrombocytopenia in 
malaria.10,11,17 In this study, we showed that thrombocytopenia constituted a hallmark of P. 
berghei NK65 infection in C57BL/6 mice, which allowed us to define whether VWF 
modulates malaria-associated thrombocytopenia. Absence of VWF, however, did not prevent 
thrombocytopenia as an equally profound decrease in platelet count was observed in P. 
berghei NK65-infected Vwf-/- mice. These data clearly suggest that VWF-mediated platelet 
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adhesion or aggregation is not involved in the multifactorial process underlying malaria-
associated platelet clearance in mice. 
 
In addition to clinical findings, in vitro experiments suggested that VWF may contribute to 
the sequestration of P. falciparum-infected red blood cells on activated endothelium, thereby 
promoting microvascular dysfunction in various organs.19 Whereas one therefore should 
expect a beneficial effect of the absence of VWF, we demonstrated that median survival 
times were slightly, but significantly shortened in P. berghei NK65-infected Vwf-/- mice 
compared to WT mice. Although we have not yet unravelled the mechanism, we hypothesize 
that differences in parasite sequestration between both genotypes may explain the difference 
in survival. Indeed, protein levels in BAL fluid of Vwf-/- mice were significantly lower 
compared to WT mice, indicating less severe lung pathology in Vwf-/- mice. In addition, we 
observed that peripheral blood parasitemia levels were significantly higher in Vwf-/- mice. In 
the absence of VWF, perhaps fewer numbers of parasites sequester in the pulmonary 
circulation, which results in less severe lung pathology but increased blood parasitemia 
levels. Preliminary data demonstrating a higher number of schizont stages in peripheral blood 
of Vwf-/- mice compared to WT mice at day 7 after infection further support this concept (data 
not shown). Future studies that focus on the parasite sequestration in lungs of P. berghei 
NK65-infected WT and Vwf-/- mice will be performed to further investigate this hypothesis.  
 
Recently, O’Regan and colleagues investigated the role of VWF in experimental cerebral 
malaria, in which C57BL/6 mice were infected with P. berghei ANKA.13 Infection with P. 
berghei ANKA was associated with early EC activation, pathological accumulation of UL-
VWF multimers, and thrombocytopenia. Interestingly, they demonstrated that clinical 
progression was delayed and overall survival was prolonged in Vwf-/- mice compared to WT 
mice.13 Absence of VWF did not affect platelet counts or peripheral blood parasitemia levels 
in the P. berghei ANKA model.13 Whereas some observations are in accordance with our 
findings, others clearly differ. Although the use of different parasite strains may explain the 
discordant results, these differences indicate that studies using different animal models are 
useful to better understand the involvement of the VWF/ADAMTS13 axis in malaria-
associated syndromes. Such insights could become valuable for the design of potential novel 
treatment strategies that interfere with VWF activity in malarial disease.43 
 
In conclusion, we used a relatively new mouse model of malaria to investigate for the first 
time the role of VWF and ADAMTS13 in MA-ARDS. Although we observed some 
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interesting findings, further research is required to elucidate the underlying biological 
mechanisms and their clinical relevance. 
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GENERAL DISCUSSION & FUTURE PERSPECTIVES 
 
During my PhD thesis we focussed on VWF and/or ADAMTS13 in stroke, TTP and malaria. 
In this section, we will briefly summarize the results, discuss the implications of our research 
results and put forward future research lines.  
 
Aim 1: To gain more insight in the relative importance of plasma VWF and platelet-
derived VWF in hemostasis and thrombosis. 
Endothelial cell- and platelet-derived VWF are products of the same gene but show 
remarkable biochemical differences which may point towards a significant difference in their 
role in hemostasis and thrombosis. Although their specific contribution to these processes has 
been addressed using chimeric pigs, their relative importance remained unclear. In this study, 
we successfully generated chimeric mice that expressed VWF only in ECs or platelets by 
performing crossed BMT between WT and Vwf-/- mice. Chimeric mice specifically lacking 
platelet VWF showed normal hemostasis in a tail clip bleeding model and normal carotid 
artery thrombosis. Chimeric mice with VWF only in platelets were not able to support normal 
hemostasis and thrombosis. Using a mouse model of transient middle cerebral artery 
occlusion, however, chimeric mice with only platelet VWF experienced significant cerebral 
infarction compared to Vwf-/- mice, suggesting a clear role for platelet-derived VWF that is 
specific to ischemic stroke injury. 
However, mice are not humans. Therefore, it will be of great interest to study whether our 
findings can be translated to the human setting. In particular, the lack of necessity for 
platelet-derived VWF in hemostasis in murine studies remains intriguing. Indeed, measuring 
hemostasis in mice is challenging, and tail clip bleeding does not always mimic clinical 
relevant bleeding. Therefore, we believe that a large-scale clinical study involving type I 
VWD patients with equally low plasma VWF concentrations but variable platelet VWF 
concentrations (‘platelet normal’, ‘platelet low’, and ‘platelet discordant’) is of great interest 
to confirm a hemostatic role of platelet VWF in humans. By linking variable platelet VWF 
content and frequency of bleeding symptoms in this specific study population, more 
information on the importance of platelet-derived VWF in hemostasis in humans could be 
obtained. Moreover, such diverse study population would be interesting to link platelet VWF 
content and frequency of thrombotic events (such as ischemic stroke). This aim, however, is 
less feasible since the number of type 1 VWD patients with thrombotic events will be very 
low. 
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In addition, our data provide an intriguing base for further study of the role of platelet VWF 
besides hemostasis. Indeed, there is increasing evidence that VWF-platelet complexes, and in 
particular VWF-GPIb interactions, play an important role in leukocyte extravasation thereby 
linking VWF to leukocyte recruitment. Therefore, future studies addressing the inflammatory 
nature of platelet-derived VWF will be highly relevant, especially in inflammation and in 
thrombo-inflammatory conditions such as transient ischemic stroke and myocardial 
ischemia/reperfusion injury. 
 
Aim 2: To develop a non-viral gene therapeutic approach that offers long-term 
protection against TTP in mice. 
TTP is a rare life-threatening condition with a high mortality rate, if left untreated. In case of 
congenital TTP, prophylactic plasma therapy is considered in patients with a chronic 
relapsing disease course. Lifelong prophylaxis, however, is stressful and not without risk, and 
has a negative impact on the lifestyle and health-related quality of life. Here, we demonstrate 
that a single administration of the Sleeping Beauty (SB) transposon system, carrying a correct 
copy of the gene, can result in long-term correction of ADAMTS13 deficiency and 
prophylaxis of TTP in Adamts13-/- mice. Therefore, we believe that our non-viral integrating 
Sleeping Beauty-mediated gene therapeutic approach can ultimately cure congenital TTP 
patients, obviating the need for prophylactic plasma infusions.  
Failed and fatal clinical trials in the late 1990s have threatened to doom gene therapy 
technology. However, recent successful viral-vector mediated gene therapy trials for 
hemophilia B and inherited immune deficiencies have led to a surprising revival in gene 
therapy research. Indeed, gene therapy continues to grow as a treatment strategy toward 
numerous diseases. This ‘renaissance’ has drawn attention from pharmaceutical and 
biotechnology companies, which has led to the marketing authorization of the first gene 
therapy-medicine, called Glybera® (an AAV-mediated gene therapy for treatment of 
lipoprotein lipase deficiency), in 2012.  
Despite its progress, clinical success of viral vector-mediated gene therapy is often hindered 
by safety concerns and other limitations concerning high production costs, scale up, and size 
of delivered gene construct. These drawbacks have drawn attention to the field of non-viral 
gene therapy in which recent advances (in terms of gene transfer efficiency, duration of gene 
expression, and safety) have led to an increased number of non-viral gene products entering 
clinical trials.  
With respect to the development of novel non-viral gene therapy platforms, the SB 
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transposon technology holds high promise as it combines low cost and simplicity of naked 
DNA with the efficiency of gene transfer associated with retroviral vectors. Interestingly, SB-
mediated gene therapy has reached clinical level in the United States, where various trials 
involving CAR T-cells generated with the SB system to treat B-cell malignancies are 
ongoing. Recently published clinical data from these trials are encouraging and support 
further clinical development of this non-viral gene therapeutic approach. 
The success of SB in early clinical trails encourages us to work out strategies that will turn 
our preclinical gene therapeutic approach for congenital TTP into a more clinical relevant 
approach. Efficient gene delivery is a crucial factor for clinically applicable gene therapy. 
Hydrodynamic gene delivery is very efficient in small animal models and significant progress 
in image-guided catheterization-based procedures has enabled researchers to deliver plasmid 
DNA in specific target organs of larger animals, such as pigs. However, the procedure is still 
not readily applicable to a human clinical setting. To circumvent this issue, the use of hybrid 
helper-dependent adenoviral vectors that incorporate the SB transposon system could be 
explored. Adenoviral vectors are widely used in gene therapy clinical trials and therefore well 
characterized in a human clinical setting. Moreover, the research group of A. Ehrhardt 
(University of Witten/Herdecke) has already successfully evaluated a similar hybrid-vector 
system in a canine model for hemophilia B. Collaboration with this group would allow us to 
develop a hybrid adenoviral/SB system carrying a correct copy of the ADAMTS13 gene and 
test its efficacy in preclinical studies using Adamts13-/- mice.  
Although the use of the SB transposon system in the field of gene therapy holds much 
promise, one should take into account that this transposon-based system is an integrating 
gene transfer technique, and therefore the risk of insertional mutagenesis is immanent. To 
overcome safety issues related to integration, the use of episomal minicircle vectors can offer 
an ideal alternative. Minicircles are circular DNA with only mammalian expression cassettes 
and devoid of bacterial backbone. Despite their non-integrating nature, minicircles lead to 
persistent expression of transgene proteins in various tissues. Recently, PharmAbs, the KU 
Leuven Antibody Center, launched the start of a spin-off company where the minicircle 
technology will be used to express human antibodies as therapeutic agents in patients. 
Preclinical animal studies showed that electrotransfer of minicircle DNA containing 
therapeutic antibody sequences to skeletal muscles of mice allowed efficient expression of 
the therapeutic antibody. Hence, it will be interesting to study if electrotransfer of minicircle 
DNA containing a correct copy of the ADAMTS13 gene to skeletal muscles of mice will be 
another interesting gene therapeutic approach to treat TTP.  
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SB-mediated gene transfer hinges on the insertion of a correct copy of the gene to achieve a 
therapeutic effect, whereas more recent strategies focus on the precise manipulation of the 
human genome. With respect to these latter strategies, the advent of the type II bacterial 
clustered, regularly interspaced, palindromic repeats (CRISPR) and CRISPR-associated (Cas) 
gene transfer system has been phenomenal. Although originally described as an adaptive 
immune system used by microbes to defend themselves against specific infections, the 
CRISPR/Cas system (and in particular the CRISPR/Cas9) has been repurposed into a cheap 
and effective genome editing tool to correct disease-causing mutations in a broad range of 
mammalian cells, including human cells. Therefore, it would be interesting to look into the 
possibility of performing CRISPR/Cas9-mediated strategies that target pathogenic genes 
found in congenital TTP patients.   
	
Aim 3: To unravel the role of the VWF/ADAMTS13 axis in a murine model of malaria-
associated acute respiratory distress syndrome. 
Severe malaria remains a major cause of death in tropical countries. Increasing clinical and 
preclinical evidence shows that alteration in the VWF/ADAMTS13 axis may play a key role 
in malaria-associated disease syndromes. However, in-depth mechanisms concerning the 
direct role of VWF and ADAMTS13 in malaria pathogenesis have not yet been elucidated. 
Many studies focus on cerebral malaria pathogenesis, while little is known about the 
pathogenesis of malaria-associated lung pathology. By infecting C57BL/6J mice with P. 
berghei NK65 parasites, we studied alterations in VWF and ADAMTS13 associated with 
murine MA-ARDS. We observed early elevated levels of VWF and late-stage reduction of 
ADAMTS13 activity without accumulation of highly reactive HMW VWF multimers. Our 
findings also showed that VWF does not contribute to malaria-associated thrombocytopenia. 
Furthermore, we believe that VWF may influence the development of parasitemia and lung 
pathology, potentially by interfering with the sequestration of infected red blood cells. 
Many findings in this study are preliminary and therefore many questions remain to be 
resolved. Is the loss of HMW VWF multimers at end-stage MA-ARDS clinically relevant? If 
so, what causes this intriguing phenotype? Is the reduction in ADAMTS13 activity despite 
normal antigen levels due to the presence of (an) inhibitor(s)? Does VWF influences the 
course of malarial disease by affecting the parasite sequestration in specific organs? 
Consequently, definitive conclusions cannot yet be drawn from this study and further 
investigations are needed before one can discuss its added value to the field. Nevertheless, in 
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depth studies using experimental models are invaluable for elucidating pathogenesis of 
human diseases, particularly infectious diseases.  
In murine malaria, no single mouse model mimics all the various clinical manifestations of 
severe malaria in humans. Therefore, it will be interesting to investigate the involvement of 
VWF and ADAMTS13 in different mouse models of malaria, ranging from lethal to non-
lethal infections. For example, infection of C57BL/6 mice with P. berghei ANKA can be used 
to unravel the role of VWF and ADAMTS13 in experimental cerebral malaria, whereas 
infection with P. chabaudi AS can be used to study the cellular and molecular mechanisms of 
the VWF/ADAMTS13 axis in a non-lethal infection. Testing these parasite strains in 
different transgenic (knockout) mouse strains will hopefully lead to a better understanding in 
the involvement of the VWF/ADAMTS13 axis in various malaria-associated syndromes. In 
this way novel targets for therapeutic interventions that improve survival may be identified. 
However, regardless of the model that is used, extrapolating results from murine models of 
malaria to human malaria will be an interesting challenge. 
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§ POSTER presentations 
 
13. Verhenne S, Libbrecht S, Vandenbulcke A, Deckmyn H, Vanhoorelbeke K, and De 
Meyer SF. The hemostatic role of platelet von Willebrand factor in mice. The 
Hemostasis Gordon Research Conference - Waterville Valley, New Hampshire, 
USA (July 22-27, 2012)  
 
14. Verhenne S, Vandeputte N, Pareyn I, Izsvák Z, Rottensteiner H, De Meyer SF, and 
Vanhoorelbeke K. Correction of murine ADAMTS13 deficiency using the ‘Sleeping 
Beauty’ transposon system. European Society of Cell and Gene Therapy congress - 
Madrid, Spain (October 25-28, 2013) 
 
15. Verhenne S, Kraisin S, Pham T, Vandeputte N, Deckmyn H, Vanhoorelbeke K, Van den 
Steen PE, and De Meyer SF: The role of von Willebrand factor in a malaria-associated 
lung pathology model. The Hemostasis Gordon Research Conference - Stowe, 
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AWARDS & GRANTS 
 
§ AWARDS 
 
1. Paul Capel Prize 2014 
Prize granted for the best oral presentation entitled “‘Sleeping Beauty’-mediated gene 
transfer of ADAMTS13 prevents the onset of TTP-like symptoms in ADAMTS13-deficient 
mice” at the XXIInd Annual Meeting of the Belgian Society on Thrombosis and 
Haemostasis, Mechelen, Belgium, 2014. (EUR 750) 
 
2. Young Investigator Award 2015 
Prize granted for the abstract entitled “Long-term gene therapy for thrombotic 
thrombocytopenic purpura using the ‘Sleeping Beauty’ transposon system” accepted as 
oral communication at the XXVth meeting of the International Society on Thrombosis 
and Haemostasis in Toronto, Canada, 2015. (CAD 700) 
 
3. PhD Poster Contest Winner 2015 
Prize granted for the best oral presentation entitled “Long-term gene therapy for 
congenital thrombotic thrombocytopenic purpura using the ‘Sleeping Beauty’ 
transposon system” at the Annual Department Event of Cardiovascular Sciences, 
Leuven, 2015. (EUR 800) 
 
§ GRANTS 
 
1. Travel grant 2012 – Belgian Society on Thrombosis and Haemostasis 
Travel grant awarded for the poster presentation entitled “The hemostatic role of platelet 
von Willebrand factor in mice” at the Hemostasis Gordon Research Conference, New 
Hampshire, USA, 2012 
 
2. Travel grant 2013 – Belgian Society on Thrombosis and Haemostasis 
Travel grant awarded for the oral communication entitled “The role of platelet von 
Willebrand factor in mice” at the XXIVth meeting of the International Society on 
Thrombosis and Haemostasis in Amsterdam, The Netherlands, 2013. 
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3. FWO travel grant 2013 
Travel grant awarded for the oral communication entitled “The hemostatic role of 
platelet von Willebrand factor in mice” at the XXIVth meeting of the International 
Society on Thrombosis and Haemostasis in Amsterdam, The Netherlands, 2013. 
 
4. FWO travel grant 2016 
Travel grant awarded for the poster presentation entitled “The role of von Willebrand 
factor in a malaria-associated lung pathology model” at the Hemostasis Gordon 
Research Conference, Vermont, USA, 2016. 
 
5. Travel grant 2016 – Belgian Society on Thrombosis and Haemostasis 
Travel grant awarded for the poster presentation entitled “The role of von Willebrand 
factor in a malaria-associated lung pathology model” at the Hemostasis Gordon 
Research Conference, Vermont, USA, 2016. 
 
